PESTICIDALLY ACTIVE FUSED BICYCLIC HETEROAROMATIC COMPOUNDS

Abstract

Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.

##STR00001##

Claims

1. A compound of the formula I ##STR00490## wherein: A.sub.1, A.sub.2 and A.sub.3 are, independently from each other, N or CR.sub.Y; A.sub.4 and A.sub.5 are, independently from each other, N or CR.sub.Y; Q is ##STR00491## R.sub.1 is hydrogen, C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6cyanoalkyl, aminocarbonylC.sub.1-C.sub.6alkyl, hydroxycarbonylC.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6nitroalkyl, trimethylsilaneC.sub.1-C.sub.6alkyl, C.sub.1-C.sub.3alkoxy-C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl, C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6haloalkenyl, C.sub.2-C.sub.6alkynyl, C.sub.2-C.sub.6haloalkynyl, C.sub.3-C.sub.4cycloalkylC.sub.1-C.sub.2alkyl-, C.sub.3-C.sub.4cycloalkylC.sub.1-C.sub.2alkyl- wherein the C.sub.3-C.sub.4cycloalkyl group is substituted with 1 or 2 halogen atoms, oxetan-3-yl-CH.sub.2—, C.sub.1-C.sub.6alkylcarbonyl, C.sub.1-C.sub.6alkoxycarbonyl, phenyloxycarbonyl, benzyloxycarbonyl, benzyl or benzyl substituted with 1 to 3 substituents independently selected from halogen, C.sub.1-C.sub.6alkoxy and C.sub.1-C.sub.6haloalkyl; R.sub.2a and R.sub.2b are each independently selected from hydrogen, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3haloalkylsulfanyl, C.sub.1-C.sub.3alkoxy, C.sub.1-C.sub.3haloalkoxy, halogen, NO.sub.2, SF.sub.5, CN, C(O)NH.sub.2, C(O)OH, C(S)NH.sub.2, C.sub.3-C.sub.6cycloalkyl, C.sub.3-C.sub.6cycloalkyl substituted with one to three substituents independently selected from R.sub.x, C.sub.3-C.sub.6cycloalkylcarbonyl, phenyl, phenyl substituted with one to three substituents independently selected from R.sub.x, heteroaryl, heteroaryl substituted with one to three substituents independently selected from R.sub.x; OR.sub.6, piperidin-2-one-1-yl, piperidin-2-one-1-yl substituted with one to two substituents independently selected from R.sub.x, pyridin-2-one-1-yl, pyridin-2-one-1-yl substituted with one to two substituents independently selected from R.sub.x, azetidin-1-yl, azetidin-1-yl substituted with one to two substituents independently selected from R.sub.x pyrrolidin-1-yl, pyrrolidin-1-yl substituted with one to two substituents independently selected from R.sub.x, C.sub.3-C.sub.6cycloalkylC.sub.1-C.sub.4alkyl, C.sub.3-C.sub.6cycloalkylC.sub.1-C.sub.4alkyl substituted with one to two substituents independently selected from R.sub.z; C.sub.3-C.sub.6cycloalkylC.sub.1-C.sub.3alkoxy, C.sub.3-C.sub.6cycloalkylC.sub.1-C.sub.3alkoxy substituted with one to two substituents independently selected from R.sub.x, C.sub.1-C.sub.5cyanoalkyl, C.sub.1-C.sub.5cyanoalkoxy, C.sub.1-C.sub.4alkylsulfanyl, C.sub.1-C.sub.4alkylsulfanyl substituted with one to three substituents independently selected from R.sub.x, C.sub.1-C.sub.4alkylsulfonyl, C.sub.1-C.sub.4alkylsulfonyl substituted with one to three substituents independently selected from R.sub.x, C.sub.1-C.sub.4alkylsulfinyl, and C.sub.1-C.sub.4alkylsulfinyl substituted with one to three substituents independently selected from R.sub.x; R.sub.3 is C.sub.1-C.sub.3alkyl or C.sub.1-C.sub.3haloalkyl; R.sub.4 is pyridine, pyrimidine, pyrazine or pyridazine; or R.sub.4 is pyridine, pyrimidine, pyrazine or pyridazine each of which, independently of each other, is substituted with one to two substituents independently selected from C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3alkoxy, C.sub.3-C.sub.4cycloalkyl, halo, hydroxyl, CN, C.sub.1-C.sub.6haloalkoxy, C.sub.2-C.sub.6haloalkenyloxy, C.sub.2-C.sub.6haloalkynyloxy, C.sub.3-C.sub.4halocycloalkoxy. NH.sub.2C(O)—, NH.sub.2C(S)—, (OH)N═C(NH.sub.2)— and a 5-membered heteroaryl ring optionally substituted by 1 to 3 substituents independently selected from halogen, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3alkoxy and C.sub.1-C.sub.3haloalkoxy; R.sub.4a is pyridine, pyrimidine, pyrazine, pyridazine; or R.sub.4a is pyridine, pyrimidine, pyrazine or pyridazine each of which, independently of each other, is substituted with one to three substituents independently selected from C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3alkoxy, C.sub.3-C.sub.4cycloalkyl, halogen, hydroxyl, cyano, and C.sub.1-C.sub.3haloalkoxy; or R.sub.4a is Y1, Y2, Y3, and Y4 ##STR00492## wherein, R′.sub.4a, R′.sub.4b, and R′.sub.4c, independently of each other and independently of Y1 to Y4, are selected from hydrogen, halogen, CN, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.3-C.sub.4cycloalkyl, C.sub.1-C.sub.3alkoxy, and C.sub.1-C.sub.3haloalkoxy; R.sub.5 is hydrogen, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.3-C.sub.4cycloalkyl, C.sub.1-C.sub.3alkoxy, C.sub.3-C.sub.4alkoxyC(O)—, (C.sub.1-C.sub.3alkoxy).sub.2CH—, halogen, CN, NH.sub.2C(O), amino (i.e NH.sub.2), (C.sub.1-C.sub.3alkyl)amino, di(C.sub.1-C.sub.3alkyl)amino, hydroxy, C.sub.3-C.sub.4halocycloalkyl, C.sub.3-C.sub.4cyanocycloalkyl, C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6haloalkenyl, C.sub.2-C.sub.6alkynyl, C.sub.2-C.sub.6haloalkynyl, C.sub.1-C.sub.4haloalkylsulfanyl, C.sub.1-C.sub.4haloalkylsulfinyl, C.sub.1-C.sub.4haloalkylsulfonyl, C.sub.1-C.sub.4alkylsulfanyl, C.sub.1-C.sub.4alkylsulfinyl, C.sub.1-C.sub.4alkylsulfonyl, C.sub.1-C.sub.3alkoxy-C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy-C.sub.1-C.sub.3alkoxy-C.sub.1-C.sub.3alkyl, (C.sub.1-C.sub.3alkyl)sulfonylamino, (C.sub.1-C.sub.3alkyl)sulfonyl(C.sub.1-C.sub.3alkyl)amino, (C.sub.1-C.sub.3alkyl)NHC(O), (C.sub.1-C.sub.3alkyl).sub.2NC(O), (C.sub.1-C.sub.3cycloalkyl)NHC(O), (C.sub.1-C.sub.3cycloalkyl)(C.sub.1-C.sub.3alkyl)NC(O), (C.sub.1-C.sub.3alkyl)C(O)(C.sub.1-C.sub.3alkyl)N, (C.sub.1-C.sub.3alkyl)C(O)NH, (C.sub.1-C.sub.3alkyl)C(O), (C.sub.1-C.sub.3alkoxy)C(O), HC(O), diphenylmethanimine, C.sub.1-C.sub.3haloalkoxy, phenyl, or a 5-membered heteroaromatic ring; or R.sub.5 is phenyl substituted with one to three substituents selected from C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3alkoxy, C.sub.3-C.sub.4cycloalkyl, halogen, CN and hydroxyl; or R.sub.5 is a 5-membered heteroaromatic ring substituted with one to three substituents selected from C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3alkoxy, C.sub.3-C.sub.4cycloalkyl, halogen, CN and hydroxyl; R.sub.5a and R.sub.5b are, independently of each other, selected from hydrogen, halogen, CN, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.3-C.sub.4cycloalkyl, C.sub.1-C.sub.3alkoxy, and C.sub.1-C.sub.3haloalkoxy; R.sub.6 is phenyl, benzyl, heteroaryl, or C.sub.3-C.sub.6 cycloalkyl; or R.sub.6 is phenyl, benzyl, heteroaryl, or C.sub.3-C.sub.6 cycloalkyl, each of which, independent of each other, is substituted with one to three substituents independently selected from R.sub.x; R.sub.x is independently selected from halogen, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3alkoxy, C.sub.1-C.sub.3haloalkoxy, NO.sub.2, SF.sub.5, CN, C(O)NH.sub.2, C(S)NH.sub.2, C.sub.1-C.sub.4haloalkylsulfanyl, C.sub.1-C.sub.4haloalkylsulfinyl, C.sub.1-C.sub.4haloalkylsulfonyl, C.sub.1-C.sub.4alkylsulfanyl, C.sub.1-C.sub.4alkylsulfinyl and C.sub.1-C.sub.4alkylsulfonyl; R.sub.Y is selected from hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.1-C.sub.3 alkoxy, C.sub.1-C.sub.3 haloalkoxy, halogen, CN and cyclopropyl; and R.sub.Z is selected from oxo, halogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3alkoxy, C.sub.1-C.sub.3haloalkoxy and CN; or an agrochemically acceptable salt, stereoisomer, enantiomer, tautomer and N-oxide of the compound of formula I.

2. The compound according to claim 1 wherein A.sub.1 and, A.sub.3 are N and A.sub.2 is CH, and A.sub.4 is CRY and A.sub.5 is CH.

3. The compound according to claim 1 wherein R.sup.1 is hydrogen, methyl, ethyl, cyanomethyl, methoxymethyl, cyclopropyl-methyl, allyl, propargyl, benzyloxycarbonyl, or benzyl.

4. The compound according to claim 1 wherein R.sub.2a is halogen, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3haloalkylsulfanyl, C.sub.1-C.sub.3haloalkoxy, C.sub.3-C.sub.6cycloalkyl, C.sub.3-C.sub.6cycloalkyl substituted with one or two substituents independently selected from C.sub.1-C.sub.3haloalkyl, cyano, and halogen, C.sub.3-C.sub.6cycloalkylC.sub.1-C.sub.4alkyl, C.sub.3-C.sub.6cycloalkylC.sub.1-C.sub.4alkyl substituted with one to three substituents independently selected from C.sub.1-C.sub.3haloalkyl, cyano, and halogen, C.sub.1-C.sub.5cyanoalkyl, C.sub.1-C.sub.4alkylsulfonyl, C.sub.1-C.sub.4haloalkylsulfonyl, C.sub.1-C.sub.4alkylsulfinyl, C.sub.1-C.sub.4haloalkylsulfinyl, C.sub.3-C.sub.6cycloalkylsulfanyl, C.sub.3-C.sub.6cycloalkylsulfinyl, or C.sub.3-C.sub.6cycloalkylsulfonyl.

5. The compound according to claim 1 wherein R.sub.2b is halogen, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3haloalkylsulfanyl, C.sub.1-C.sub.3haloalkylsulfonyl, C.sub.1-C.sub.3alkoxy, C.sub.1-C.sub.3haloalkoxy, or CN.

6. The compound according to claim 1 wherein R.sub.3 is C.sub.1-C.sub.3alkyl or C.sub.1-C.sub.3haloalkyl.

7. The compound according to claim 1 wherein Q is Q.sup.a, and R.sub.4 is pyridine, or pyrimidine; wherein the pyridine or pyrimidine, independently of each other, is optionally substituted with one substituent selected from C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.1-C.sub.3alkoxy, C.sub.3-C.sub.4cycloalkyl, halo, hydroxyl, CN, C.sub.1-C.sub.6haloalkoxy, C.sub.2-C.sub.6haloalkenyloxy, C.sub.2-C.sub.6haloalkynyloxy, C.sub.3-C.sub.4halocycloalkoxy, and C.sub.3-C.sub.6cycloalkylC.sub.1-C.sub.4haloalkoxy; and R.sub.5 is hydrogen, methyl, trifluoromethoxy, methoxy, cyclopropyl, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, difluoromethoxy, 2,2,2-trifluoroethyl, chloro, bromo, methoxyethoxy, methylcarbonyl, or methoxycarbonyl.

8. The compound according to claim 1 wherein Q is Q.sup.b, and R.sub.4a is pyridine, pyrimidine, pyrazine or pyridazine, wherein the pyridine, pyrimidine, pyrazine or pyridazine, independent of each other, is optionally substituted with one substituent selected from C.sub.1-C.sub.3haloalkyl, C.sub.3-C.sub.4cycloalkyl, halogen, cyano, C.sub.1-C.sub.3haloalkoxy and selected from Y-1 to Y-4; R.sub.5a is hydrogen, halogen, CN, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.3-C.sub.4cycloalkyl, C.sub.1-C.sub.3alkoxy or C.sub.1-C.sub.3haloalkoxy; R.sub.5b is hydrogen, halogen, CN, C.sub.1-C.sub.3haloalkyl, C.sub.3-C.sub.4cycloalkyl, C.sub.1-C.sub.3alkoxy, or C.sub.1-C.sub.3haloalkoxy; and R.sub.4a, R′.sub.4a and R′.sub.4c independently of each other, are hydrogen, halogen, CN, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3haloalkyl, C.sub.3-C.sub.4cycloalkyl, C.sub.1-C.sub.3alkoxy, and C.sub.1-C.sub.3haloalkoxy.

9. The compound according to claim 1 wherein the formula I is represented by ##STR00493## wherein R.sub.1, R.sub.2a, R.sub.2b, R.sub.3 are as defined in claim 1, and Q.sub.1 is selected from Q.sup.aa to Q.sup.ag and Q.sup.ba to Q.sup.bf.

10. A composition comprising a compound as defined in claim 1, one or more auxiliaries and diluent, and optionally one or more other active ingredient.

11. A method (i) of combating and controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound as defined in claim 1; or (ii) for the protection of plant propagation material from the attack by insects, acarines, nematodes or molluscs, which comprises treating the propagation material or the site, where the propagation material is planted, with an effective amount of a compound as defined in claim 1; or (iii) of controlling parasites in or on an animal in need thereof comprising administering an effective amount of a compound as defined in claim 1.

12. A plant propagation material, such as a seed, comprising, or treated with or adhered thereto, a compound as defined in claim 1.

13. A compound of the formula XI(i) ##STR00494## wherein A.sub.1, A.sub.2, A.sub.3, A.sub.4, A.sub.5, R.sub.1, R.sub.2a, R.sub.2b and R.sub.3 are as defined in claim 1.

14. A compound of the formula XIV(i) ##STR00495## wherein A.sub.1, A.sub.2, A.sub.3, A.sub.4, A.sub.5, R.sub.1, R.sub.2a, R.sub.2b and R.sub.3 are as defined in claim 1.

15. A compound of the formula II(i) ##STR00496## wherein A.sub.1, A.sub.2, A.sub.3, A.sub.4, A.sub.5, R.sub.2a, and R.sub.2b are as defined in claim 1; and X1 is a halogen, such as Cl or Br.

16. A method (i) of combating and controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a composition as defined in claim 10; or (ii) for the protection of plant propagation material from the attack by insects, acarines, nematodes or molluscs, which comprises treating the propagation material or the site, where the propagation material is planted, with an effective amount of a composition as defined in claim 10; or (iii) of controlling parasites in or on an animal in need thereof comprising administering an effective amount of a composition as defined in claim 10.

17. A plant propagation material, such as a seed, comprising, or treated with or adhered thereto, a composition as defined in claim 10.

18. A compound of the formula IV(i) ##STR00497## wherein A.sub.1, A.sub.2, A.sub.3, A.sub.4, A.sub.5, R.sub.2a, and R.sub.2b are as defined in claim 1.

Description

PREPARATORY EXAMPLES

[0531] LCMS Methods:

[0532] Method 1:

[0533] Spectra were recorded on a Mass Spectrometer from Waters (SQD, SQDII Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and negative ions, Capillary: 3.00 kV, Cone range: 30 V, Extractor: 2.00 V, Source Temperature: 150° C., Desolvation Temperature: 350° C., Cone Gas Flow: 50 l/h, Desolvation Gas Flow: 650 l/h, Mass range: 100 to 900 Da) and an Acquity UPLC from Waters: Binary pump, heated column compartment, diode-array detector and ELSD detector. Column: Waters UPLC HSS T3, 1.8 μm, 30×2.1 mm, Temp: 60° C., DAD Wavelength range (nm): 210 to 500, Solvent Gradient: A=water+5% MeOH+0.05% HCOOH, B=Acetonitrile+0.05% HCOOH, gradient: 10-100% B in 1.2 min; Flow (ml/min) 0.85.

[0534] Method 2:

[0535] Spectra were recorded on a Mass Spectrometer from Waters (SQD, SQDII Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and negative ions, Capillary: 3.00 kV, Cone range: 41 V, Extractor: 2.00 V, Source Temperature: 150° C., Desolvation Temperature: 5000° C., Cone Gas Flow: 50 l/h, Desolvation Gas Flow: 1000 l/h, Mass range: 110 to 800 Da) and an Acquity UPLC from Waters: Binary pump, heated column compartment, diode-array detector and ELSD detector. Column: Waters UPLC HSS T3, 1.8 μm, 30×2.1 mm, Temp: 40° C., PDA Wavelength range (nm): 200 to 400, Solvent Gradient: A=water+5% Acetonitrile+0.1% HCOOH, B=Acetonitrile+0.05% HCOOH, gradient: 10-100% B in 1.3 min; Flow (ml/min) 0.6.

[0536] Method 3:

[0537] Spectra were recorded on a Mass Spectrometer from Waters Corporation (SQD, SQDII or QDA Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and negative ions, Capillary: 0.8-3.00 kV, Cone: 5-30 V, Source Temperature: 120-150° C., Desolvation Temperature: 350-600° C., Cone Gas Flow: 50-150 l/h, Desolvation Gas Flow: 650-1000 l/h, Mass range: 50 to 900 Da and an Acquity UPLC from Waters Corporation: Binary pump, heated column compartment, diode-array detector and ELSD. Column: Waters UPLC HSS T3, 1.8 μm, 30×2.1 mm, Temp: 60° C., DAD Wavelength range (nm): 210 to 400, Runtime: 1.5 min; Solvents: A=water+5% MeOH+0.05% HCOOH, B=Acetonitrile+0.05% HCOOH; Flow (ml/min) 0.85, Gradient: 10% B isocratic for 0.2 min, then 10-100% B in 1.0 min, 100% B isocratic for 0.2 min, 100-10% B in 0.05 min, 10% B isocratic for 0.05 min.

[0538] Method 4:

[0539] Spectra were recorded on a Mass Spectrometer from Waters Corporation (SQD, SQDII or QDA Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and negative ions, Capillary: 3.00 kV, Cone: 41 V, Source Temperature: 150° C., Desolvation Temperature: 500° C., Cone Gas Flow: 50 l/h, Desolvation Gas Flow: 1000 l/h, Mass range: 110 to 800 Da and an Acquity UPLC from Waters Corporation: Binary pump, heated column compartment, diode-array detector and ELSD. Column: Waters UPLC HSS T3, 1.8 μm, 30×2.1 mm, Temp: 40° C., DAD Wavelength range (nm): 200 to 400, Runtime: 1.6 min; Solvents: A=water+5% Acetonitrile+0.1% HCOOH, B=Acetonitrile+0.05% HCOOH; Flow (ml/min) 0.6, Gradient: 10-50% B in 0.2 min, then 50-100% B in 0.5 min, 100% B isocratic for 0.6 min, 100-10% B in 0.05 min, 100% to 10% B in 0.1 min, then 10% B isocratic for 0.2 min.

[0540] Method 5:

[0541] Spectra were recorded on a Mass Spectrometer from Agilent Technologies (SQD, SQDII or QDA Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and negative ions, Capillary: 4.00 kV, Fragmentor: 100 V, Gas Temperature (C): 350, Gas Flow: 11 l/min, Mass range: 110 to 1000 Da and an Agilent HPLC from Agilent Technologies: Column: KINETEX EVO C18, 2.6 μm, 50×4.6 mm, Temp: 40° C., DAD Wavelength range (nm): 210 to 400, Runtime: 2.5 min; Solvents: A=water+5% Acetonitrile+0.1% HCOOH, B=Acetonitrile+0.1% HCOOH; Flow (ml/min) 1.8, Gradient: 10-100% B in 0.9 min, 100% B isocratic for 0.9 min, 100-10% B in 0.4 min, 10% B isocratic for 0.3 min.

Example 1: Preparation of N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinolin-4-amine (compound P.5)

[0542] ##STR00084##

Step A: Preparation of 5-[[2,4-bis(trifluoromethyl)anilino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione (intermediate I-1)

[0543] ##STR00085##

[0544] 2,2-dimethyl-1,3-dioxane-4,6-dione (3.46 g, 24 mmol, 1.2 equiv.) and trimethoxymethane (11 mL, 96 mmol, 4.8 equiv.) are heated to reflux for 90 mins. Next, 2,4-bis(trifluoromethyl)aniline (4.72 g, 20 mmol, 1 equiv.) was added at the same temperature and the solution stirred for 50 minutes. Stirring and heating were turned off and a solid started precipitating. The solid was collected at room temperature and washed with cyclohexane and air dried. A second crop of solid can be collected from the filtrate and washed with cyclohexane. The product 1-1 is obtained as an off-white solid (6.27 g, 82%).

[0545] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 1.80 (s, 6H), 7.64 (d, J=8.80 Hz, 1H), 7.96 (d, J=8.44 Hz, 1H), 7.98-8.03 (m, 1H), 8.67 (d, J=13.20 Hz, 1H), 11.87 (br d, J=12.84 Hz, 1H).

Step B: Preparation of 6,8-bis(trifluoromethyl)-1H-quinolin-4-one (intermediate I-2)

[0546] ##STR00086##

[0547] 5-[[2,4-bis(trifluoromethyl)anilino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione (I-1, 3.12 g, 8.14 mmol) is added to diphenyl ether (15 mL) while refluxing. The mixture was stirred at reflux for 30 minutes, then allowed to cool to room temperature. Reaction was diluted with cyclohexane (20 mL), then the precipitate was filtered and washed with copious amounts of cyclohexane. The desired product was obtained as a light-brown powder (1.63 g, 71%).

[0548] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 6.33 (br s, 1H), 7.97 (br s, 1H), 8.33 (s, 1H), 8.66 (br s, 1H), 11.57 (br s, 1H).

[0549] LC-MS (method 3): retention time 0.86 min, m/z 282 [M+H.sup.+].

Step C: Preparation of 4-chloro-6,8-bis(trifluoromethyl)quinoline (intermediate I-3)

[0550] ##STR00087##

[0551] To a flask containing 6,8-bis(trifluoromethyl)-1H-quinolin-4-one (I-3, 2.76 g, 9.81 mmol) was added phosphoryl trichloride (3 mL, 31.5 mmol, 3.21 equiv.) and the mixture was stirred at 100° C. for 15 minutes, then allowed to cool to room temperature, then placed in an ice bath. The reaction was quenched with water and aqueous ammonia is added till the pH reached 8-9. The mixture was then extracted three times with dichloromethane (3×100 mL) and concentrated under reduced pressure to provide desired product as a light brown powder (2.5 g, 8.3 mmol, 85%).

[0552] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 7.75 (d, J=4.77 Hz, 1H), 8.34 (s, 1H), 8.82 (s, 1H), 9.08 (d, J=4.77 Hz, 1H).

[0553] LC-MS (method 3): retention time 1.18 min, m/z 300 [M+H.sup.+].

Step D: Preparation of (2S)-2-[[6,8-bis(trifluoromethyl)-4-quinolyl]amino]propanamide (intermediate I-4)

[0554] ##STR00088##

[0555] To a solution of 4-chloro-6,8-bis(trifluoromethyl)quinoline (I-3, 1.51 g, 5.04 mmol) in N,N-dimethylformamide (50 mL) was added (2S)-2-aminopropanamide hydrochloride (3.24 g, 25.2 mmol, 5.00 equiv.) and potassium carbonate (4.88 g, 35.3 mmol, 7 equiv.). The reaction mixture was heated to 100° C. overnight. The reaction was cooled, diluted with water and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded the desired product as a brown solid (541 mg, 31% yield).

[0556] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 1.49-1.58 (m, 3H), 4.09-4.19 (m, 1H), 6.49-6.55 (m, 1H), 7.13-7.22 (m, 1H), 7.63-7.71 (m, 1H), 7.83-7.90 (m, 1H), 8.17-8.24 (m, 1H), 8.60-8.66 (m, 1H), 9.23-9.29 (m, 1H).

[0557] LC-MS (method 3): retention time 0.75 min, m/z 352 [M+H.sup.+].

Step E: Preparation of (2S)-2-[[6,8-bis(trifluoromethyl)-4-quinolyl]amino]-N-(dimethylaminomethylene)propanamide (compound I-5)

[0558] ##STR00089##

[0559] To a solution of (2S)-2-[[6,8-bis(trifluoromethyl)-4-quinolyl]amino]propanamide (I-4, 0.74 g, 2.1 mmol) in 2-methyltetrahydrofuran (21 mL) was added 1,1-dimethoxy-N,N-dimethyl-methanamine (0.56 mL, 4.2 mmol, 2 equiv.) and the reaction mixture was stirred at 50° C. for 30 minutes. The reaction was cooled and concentrated under reduced pressure to provide (2S)-2-[[6,8-bis(trifluoromethyl)-4-quinolyl]amino]-N-(dimethylaminomethylene)propanamide (I-5) as a brown solid (755 mg, 80%).

[0560] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 1.57 (d, J=6.97 Hz, 3H), 2.98-3.09 (m, 3H), 3.10-3.19 (m, 3H), 4.22-4.37 (m, 1H), 6.45-6.55 (m, 1H), 7.83-7.94 (m, 1H), 8.17-8.25 (m, 1H), 8.43-8.52 (m, 1H), 8.52-8.60 (m, 1H), 9.20-9.31 (m, 1H).

Step F: Preparation of N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinolin-4-amine (compound P.5)

[0561] ##STR00090##

[0562] (2S)-2-[[6,8-bis(trifluoromethyl)-4-quinolyl]amino]-N-(dimethylaminomethylene)propenamide (I-5 prepared above, 755 mg, 1.86 mmol, 1 equiv.) was dissolved in 2-methyltetrahydrofuran (7.4 mL). Next, pyrimidin-2-ylhydrazine hydrochloride (0.49 g, 3.35 mmol) and acetic acid (4.65 mL) were added and the reaction was stirred at 80° C. for 1 hour. The reaction was cooled, diluted with ethyl acetate and extracted with water. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded the desired product (P.5) as a light brown solid (631.5 mg, 75% yield).

[0563] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 1.76 (d, J=6.97 Hz, 3H), 5.96 (quin, J=7.06 Hz, 1H), 6.60 (d, J=5.87 Hz, 1H), 7.51-7.62 (m, 1H), 8.15-8.22 (m, 2H), 8.26 (d, J=7.34 Hz, 1H), 8.55 (d, J=5.50 Hz, 1H), 8.92 (d, J=5.14 Hz, 2H), 9.14 (s, 1H).

[0564] LC-MS (method 3): retention time 0.88 min, m/z 455 [M+H.sup.+].

Example 2: Preparation of N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinazolin-4-amine (compound P.16)

[0565] ##STR00091##

Step A: Preparation of 2-iodo-4,6-bis(trifluoromethyl)aniline (intermediate I-6)

[0566] ##STR00092##

[0567] 2,4-Bis(trifluoromethyl)aniline (CAS No. 367-71-5, 1.50 g, 6.2 mmol) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol and the solution cooled to 0° C. N-iodosuccinimide (1.47 g, 6.2 mmol, 1 equiv.) was added and the reaction stirred at 0° C. for 1 h and then at room temperature overnight. The reaction was concentrated under reduced pressure and the crude material purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to obtain product (I-6) as a light pink crystalline solid (2.09 g, 95%).

[0568] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 5.08 (br s, 2H), 7.70-7.74 (m, 1H), 8.06 (d, J=1.47 Hz, 1H).

Step B: Preparation of 2-amino-3,5-bis(trifluoromethyl)benzonitrile (intermediate I-7)

[0569] ##STR00093##

[0570] A sealed tube was charged with 2-iodo-4,6-bis(trifluoromethyl)aniline (I-6, 1.00 g, 2.82 mmol), N,N-dimethylformamide (5.63 mL) and copper(I) cyanide (0.31 g, 3.38 mmol, 1.2 equiv.). The mixture was stirred at 100° C. overnight. The mixture was cooled, filtered through celite and extracted twice with MTBE (2×20 mL). The combined organic layers were washed with brine, dried over sodium sulfate and concentrated under vacuum. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded the desired product (I-7) as a brown solid (567 mg, 79%).

[0571] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 5.33 (br s, 2H), 7.83-7.90 (m, 2H).

[0572] .sup.19F NMR (377 MHz, CDCl.sub.3) δ ppm: −63.94 (s, 1 F), −62.19 (s, 1 F).

[0573] LC-MS (method 3): retention time 1.01 min, m/z 253 [M−H.sup.−].

Step C: Preparation of 6,8-bis(trifluoromethyl)quinazolin-4-ol (intermediate I-8)

[0574] ##STR00094##

[0575] A flask was charged with 2-amino-3,5-bis(trifluoromethyl)benzonitrile (I-7, 8.8 g, 35 mmol), formic acid (83 mL) and sulfuric acid (2.8 mL, 52 mmol, 1.5 equiv.) and the mixture was stirred at 50° C. for 3 hours. The reaction was then cooled to room temperature and poured slowly in 300 mL of ice-water and stirred for 15 minutes. Resulting solid was filtered off and dried, resulting in desired product (I-8) as an off-white solid (8.9 g, 91%).

[0576] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: .sup.1H NMR (400 MHz, Solvent) δ ppm 8.31-8.47 (m, 2H), 8.61 (s, 1H), 12.97 (br s, 1H).

[0577] LC-MS (method 3): retention time 0.90 min, m/z 283 [M+H.sup.+].

Step D: Preparation of 4-chloro-6,8-bis(trifluoromethyl)quinazoline (intermediate I-9)

[0578] ##STR00095##

[0579] To a solution of 6,8-bis(trifluoromethyl)quinazolin-4-ol (I-8, 0.5 g, 5.04 mmol) in thionyl chloride (8.87 mL) was added 5 drops of N,N-dimethylformamide. The reaction mixture was heated to 100° C. for 1 hour, at which point the reaction became homogeneous. The reaction was cooled and concentrated under reduced pressure to afford the desired product (I-9) which was used as such for the next step.

[0580] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 8.50 (s, 1H), 8.84 (s, 1H), 9.33 (s, 1H).

[0581] .sup.19F NMR (377 MHz, CDCl.sub.3) δ ppm: −62.86 (s, 1 F), −60.78 (s, 1 F).

[0582] LC-MS (method 3): retention time 0.75 min, m/z 352 [M+H.sup.+].

Step E: Preparation of N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinazolin-4-amine (compound P.16)

[0583] ##STR00096##

[0584] A flask was charged with 4-chloro-6,8-bis(trifluoromethyl)quinazoline (I-9, 200 mg, 0.67 mmol), 1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethylammonium chloride (prepared as in WO2019/197468) (201 mg, 0.80 mmol, 1.2 equiv), potassium carbonate (276 mg, 2.0 mmol, 3 equiv.) and acetonitrile (3 mL) and heated at 80° C. for 4 hours. The reaction was cooled, salts were removed by filtration and the resulting crude was concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) provided the desired product (P.16) as a beige solid (120 mg, 40%).

[0585] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 1.85 (d, J=6.97 Hz, 3H), 6.71 (quin, J=6.97 Hz, 1H), 7.49 (t, J=4.77 Hz, 1H), 8.14 (s, 1H), 8.16 (s, 1H), 8.27 (br d, J=4.03 Hz, 1H), 8.38 (s, 1H), 8.68 (s, 1H), 9.01 (d, J=4.77 Hz, 2H).

[0586] LC-MS (method 3): retention time 0.97 min, m/z 455 [M+H.sup.+].

Example 3: Preparation of 2-chloro-N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinazolin-4-amine (compound P.25)

[0587] ##STR00097##

Step A: Preparation of 6,8-bis(trifluoromethyl)quinazoline-2,4-diol (intermediate I-10)

[0588] ##STR00098##

[0589] A flask was charged with 2-amino-3,5-bis(trifluoromethyl)benzonitrile (I-7 prepared in Example 2, 2 g, 7.87 mmol) and dichloromethane (20 mL). To this mixture was added chlorosulfonyl isocyanate (0.85 mL, 9.44 mmol, 1.2 equiv.) and the resulting mixture was stirred for 3 hours. The reaction was concentrated under reduced pressure and the residue heated in water (50 mL) at 100° C. for 18 hours. The resulting white solid was isolated by filtration to provide the desired product (I-10) (800 mg, 34%).

[0590] .sup.1H NMR (400 MHz, CD.sub.3CN) δ ppm: 8.20-8.23 (m, 1H), 8.50 (s, 1H), 8.73 (br s, 1H), 9.51 (br s, 1H).

Step B: Preparation of 2,4-dichloro-6,8-bis(trifluoromethyl)quinazoline (intermediate I-11)

[0591] ##STR00099##

[0592] A flask was charged with 6,8-bis(trifluoromethyl)quinazoline-2,4-diol (I-10, 100 mg, 0.34 mmol) and phosphorous oxychloride (0.32 mL, 3.4 mmol, 10 equiv.). To this mixture was then added N,N-diisopropylethylamine (0.118 mL, 0.67 mmol, 2 equiv.) and the resulting mixture was heated at 100° C. for 2 hours. The reaction was concentrated under reduced pressure and the crude material was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to provide the desired product (I-11) as an off-white solid (84 mg, 75%).

[0593] .sup.1H NMR (400 MHz, CD3CN) δ ppm: 8.66 (s, 1H), 8.90 (s, 1H).

Step C: Preparation of 2-chloro-N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinazolin-4-amine (compound P.25)

[0594] ##STR00100##

[0595] A flask was charged with 2,4-dichloro-6,8-bis(trifluoromethyl)quinazoline (I-11, 100 mg, 0.30 mmol), 1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethylammonium chloride (prepared as in WO2019/197468) (68 mg, 0.27 mmol, 0.9 equiv), potassium carbonate (123 mg, 0.90 mmol, 3 equiv.) and acetonitrile (1.5 mL) and heated at 80° C. for 16 hours. The reaction was cooled, diluted with water and extracted two times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded the desired product (P.25) as a pale yellow solid (60 mg, 41% yield).

[0596] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 1.79 (d, J=6.72 Hz, 3H) 6.38 (t, J=6.72 Hz, 1H) 7.65 (t, J=4.65 Hz, 1H) 8.18 (s, 1H) 8.37 (br s, 1H) 8.99 (d, J=4.65 Hz, 2H) 9.24 (br s, 1H) 9.90 (br d, J=6.36 Hz, 1H).

[0597] LC-MS (method 4): retention time 1.09 min, m/z 489 [M+H.sup.+].

Example 4: Preparation of N-methyl-N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinazolin-4-amine (compound P.27)

[0598] ##STR00101##

[0599] A flask was charged with N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinazolin-4-amine (P.16 prepared in Example 2, 148 mg, 0.33 mmol), cesium carbonate (319 mg, 0.98 mmol, 3 equiv.), acetonitrile (1.3 mL) and iodomethane (0.041 mL, 0.65 mmol, 2 equiv.). The mixture was heated at 50° C. overnight. The reaction was cooled and diluted with water (10 mL). The mixture was extracted three times with ethyl acetate (3×10 mL) and the combined organic layers were washed with brine, dried over sodium sulfate and concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) provided the desired product (P.27) (92 mg, 60%).

[0600] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 1.98 (d, J=6.97 Hz, 3H), 3.37 (s, 3H), 6.89 (q, J=6.97 Hz, 1H), 7.23 (t, J=4.95 Hz, 1H), 8.11 (s, 1H), 8.24 (d, J=6.60 Hz, 2H), 8.57 (d, J=4.77 Hz, 2H), 8.60 (s, 1H).

[0601] LC-MS (method 3): retention time 0.97 min, m/z 455 [M+H.sup.+].

[0602] .sup.19F NMR (376 MHz, CDCl.sub.3) δ ppm: −62.40 (s, 1 F), −61.33 (s, 1 F).

[0603] LC-MS (method 3): retention time 1.01 min, m/z 469 [M+H.sup.+].

Example 5: 8-chloro-N-(cyclopropylmethyl)-2-methoxy-N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6-(trifluoromethyl)quinazolin-4-amine (compound P.36)

[0604] ##STR00102##

Step A: Preparation of 8-chloro-4-[cyclopropylmethyl-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]amino]-6-(trifluoromethyl)-1H-quinazolin-2-one (intermediate I-12)

[0605] ##STR00103##

[0606] A flask was charged with 2,8-dichloro-N-(cyclopropylmethyl)-N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6-(trifluoromethyl)quinazolin-4-amine (P.49 prepared analogously to P.25 in Example 3, 180 mg, 0.35 mmol) and acetic acid (1.8 mL). This mixture was stirred for 2 hours at 80° C. The reaction was concentrated under reduced pressure and the residue purified by reverse-phase chromatography (acetonitrile in water) to provide the desired product (I-12) (90 mg, 52%).

[0607] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 0.02-0.07 (m, 1H), 0.09-0.16 (m, 1H), 0.25-0.32 (m, 1H), 0.35-0.41 (m, 1H), 0.77-0.85 (m, 1H), 1.87 (d, 3H), 3.06 (dd, 1H), 3.36 (dd, 1H), 6.40-6.46 (m, 1H), 7.38 (t, 1H), 7.69 (s, 1H), 8.19 (s, 1H), 8.25 (s, 1H), 8.54 (d, 2H), 10.84-10.92 (m, 1H).

Step B: Preparation of 8-chloro-N-(cyclopropylmethyl)-2-methoxy-N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6-(trifluoromethyl)quinazolin-4-amine (compound P.36)

[0608] ##STR00104##

[0609] 8-Chloro-4-[cyclopropylmethyl-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]amino]-6-(trifluoromethyl)-1H-quinazolin-2-one (I-12, 35 mg, 0.07 mmol) was dissolved in acetonitrile (0.53 mL) and potassium carbonate (30 mg, 0.21 mmol, 3 equiv.), followed by dimethyl sulfate (7.5 μL, 0.08 mmol, 1.1 equiv) were added. The resulting mixture was heated at 80° C. for 5 hours. The reaction was cooled and filtered through celite with acetonitrile washes. The filtrate was concentrated under reduced pressure and the crude material was purified by reverse-phase chromatography (acetonitrile in water) to provide the desired product (P.36) (90 mg, 52%).

[0610] .sup.1H NMR (400 MHz, methanol-d4) δ ppm: 0.23 (qd, 1H), 0.31-0.06 (m, 1H), 0.55-0.39 (m, 2H), 0.94-0.83 (m, 1H), 2.02 (d, 3H), 3.36 (dd, 1H), 3.56 (dd, 1H), 3.97 (s, 3H), 6.78 (q, 1H), 7.29 (t, 1H), 8.08 (d, 1H), 8.18 (s, 1H), 8.21 (d, 1H), 8.42 (d, 2H).

[0611] LC-MS (method 4): retention time 1.17 min, m/z 505 [M+H.sup.+].

Example 6: Preparation of 6,8-dibromo-N-[1-(3-pyrimidin-2-ylpyrazin-2-yl)ethyl]quinazolin-4-amine (compound P.38)

[0612] ##STR00105##

Step A: Preparation of N′-(2,4-dibromo-6-cyano-phenyl)-N,N-dimethyl-formamidine (intermediate I-13)

[0613] ##STR00106##

[0614] To a solution of 2-amino-3,5-dibromobenzonitrile (CAS No. 68385-95-5, 150 mg, 0.54 mmol) in methanol (5 mL) was added 1,1-dimethoxy-N,N-dimethyl-methanamine (0.228 mL, 1.63 mmol, 3 equiv.) and the reaction was stirred at 80° C. for 1 hour. The mixture was concentrated under reduced pressure to obtain product (I-13) as a solid (179 mg, 99.5%) which was used directly in the next step.

[0615] LC-MS (method 3): retention time 1.17 min, m/z 505 [M+H.sup.+].

Step B: Preparation of 1-(3-pyrimidin-2-ylpyrazin-2-yl)ethanone (intermediate I-14)

[0616] ##STR00107##

[0617] A flask was charged with tributyl(pyrimidin-2-yl)stannane (CAS No. 153435-63-3, 25 g, 67.7 mmol, 1 equiv.), 1-(3-chloropyrazin-2-yl)ethanone (CAS No. 2142-68-9, 12.37 g, 71.12 mmol, 1.05 equiv.) and toluene (500 mL). Reaction mixture was purged with nitrogen for 10 minutes and then copper(I) iodide (2.58 g, 13.55 mmol, 0.2 equiv.) and tetrakis(triphenylphosphine)palladium(0) (3.91 g, 3.39 mmol, 0.05 equiv.) were added. The reaction was then heated at 95° C. for 5 hours. The mixture was cooled, filtered through a pad of celite with ethyl acetate washings and the filtrate was concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded product (I-14) as a brown solid (10 g, 51.6%).

[0618] LC-MS (method 4): retention time 0.37 min, m/z 201 [M+H.sup.+].

Step C: Preparation of 1-(3-pyrimidin-2-ylpyrazin-2-yl)ethanamine (intermediate I-15)

[0619] ##STR00108##

[0620] A flask was charged with 1-(3-pyrimidin-2-ylpyrazin-2-yl)ethanone (I-14, 500 mg, 2.5 mmol, 1 equiv.), ammonium acetate (3.85 g, 50.0 mmol, 20 equiv.) and ethanol (25 mL). Next aq. NH.sub.3 (28%) (7.5 mL) and sodium cyanoborohydride (0.50 g, 7.5 mmol, 3 equiv.) were added and the mixture was heated at 80° C. for 2 hours. The mixture was cooled and concentrated under reduced pressure. Purification of the crude material by reverse-phase column chromatography (C18 40-60 μm, acetonitrile in water) afforded product (I-15) as a brown gum (210 mg, 42%).

[0621] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 1.50 (d, J=6.6 Hz, 3H), 4.93 (d, J=6.6 Hz, 1H), 7.70 (t, J=5.0 Hz, 1H), 8.86 (d, J=2.3 Hz, 1H), 8.90 (d, J=2.4 Hz, 1H), 9.07 (d, J=4.9 Hz, 2H).

Step D: Preparation of 6,8-dibromo-N-[1-(3-pyrimidin-2-ylpyrazin-2-yl)ethyl]quinazolin-4-amine (compound P.38)

[0622] ##STR00109##

[0623] A vial was charged with 1-(3-pyrimidin-2-ylpyrazin-2-yl)ethanone (I-15, 120 mg, 0.59 mmol, 1.1 equiv.), N′-(2,4-dibromo-6-cyano-phenyl)-N,N-dimethyl-formamidine (I-13, 179 mg, 0.54 mmol, 1 equiv.) and acetic acid (2.7 mL). The mixture was stirred at 120° C. for 1 hour. Another batch of 1-(3-pyrimidin-2-ylpyrazin-2-yl)ethanone (I-15, 135 mg) was added and the stirring continued till reaction completion. The mixture was cooled, diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate aqueous solution, dried over sodium sulfate and concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane), followed by reverse-phase purification (acetonitrile in water) afforded the desired product (I-7) as a brown solid (83 mg, 32%).

[0624] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 1.71 (d, J=6.97 Hz, 3H), 5.92 (quin, J=6.79 Hz, 1H), 7.53 (t, J=4.77 Hz, 1H), 8.15 (s, 1H), 8.28 (d, J=1.83 Hz, 1H), 8.65 (d, J=1.83 Hz, 1H), 8.66 (d, J=2.57 Hz, 1H), 8.74 (d, J=2.20 Hz, 1H), 8.77 (d, J=6.97 Hz, 1H), 8.92 (d, J=5.14 Hz, 2H).

[0625] LC-MS (method 3): retention time 0.87 min, m/z 488 [M+H.sup.+].

Example 7: Preparation of 6-[5-[1-[[2-methyl-6,8-bis(trifluoromethyl)quinazolin-4-yl]amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (compound P.60)

[0626] ##STR00110##

Step A: Preparation of 2-methyl-6,8-bis(trifluoromethyl)quinazolin-4-amine (intermediate I-16)

[0627] ##STR00111##

[0628] A sealed tube was charged with 2-amino-3,5-bis(trifluoromethyl)benzonitrile (I-7 prepared in Example 2, 300 mg, 1.18 mmol) and acetamide (0.7 g, 11.8 mmol, 10 equiv.). The mixture was stirred at 180° C. for 4 days. The reaction was then cooled to room temperature and diluted with water (25 mL). The mixture was extracted three times with ethyl acetate (3×20 mL) and the combined organic layers were washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude material was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to provide desired product (I-16) as a pale yellow solid (102 mg, 29%).

[0629] .sup.19F NMR (377 MHz, DMSO-d6) δ ppm: −60.36 (s, 1 F), −59.63 (s, 1 F).

[0630] LC-MS (method 3): retention time 0.95 min, m/z 296 [M+H.sup.+].

Step B: Preparation of 6-[5-(1-bromoethyl)-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (intermediate I-18)

[0631] ##STR00112##

[0632] To a solution of 2-Bromopropanamide (CAS No. 5875-25-2, 4.00 g, 26.3 mmol, 1 equiv.) in dichloromethane was added N,N-Dimethylformamide dimethyl acetal (CAS No. 4637-24-5, 5.58 mL. 39.5 mmol, 1.5 equiv.). The mixture was heated to reflux for 30 minutes. The reaction was then cooled to room temperature and concentrated under reduced pressure to provide crude desired product 2-bromo-N-(dimethylaminomethylene)propanamide (I-17) as a yellow oil (5.6 g, 98%) which was used as such in the next step.

[0633] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 1.85 (d, J=6.97 Hz, 3H), 3.14 (d, J=0.73 Hz, 3H), 3.17 (s, 3H), 4.55 (q, J=6.85 Hz, 1H), 8.49 (s, 1H).

[0634] To a solution of 2-bromo-N-(dimethylaminomethylene)propenamide (I-17, 5.40 g, 24 mmol, 1 equiv.) in 1,4-dioxane (54 mL) was added 5-cyano-2-hydrazinopyridine (CAS No. 104408-24-4, 4.68 g, 25.2 mmol, 1.05 equiv.). Next, acetic acid (54 mL) was added slowly. The resulting red solution was heated to 80° C. for 1 hour. The reaction was cooled and concentrated under reduced pressure. The mixture was then taken up in ethyl acetate and washed with a saturated aqueous sodium bicarbonate solution and water. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded the desired product (I-18) as a white solid (3.1 g, 46%).

[0635] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 2.26 (d, J=6.97 Hz, 3H), 6.43 (q, J=6.97 Hz, 1H), 8.05 (s, 1H), 8.14-8.20 (m, 2H), 8.85 (dd, J=1.83, 1.10 Hz, 1H).

[0636] LC-MS (method 3): retention time 0.88 min, m/z 278-280 (Br pattern) [M+H.sup.+].

Step C: Preparation of 6-[5-[1-[[2-methyl-6,8-bis(trifluoromethyl)quinazolin-4-yl]amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (compound P.60)

[0637] ##STR00113##

[0638] A sealed tube was charged with 2-methyl-6,8-bis(trifluoromethyl)quinazolin-4-amine (I-16, 106 mg, 0.36 mmol), acetonitrile (1.43 mL), cesium carbonate (351 mg, 1.08 mmol, 3 equiv.) and 6-[5-(1-bromoethyl)-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-18, 110 mg, 0.40 mmol, 1.1 equiv.) and the reaction mixture was heated to 50° C. for 3 h. The reaction was cooled, diluted with water (60 mL) and extracted three times with ethyl acetate (3×60 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded the desired product as a yellow solid (134 mg, 76% yield).

[0639] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 1.49-1.58 (m, 3H), 4.09-4.19 (m, 1H), 6.49-6.55 (m, 1H), 7.13-7.22 (m, 1H), 7.63-7.71 (m, 1H), 7.83-7.90 (m, 1H), 8.17-8.24 (m, 1H), 8.60-8.66 (m, 1H), 9.23-9.29 (m, 1H).

[0640] LC-MS (method 3): retention time 1.16 min, m/z 494 [M+H.sup.+].

Example 8: Preparation of 6,8-dichloro-N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]quinolin-4-amine (compound P.67)

[0641] ##STR00114##

[0642] To a solution of 6,8-dichloroquinolin-4-amine (100 mg, 0.469 mmol) in N,N-dimethylformamide (0.94 mL) was added portionwise at room temperature sodium hydride (20.7 mg, 0.516 mmol, 1.10 equiv.). The reaction mixture was kept stirring at this temperature for 10 minutes. A solution of 2-[5-(1-bromoethyl)-1,2,4-triazol-1-yl]pyrimidine (intermediate I-20 prepared as described before, 125 mg, 0.493 mmol, 1.05 equiv.) in N,N-dimethylformamide (0.94 mL) was then added dropwise to the reaction mixture and it was stirred at room temperature for 1 hour. It was poured into water and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (ethyl acetate in cyclohexane, then methanol in dichloromethane) afforded the desired product as a pale orange solid (39 mg, 0.10 mmol).

[0643] .sup.1H NMR (400 MHz, chloroform-d) δ ppm: 1.75-1.84 (m, 3H) 6.08-6.20 (m, 1H) 6.28-6.37 (m, 1H) 6.51-6.58 (m, 1H) 7.45-7.51 (m, 1H) 7.75-7.86 (m, 2H) 8.17-8.12 (m, 1H) 8.60-8.66 (m, 1H) 8.94-9.02 (m, 2H).

[0644] LC-MS (method 1): retention time 0.63 min, m/z 386-390 [M+H.sup.+] (dichloro pattern).

Example 9: Preparation of 6,8-dichloro-N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]quinazolin-4-amine (compound P.68)

[0645] ##STR00115##

Step A: Preparation of 2-[5-(1-bromoethyl)-1,2,4-triazol-1-yl]pyrimidine (intermediate I-20)

[0646] ##STR00116##

[0647] To a solution of 2-bromopropanamide (CAS 5875-25-2, 1.50 g, 9.38 mmol) in dichloromethane (37.5 mL) was added at room temperature 1,1-dimethoxy-N,N-dimethyl-methanamine (CAS 4637-24-5, 2.49 mL, 18.8 mmol, 2.00 equiv.). The reaction mixture was heated up to 40° C. and stirred for 2.5 hours. After cooling down to room temperature, the reaction mixture was concentrated under reduced pressure to afford quantitatively crude intermediate (I-19).

[0648] LC-MS (method 1): retention time 0.26 min, m/z 207-209 [M+H.sup.+] (Br pattern).

[0649] A mixture of intermediate I-1 (1.94 g, 9.38 mmol), acetic acid (28.1 mL) and pyrimidin-2-ylhydrazine (1.24 g, 11.3 mmol, 1.20 equiv.) was heated up to 65° C. and stirred for 2 hours. After cooling down to room temperature, the reaction mixture was concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded the desired product (I-20) as a pale yellow solid (1.70 g, 6.69 mmol).

[0650] .sup.1H NMR (400 MHz, chloroform-d) δ ppm: 2.20-2.31 (m, 3H) 6.34-6.48 (m, 1H) 7.37-7.45 (m, 1H) 8.05-8.15 (m, 1H) 8.88-8.95 (m, 2H).

[0651] LC-MS (method 1): retention time 0.66 min, m/z 254-256 [M+H.sup.+] (Br pattern).

Step B: Preparation of 6,8-dichloro-N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]quinazolin-4-amine (compound P.68)

[0652] ##STR00117##

[0653] To a solution of 6,8-dichloroquinazolin-4-amine (400 mg, 1.87 mmol) in acetonitrile (7.47 mL) were added at room temperature cesium carbonate (1.83 g, 5.61 mmol, 3.00 equiv.) and 2-[5-(1-bromoethyl)-1,2,4-triazol-1-yl]pyrimidine (intermediate I-20 prepared as described before, 522 mg, 2.06 mmol, 1.10 equiv.). The reaction mixture was heated up to 50° C. and stirred overnight. After cooling down to room temperature, the reaction mixture was diluted with water and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded the desired product as a yellow solid (351 mg, 0.907 mmol).

[0654] LC-MS (method 1): retention time 0.81 min, m/z 387-391 [M+H.sup.+] (dichloro pattern).

Example 10: Preparation of N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-5,7-bis(trifluoromethyl)isoquinolin-1-amine (compound P.83)

[0655] ##STR00118##

Step A: Preparation of 2-iodo-3,5-bis(trifluoromethyl)benzonitrile (intermediate I-21)

[0656] ##STR00119##

[0657] 2-Amino-3,5-bis(trifluoromethyl)benzonitrile (I-7, prepared as in Example 2, 2.19 g, 8.62 mmol, 1 equiv.) was dissolved in diiodomethane (6.9 mL) and acetonitrile (13.8 mL). Isoamylnitrite (2.3 mL, 16.4 mmol, 1.9 equiv.) was then added under an argon atmosphere. The reaction was stirred at 50° C. for 60 minutes, then at 80° C. for another 60 minutes. The reaction was concentrated under reduced pressure and diluted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a crude mixture of oil and solid. The oil was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) and the resulting solid combined with the crude solid material to afford desired product (I-21) (2.2 g, 70%).

[0658] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 7.99-8.02 (m, 1H), 8.03-8.07 (m, 1H).

Step B: Preparation of 3,5-bis(trifluoromethyl)-2-(2-trimethylsilylethynyl)benzaldehyde (intermediate I-23)

[0659] ##STR00120##

[0660] 2-iodo-3,5-bis(trifluoromethyl)benzonitrile (I-21 prepared above, 3.52 g, 9.64 mmol, 1 equiv.) was dissolved in toluene (72 mL) and the solution cooled to −78° C. and stirred for 90 minutes. The reaction was warmed to room temperature and quenched by the slow addition of aqueous hydrochloric solution (1 M, 50 mL). The mixture was extracted with ethyl acetate (50 mL) and the combined organic layers were washed with brine, dried over sodium sulfate and concentrated under reduced pressure to afford crude 2-iodo-3,5-bis(trifluoromethyl)benzaldehyde (1-22) which was used as such for the next step. 2-iodo-3,5-bis(trifluoromethyl)benzaldehyde (1-22 prepared above, 3.5 g, 9.51 mmol, 1 equiv.) was dissolved in triethylamine (47.5 mL) under an Ar atmosphere. Next, copper(I) iodide (0.073 g, 0.38 mmol, 0.04 equiv.), bis(triphenylphosphine)palladium(II) dichloride (0.135 g, 0.19 mmol, 0.02 equiv.) and trimethylsilylacetylene (3.39 mL, 23.8 mmol, 2.5 mmol) were added successively and the mixture was stirred at 80° C. After 17 hours, the reaction was cooled, concentrated under reduced pressure and the material was dissolved in ethyl acetate. The organic layer was washed twice with dilute aqueous hydrochloric solution (2×20 mL), brine and then filtered and concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded desired product (I-23) (1.076 g, 33%).

[0661] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 6.33 (br s, 1H), 7.97 (br s, 1H), 8.33 (s, 1H), 8.66 (br s, 1H), 11.57 (br s, 1H).

[0662] LC-MS (method 3): retention time 1.34 min, m/z 339 [M+H.sup.+].

Step C: Preparation of 5,7-bis(trifluoromethyl)isoquinoline (intermediate I-24)

[0663] ##STR00121##

[0664] 3,5-bis(trifluoromethyl)-2-(2-trimethylsilylethynyl)benzaldehyde (1-23 prepared above, 1.075 g, 3.18 mmol, 1 equiv.) was weighed in a microwave tube and ammonia solution (7M in methanol, 10 mL) was added. The tube was capped and irradiated in a microwave reactor for 15 minutes at 130° C. The solvent was then removed under reduced pressure to afford desired product (I-24) (820 mg, 97%).

[0665] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 7.99-8.10 (m, 1H), 8.26 (s, 1H), 8.53 (s, 1H), 8.85 (d, J=6.24 Hz, 1H), 9.50 (s, 1H).

[0666] LC-MS (method 3): retention time 1.05 min, m/z 266 [M+H.sup.+].

Step D: Preparation of 2-oxido-5,7-bis(trifluoromethyl)isoquinolin-2-ium (intermediate I-25)

[0667] ##STR00122##

[0668] 5,7-bis(trifluoromethyl)isoquinoline (I-24 prepared above, 875 mg, 3.3 mmol, 1 equiv.) was taken in acetic acid (5.5 mL) and H.sub.2O.sub.2 (35 wt %) (0.85 mL, 9.9 mmol, 3 equiv.) was added. The mixture was then heated to 70° C. After 17 hours, the reaction was cooled and diluted with ethyl acetate and water and NaOH (4M) was added until pH 12 was reached. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to afford desired product (I-25) (1.040 g, quantitative).

[0669] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: .sup.1H NMR (400 MHz, Solvent) δ ppm 8.05 (brd, J=7.34 Hz, 1H), 8.08 (s, 1H), 8.20 (s, 1H), 8.36 (dd, J=7.52, 1.65 Hz, 1H), 8.90 (s, 1H).

[0670] LC-MS (method 3): retention time 0.85 min. m/z 282 [M+H.sup.+].

Step E: Preparation of N-[1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-5,7-bis(trifluoromethyl)isoquinolin-1-amine (compound P.83)

[0671] ##STR00123##

[0672] To a flask containing 2-oxido-5,7-bis(trifluoromethyl)isoquinolin-2-ium (I-25 prepared above, 50 mg, 0.18 mmol. 1 equiv.) and 1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethanamine hydrochloride (prepared analog to WO2019/197468 page 128, 80.6 mg, 0.356 mmol, 2 equiv.) dissolved in dichloromethane (0.89 mL) was added N,N-diisopropylethylamine (0.155 mL, 0.89 mmol, 5 equiv.) and bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP®, 211 mg, 0.44 mmol, 2.5 equiv.) and the reaction stirred at room temperature. After 4 hours, more N,N-diisopropylethylamine (0.155 mL, 0.89 mmol, 5 equiv.) and bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP®, 211 mg, 0.44 mmol, 2.5 equiv.) were added. After 17 hours, the reaction was filtered and the crude purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to provide desired product P.38 (30 mg, 37%).

[0673] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 1.84 (d, J=6.60 Hz, 3H), 6.15-6.97 (m, 1H), 6.56 (quin, J=7.06 Hz, 1H), 7.04 (dd, J=5.69, 2.02 Hz, 1H), 7.44 (t, J=4.77 Hz, 1H), 7.63 (br d, J=7.34 Hz, 1H), 7.92 (d, J=6.24 Hz, 1H), 7.94 (br s, 1H), 8.10 (s, 1H), 8.41 (s, 1H), 8.98 (d, J=4.77 Hz, 2H).

[0674] .sup.19F NMR (377 MHz, CDCl.sub.3) δ ppm: −62.15 (s, 1 F), −61.08 (s, 1 F).

[0675] LC-MS (method 3): retention time 1.08 min, m/z 454 [M+H.sup.+].

Example 11: Preparation of 6-[5-[(1R)-1-[[6,8-bis(trifluoromethyl)cinnolin-4-yl]amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (compound P. 135)

Step A: Preparation of 6,8-bis(trifluoromethyl)cinnoline-4-ol (I-26)

[0676] ##STR00124##

[0677] 1-[2-amino-3,5-bis(trifluoromethyl)phenyl]ethanone (CAS-No.: 1805121-99-6, 1.25 g, 4.61 mmol, 1 eq) was dissolved in glacial acetic acid (18.4 ml) and Sulfuric acid 70% (0.92 ml, 12.1 mmol, 2.63 eq). The solution was cooled to 22° C. and a ice cold solution of sodium nitrite (389 mg, 5.53 mmol, 1.2 eq) in water (3.55 ml) was added dropwise under cooling. After 45 min Triethylamine (1.81 ml, 12.91 mmol, 2.8 eq) was added and the reaction was stirred at room temperature for 17 h. It was poured on 100 ml ice water and it was extracted with Ethylacetate (2×60 ml). The combined organic layer was washed saturated Na.sub.2CO.sub.3-solution and brine, it was dried over anhydrous MgSO.sub.4 and concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded desired product (I-26) (907 mg, 63%).

[0678] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 10.32 (br s, 1H) 8.79 (s, 1H) 8.21 (s, 1H) 7.99 (s, 1H).

[0679] .sup.19F NMR (377 MHz, CDCl.sub.3) δ ppm: −60.61 (s, 3F) −62.65 (s, 3F).

[0680] LC-MS (method 3) retention time 0.88 min m/z 283 [M+H.sup.+].

Step B: Preparation of 4-chloro-6,8-bis(trifluoromethyl)cinnoline (I-27)

[0681] ##STR00125##

[0682] 6,8-bis(trifluoromethyl)cinnolin-4-ol (I-26, 840 mg, 2.98 mmol, 1 eq) was suspended in Toluene (5.95 ml) and Phosphoryl trichloride (0.31 ml, 3.28 mmol, 1.1 eq) was added. The mixture was heated to 50° C. for 17 h. The reaction was quenched with sat. Ammonium chloride solution and diluted with Ethylacetate. The pH was adjusted with aqueous Ammonia to 10-12. The organic layer was washed five times with brine. It was dried over anhydrous MgSO.sub.4 and concentrated under reduced pressure to give (1-27) (1.04 g, 93% yield, 80% purity).

[0683] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 9.67 (s, 1H) 8.78 (s, 1H) 8.43 (s, 1H).

[0684] .sup.19F NMR (377 MHz, CDCl.sub.3) δ ppm: −59.6 (s, 3F) −63.4 (s, 3F).

[0685] LC-MS (method 3) retention time 1.11 min m/z 301 [M+H.sup.+].

Step C: Preparation of (2S)-2-[[6,8-bis(trifluoromethyl)cinnoline-4-yl]amino]propenamide (I-28)

[0686] ##STR00126##

[0687] 4-chloro-6,8-bis(trifluoromethyl)cinnoline (I-27, 1.04 g, 3.46 mmol, 1 eq), Potassium carbonate (2.39 g, 17.3 mmol, 5 eq) and (2S)-2-aminopropanamide;hydrochloride (2.22 g, 17.3 mmol, 5 eq) were heated to 50° C. in NMP (13.8 ml) for 60 h. The reaction mixture was diluted with water (100 ml) and Ethyl acetate (100 ml). The organic layer was washed with water (30 ml), brine (30 ml), dried with anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure to yield (I-28) (1.57 g, 73%)

[0688] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 9.35 (s, 1H) 8.78 (s, 1H) 8.38-8.19 (m, 2H) 7.76 (s, 1H) 7.29 (s, 1H) 4.41 (quin, J=7.0 Hz, 1H) 1.56 (d, J=7.0 Hz, 3H)

[0689] .sup.19F NMR (377 MHz, DMSO-d6) δ ppm: −58.9 (s, 3F) −60.9 (s, 3F) LC-MS (method 3): retention time 0.86 min, m/z 353 [M+H.sup.+].

Step D: Preparation of (NE,2S)-2-[[6,8-bis(trifluoromethyl)cinnolin-4-yl]amino]-N-(dimethylaminomethylene)propenamide (I-29)

[0690] ##STR00127##

[0691] (2S)-2-[[6,8-bis(trifluoromethyl)cinnolin-4-yl]amino]propenamide (I-28, 500 mg, 1.42 mmol, 1 eq) was mixed with 2-Methyltetrahydrofuran (14.2 ml) and DMF-DMA (377 μl, 2.84 mmol, 2 eq) and heated to 50° C. for 30 min. The reaction mixture was evaporated under reduced pressure to yield (I-29) (642 mg, 99%).

[0692] LC-MS (method 3): retention time 0.92 min, m/z 408 [M+H.sup.+].

Step E: Preparation of 6-[5-[(1R)-1-[[6,8-bis(trifluoromethyl)cinnolin-4-yl]amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (compound P. 135)

[0693] ##STR00128##

[0694] (NE,2S)-2-[[6,8-bis(trifluoromethyl)cinnolin-4-yl]amino]-N-(dimethylaminomethylene)propenamide (I 29, 306 mg, 0.75 mmol, 1 eq) was dissolved in 2-Methyltetrahydrofuran (3 ml). 6-Hydrazinylnicotinonitrile (191 mg, 1.35 mmol, 1.8 eq) and acetic acid (1.88 ml) were added. The mixture was heated to 70° C. for 1 h. It was cooled to 25° C. and it was diluted with Ethylacetat (30 ml). It washed with water, saturated Na.sub.2CO.sub.3-solution and brine, it was dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane), followed by reverse-phase purification (acetonitrile in water) afforded the desired product (P. 135) (87 mg, 24%).

[0695] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 9.03-8.99 (m, 2H) 8.94 (br s, 1H) 8.30 (s, 1H), 8.27-8.23 (m, 2H) 8.06 (s, 1H) 6.44 (q, J=6.6 Hz, 1H) 1.95 (d, J=6.6 Hz, 3H).

[0696] .sup.19F NMR (377 MHz, CDCl.sub.3) δ ppm: −60.14 (s, 3F) −62.78 (s, 3F).

[0697] LC-MS (method 3): retention time 1.01 min, m/z 480 [M+H.sup.+].

Example 12: Preparation of 4-[[(1S)-1-[2-(5-cyano-2-pyridyl)-1,2,4-triazol-3-yl]ethyl]amino]-6,8-bis(trifluoromethyl)quinoline-3-carbonitrile (compound P.139)

[0698] ##STR00129##

Step A: Preparation of Ethyl (Z)-3-[2,4-bis(trifluoromethyl)anilino]-2-cyano-prop-2-enoate (compound I-30)

[0699] ##STR00130##

[0700] A mixture of Ethyl (ethoxymethylene)cyanoacetate (1.46 g, 8.47 mmol, 2 eq) and 2,4-Bis(trifluoromethyl)aniline (1 g, 4.23 mmol, 1 eq) was heated to 140° C. for 1 h. The mixture was cooled to 25° C. and it was washed with a mixture of TBME: Cyclohexane 30:70. The solid was filtered off and dried to give (1-30) (490 mg, 33%).

[0701] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 11.34 (br d, J=12.5 Hz, 1H) 8.82 (d, J=12.4 Hz, 1H) 810-8.18 (m, 2H) 8.05 (s, 1H) 4.28 (q, J=7.2 Hz, 2H) 1.28 (t, J=7.1 Hz, 3H).

[0702] LC-MS (method 4): retention time 1.19 min, m/z 353 [M+H.sup.+].

Step B: Preparation of 4-oxo-6,8-bis(trifluoromethyl)-1H-quinoline-3-carbonitrile (compound I-31)

[0703] ##STR00131##

[0704] Ethyl (Z)-3-[2,4-bis(trifluoromethyl)anilino]-2-cyano-prop-2-enoate (I-30, 500 mg, 1.42 mmol, 1 eq) was heated in Phenyl ether-biphenyl eutectic (2.5 ml) to 260° C. for 8 h. After cooling to room temperature it was diluted with Cyclohexane to precipitate the product. It was washed with tert-butyl methyl ether and dried under reduced pressure to give (1-31) (180 mg, 41%).

[0705] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 8.68 (s, 1H) 8.66 (s, 1H) 8.45 (s, 1H).

[0706] LC-MS (method 4): retention time 0.95 min, m/z 307 [M+H.sup.+].

Step C: Preparation of 4-chloro-6,8-bis(trifluoromethyl)quinoline-3-carbonitrile (compound I-32)

[0707] ##STR00132##

[0708] 4-oxo-6,8-bis(trifluoromethyl)-1H-quinoline-3-carbonitrile (I-31, 600 mg, 1.96 mmol, 1 eq) and Thionyl chloride (6 ml, 80.6 mmol, 41 eq) were mixed together with N,N-dimethylformamide (30 μl, 0.39 mmol, 0.2 eq). The mixture was heated to 80° C. for 3 h. It was concentrated under reduced pressure and it was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to give (1-32) (423 mg, 66%).

[0709] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 9.24 (s, 1H) 8.86 (s, 1H) 8.47 (s, 1H).

[0710] LC-MS (method 4): retention time 1.16 min, m/z 325 [M+H.sup.+].

Step D: Preparation of tert-butyl N-[(1S)-2-[(E)-dimethylaminomethyleneamino]-1-methyl-2-oxo-ethyl]carbamate (compound I-33)

[0711] ##STR00133##

[0712] tert-butyl N-[(1S)-2-amino-1-methyl-2-oxo-ethyl]carbamate (70 g, 353 mmol, 1 eq) was mixed with 2-Methyltetrahydrofuran (1.121) and DMF-DMA (70 ml, 530 mmol, 1.5 eq) and heated to 40° C. for 2 h. The reaction mixture was concentrated under reduced pressure to yield (I-33) (105 g, 97% yield, 80% purity).

[0713] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 8.38 (s, 1H) 5.98-6.15 (m, 1H) 4.25-4.37 (m, 1H) 3.16 (s, 3H) 3.09 (s, 3H) 1.46 (s, 9H) 1.40 (m, 3H).

Step E: Preparation of N-[(1S)-1-[2-(5-cyano-2-pyridyl)-1,2,4-triazol-3-yl]ethyl]carbamate (compound I-34)

[0714] ##STR00134##

[0715] Tert-butyl N-[(1S)-2-[(E)-dimethylaminomethyleneamino]-1-methyl-2-oxo-ethyl]carbamate (I-33, 80% purity, 50 g, 164 mmol, 1 eq) was dissolved in 1,4-Dioxane (510 ml). To this was added 6-hydrazinopyridine-3-carbonitrile (33.1 g, 247 mmol, 1.5 eq) and glacial acetic acid (510 ml). The mixture was heated to 90° C. for 30 min. After cooling to 25° C. the reaction mixture was concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) gave (I-34) (23 g, 32%)

[0716] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm: 8.80 (dd, J=1.90, 0.8 Hz, 1H) 8.10-8.20 (m, 1H) 7.98 (s, 1H) 5.92-6.02 (m, 1H) 5.77 (br d, J=8.6 Hz, 1H) 4.12 (q, J=7.1 Hz, 2H) 1.58 (d, J=6.8 Hz, 3H) 1.42 (s, 6H).

Step F: Preparation of [(1S)-1-[2-(5-cyano-2-pyridyl)-1,2,4-triazol-3-yl]ethyl]ammonium;2,2,2-trifluoroacetate (compound I-35)

[0717] ##STR00135##

[0718] Tert-butyl N-[(1S)-1-[2-(5-cyano-2-pyridyl)-1,2,4-triazol-3-yl]ethyl]carbamate (I-34, 1.1 g, 3.5 mmol, 1 eq) was dissolved in Methanol (11 ml) and Trifluoroacetic acid (5.6 ml, 70 mmol, 20 eq) was added. The mixture was stirred at 25° C. for 2 h. The reaction mixture was concentrated under reduced pressure. MTBE was added to the crude oil and it was stirred for 5 min. The MTBE was decanted and second time MTBE was added. The product precipitated out, it was filtered off and dried to yield (I-35) (600 mg, 50%).

[0719] LC-MS (method 5): retention time 0.31 min, m/z 215 [M+H.sup.+].

Step G: Preparation of 4-[[(1S)-1-[2-(5-cyano-2-pyridyl)-1,2,4-triazol-3-yl]ethyl]amino]-6,8-bis(trifluoromethyl)quinoline-3-carbonitrile (compound P.139)

[0720] ##STR00136##

[0721] In a round bottom flask [(1S)-1-[2-(5-cyano-2-pyridyl)-1,2,4-triazol-3-yl]ethyl]ammonium;2,2,2-trifluoroacetate (I-34, 546 mg, 1.66 mmol, 1.2 eq), 4-chloro-6,8-bis(trifluoromethyl)quinoline-3-carbonitrile (I-32, 450 mg, 1.3863 mmol, 1 eq) and Potassium carbonate (581 mg, 4.16 mmol, 3 eq) were suspended in Acetonitrile (9 ml). The reaction mass were heated to 60° C. for 2 h. The reaction mass was quenched with water and stirred for 20 min. P. 139 (432 mg, 62%) precipitated as a solid which was filtered, washed with water and was dried under reduced pressure.

[0722] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm 9.30 (s, 1H) 8.95 (d, J=7.8 Hz, 1H) 8.89-8.93 (m, 1H) 8.73 (s, 1H) 8.49 (dd, J=8.6, 2.1 Hz, 1H) 8.35 (s, 1H) 8.31 (s, 1H) 8.07 (d, J=8.7 Hz, 1H) 6.58 (t, J=7.1 Hz, 1H) 1.91 (d, J=6.6 Hz, 3H).

[0723] .sup.19F NMR (377 MHz, DMSO-d6) δ ppm −59.16 (s, 3F), −60.26 (s, 3F).

[0724] LCMS (method 4): retention time: 1.18 min, m/z 503 [M+H.sup.+].

Example 13: Preparation of 6-chloro-N-methyl-8-(trifluoromethyl)-N-[(1S)-1-[2-[5-[4-(trifluoromethyl)thiazol-2-yl]-2-pyridyl]-1,2,4-triazol-3-yl]ethyl]quinazolin-4-amine (compound P. 142)

[0725] ##STR00137##

Step A: Preparation of 6-[5-[(1S)-1-[[6-chloro-8-(trifluoromethyl)quinazolin-4-yl]amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-36)

[0726] ##STR00138##

[0727] A flask was charged with 4,6-dichloro-8-(trifluoromethyl)quinazoline (CAS-No.: 1565368-05-9, 100 mg, 0.37 mmol, 1 eq), [(1S)-1-[2-(5-cyano-2-pyridyl)-1,2,4-triazol-3-yl]ethyl]ammonium;2,2,2-trifluoroacetate (I-35 from example 12, 74% purity, 199 mg, 0.45 mmol, 1.2 eq), cesium carbonate (366 mg, 1.12 mmol, 3 eq) and acetonitrile (1 ml). The reaction mass was stirred at 25° C. for 16 h. It was diluted with water and extracted with two times with ethyl acetate. The combined organic layer was washed with brine, dried aver anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure. The crude material was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to provide desired product (I-36). (107 mg, 64%).

[0728] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm: 9.11 (d, J=6.9 Hz, 1H) 9.04 (d, J=1.5 Hz, 1H) 8.98-9.00 (m, 1H) 8.93 (d, J=2.2 Hz, 1H) 8.57 (dd, J=8.6, 2.2 Hz, 1H) 8.34 (s, 1H) 8.18-8.23 (m, 2H) 8.06-8.10 (m, 1H) 6.37 (t, J=6.85 Hz, 1H) 1.74 (, J=7.0 Hz, 3H).

[0729] LCMS (method 4): retention time: 1.07 min. m/z 445 [M+H.sup.+].

Step B: Preparation of 6-[5-[(1S)-1-[[6-chloro-8-(trifluoromethyl)quinazolin-4-yl]-methyl-amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-37)

[0730] ##STR00139##

[0731] 6-[5-[(1S)-1-[[6-chloro-8-(trifluoromethyl)quinazolin-4-yl]amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-36, 1.40 g, 3.15 mmol, 1 eq) was weighed in a sealable tube together with Acetonitrile (15.7 ml), cesium carbonate (3.08 g, 9.44 mmol, 3 eq) and iodomethane (396 μl, 6.29 mmol, 2 eq). The tube was closed and heated to 50° C. for 16 h. After cooling to 25° C. it was extracted two times with ethyl acetate. It was washed with water and brine, dried over anhydrous MgSO.sub.4 and concentrated under reduced pressure. It was purified by flash chromatography over silica gel (ethyl acetate in dichloromethane 3:1) to give (1-37).

[0732] .sup.1H NMR (600 MHz, DMSO-d6) δ ppm 8.50 (dd, J=8.5, 2.20 Hz, 1H) 8.45 (s, 2H) 8.32 (s, 1H) 8.32 (s, 1H) 8.22 (d, J=1.9 Hz, 1H) 8.09 (d, J=2.1 Hz, 1H) 8.05 (d, J=8.5 Hz, 1H) 6.67 (q, J=6.9 Hz, 1H) 3.26 (s, 3H) 1.83 (d, J=6.9 Hz, 3H).

[0733] LCMS (method 3): retention time: 1.08 min, m/z 459 [M+H.sup.+].

Step C: Preparation of 6-[5-[(1S)-1-[[6-chloro-8-(trifluoromethyl)quinazolin-4-yl].methyl-amino]ethyl]-1,2,4-triazol-1-yl]pyridine-2-carbothioamide (I-38)

[0734] ##STR00140##

[0735] To a solution of 6-[5-[(1S)-1-[[6-chloro-8-(trifluoromethyl)quinazolin-4-yl]-methyl-amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-37, 600 mg, 1.31 mmol, 1 eq) in Pyridine (4.8 ml) was added ammonium sulfide solution in water (2.23 ml, 6.54 mmol, 5 eq). It was stirred for 16 h at 25° C. It was diluted with water and extracted three times with ethyl acetate. The combined organic layer was washed brine, dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure. It was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to give (1-38) (468 mg, 73%).

[0736] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm 10.06 (br s, 1H) 9.66 (br s, 1H) 8.44 (s, 1H) 8.40 (s, 1H) 8.41 (d, J=7.4 Hz, 2H) 8.27 (s, 1H) 8.17 (d, J=2.0 Hz, 1H) 8.05 (d, J=2.1 Hz, 1H) 7.89 (d, J=8.0 Hz, 1H) 6.68 (d, J=7.0 Hz, 1H) 3.26 (s, 3H) 1.83 (d, J=7.0 Hz, 3H).

[0737] .sup.19F NMR (377 MHz, DMSO-d6) δ ppm −59.39 (s, 3F).

[0738] LCMS (method 4): retention time: 1.10 min, m/z 493 [M+H.sup.+].

Step D: Preparation of 2-[6-[5-[(1S)-1-[[6-chloro-8-(trifluoromethyl)quinazolin-4-yl]-methyl-amino]ethyl]-1,2,4-triazol-1-yl]-3-pyridyl]-4-(trifluoromethyl)-5H-thiazol-4-ol (I-39)

[0739] ##STR00141##

[0740] 6-[5-[(1S)-1-[[6-chloro-8-(trifluoromethyl)quinazolin-4-yl].methyl-amino]ethyl]-1,2,4-triazol-1-yl]pyridine-2-carbothioamide (I-38, 100 mg, 0.20 mmol, 1 eq) was dissolved in N,N-Dimethylformamide (2.5 ml). To the solution was added 3-Bromo-1,1,1-trifluoroacetone (32.2 μl, 0.30 mmol, 1.5 eq) and it was heated to 60° C. for 2 h. It was cooled to 25° C. and it was diluted with ethyl acetate. It was washed with water and brine, dried over anhydrous Na.sub.2SO.sub.4 and it was concentrated under reduced pressure.

[0741] It was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to give (1-39) (103 mg, 76%, 90% purity).

[0742] .sup.1H NMR (400 MHz, Acetonitrile-d3) δ ppm: 8.52 (d, J=4.4 Hz, 1H) 8.32 (ddd J=12.2, 8.6, 2.3 Hz) 8.07-8.15 (m, 1H) 8.06-8.12 (m, 1H), 8.03 (s, 1H) 7.95 (dd, J=8.6, 5.1 Hz, 1H) 7.8 (d, J=2.3 Hz, 1H) 7.73 (d, J=2.2 Hz, 1H) 6.76 (t, J=7.6 Hz, 1H) 5.05 (br dd, J=16.7, 2.6 Hz, 1H) 3.78 (dd, J=13.0 Hz, 10.8 Hz, 1H) 3.61 (s, 1H) 3.47-3.55 (m, 1H) 3.12 (d, J=7.5 Hz, 3H) 2.09-2.21 (m, 5H) 1.87 (dd, J=6.9, 1.3 Hz, 3H).

[0743] LCMS (method 4): retention time: 1.17 min, m/z 604 [M+H.sup.+].

Step E: Preparation of 6-chloro-N-methyl-8-(trifluoromethyl)-N-[(1S)-1-[2-[5-[4-(trifluoromethyl)thiazol-2-yl]-2-pyridyl]-1,2,4-triazol-3-yl]ethyl]quinazolin-4-amine (compound P. 142)

[0744] ##STR00142##

[0745] To a solution of 2-[6-[5-[(1S)-1-[[6-chloro-8-(trifluoromethyl)quinazolin-4-yl]-methyl-amino]ethyl]-1,2,4-triazol-1-yl]-3-pyridyl]-4-(trifluoromethyl)-5H-thiazol-4-ol (I-39, 100 mg, 0.17 mmol, 1 eq) in Tetrahydrofuran (4 ml) was added Triethylamine (58.4 μl, 0.41 mmol, 2.5 eq) and it was cooled to 0° C. Trifluoroacetic anhydride (118 μl, 0.83 mmol, 5 eq) was added at 0° C. The reaction mixture was warmed to room temperature and it was stirred for 16 h. It was quenched with saturated NaHCO.sub.3-solution and it was extracted with EtOAc (2×20 ml). The combined organic layer was washed with brine, dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure to get gummy mass. The crude material was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to provide desired product P. 142 (47 mg, 48% yield).

[0746] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm 8.65 (s, 1H) 8.55 (s, 1H) 8.50 (dd, J=8.5, 2.3 Hz, 1H) 8.31 (s, 1H) 8.27-8.30 (m, 1H) 8.06 (s, 1H) 7.97 (d, J=8.3 Hz 1H) 7.85 (s, 1H) 6.65 (br d, J=6.8 Hz, 1H) 3.10 (s, 3H) 1.88 (d, J=6.8 Hz, 3H).

[0747] .sup.19F NMR (377 MHz, DMSO-d6) δ ppm −59.6 (s, 3 F) −62.5 (s, 3 F).

[0748] LCMS (method 4): retention time: 1.26 min, m/z 585 [M+H.sup.+].

Example 14: Preparation of N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)-1,2,3-benzotriazin-4-amine (compound P. 145)

[0749] ##STR00143##

Step A: Preparation of 2-amino-3,5-bis(trifluoromethyl)benzamide (I-40)

[0750] ##STR00144##

[0751] 2-Amino-3,5-bis(trifluoromethyl)benzonitrile (CAS-No. 473740-86-2, 1.00 g, 3.94 mmol, 1 eq) and potassium carbonate (109 mg, 0.79 mmol, 0.2 eq) were dissolved in Methanol (15 ml) and water (2 ml). While stirring at 25° C. urea hydrogen peroxide (1.14 g, 11.81 mmol, 3 eq) was added and stirred for 1 h. After that a second batch of urea hydrogen peroxide (1.14 g, 11.81 mmol, 3 eq) was added and stirred for 16 h. Sodium metabisulfite (1 g) was added and stirred for 5 min. It was diluted with ethyl acetate. The solid was filtered off and the filtrate was concentrated under reduced pressure. The crude material was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to provide desired product (I-40) (818 mg, 76%).

[0752] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm 8.22-8.39 (br s, 1H) 8.18 (s, 1H) 7.78 (s, 1H) 7.50-7.70 (br s, 3H).

[0753] LCMS (method 3): retention time: 0.91 min, m/z 273 [M+H.sup.+].

Step B: Preparation of 6,8-bis(trifluoromethyl)-3H-1,2,3-benzotriazin-4-one (I-41)

[0754] ##STR00145##

[0755] A solution of 2-amino-3,5-bis(trifluoromethyl)benzamide (I-40, 816 mg, 3 mmol, 1 eq) in 1N hydrogen chloride (12 ml) was stirred for 20 min at 0° C. A solution of sodium nitrite (414 mg, 6 mmol, 2 eq) in water (10 ml) was added dropwise over 40 min. After that it was stirred for 2 h at 0° C. 4M sodium hydroxide was added to adjust the pH to 8 and it was vigorously stirred for 15 min. The solid was filtered off and filtrate was acidified to pH 2-3 with HCl. The solid product was filtered off and dried to get (1-41) (382 mg, 45%).

[0756] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm 15.56-15.89 (br s, 1H) 8.77 (s, 1H) 8.71 (s, 1H).

[0757] LCMS (method 3): retention time: 0.92 min, m/z 284 [M+H.sup.+].

Step C: Preparation of tert-butyl N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]carbamate (I-42)

[0758] ##STR00146##

[0759] Tert-butyl N-[(1S)-2-[(E)-dimethylaminomethyleneamino]-1-methyl-2-oxo-ethyl]carbamate (I-33 from example 12, 4.23 g, 17.4 mmol, 1 eq) pyrimidin2-ylhydrazine (2.87 g, 26.1 mmol, 1.5 eq) was mixed together with 1,4-Dioxane (43.5 ml) and glacial acetic acid (43.5 ml). The mixture was heated to 90° C. for 35 min. It was concentrated under reduced pressure and purified with flash column chromatography over silica gel (ethyl acetate in cyclohexane) to provide desired product (I-42) (4.03 g, 80%).

[0760] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm 8.89 (d, J=4.8 Hz, 2H) 8.03 (s, 1H) 7.37 (t, J=5.0 Hz, 1H) 5.91-6.11 (m, 1H) 5.55-5-77 (m, 1H) 1.58 (d, J=6.6 Hz, 3H) 1.35-1.47 (m, 9H).

[0761] LCMS (method 3): retention time: 0.73 min, m/z 291 [M+H.sup.+].

Step D: Preparation of [(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]ammonium;2,2,2-trifluoroacetate (I-43)

[0762] ##STR00147##

[0763] tert-butyl N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]carbamate (I-42, 36.0 g, 86.6 mmol, 1 eq) was dissolved in Dichloromethane (540 ml) and Trifluoroacetic acid (180 ml, 2.27 mol, 26.2 eq) was added. The mixture was stirred at 25° C. for 2 h. The reaction mixture was concentrated under reduced pressure.

[0764] Tert-butyl methyl ether (72 ml) was added to the crude oil and it was stirred for 5 min. The MTBE was decanted off and Acetonitrile (72 ml) was added. The product precipitated out, it was filtered off and dried to yield (I-43) (22.3 g, 83%).

[0765] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm 9.02 (d, 2H) 8.55-8.75 (br s, 3H) 8.37 (s, 1H) 7.68 (t, 1H) 5.34 (m, 1H) 3.20-4.40 (br s, 1H) 1.63 (d, 3H).

[0766] LC-MS (method 5): retention time 0.27 min, m/z 191 [M+H.sup.+].

Step E: Preparation of N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)-1,2,3-benzotriazin-4-amine (compound P. 145)

[0767] ##STR00148##

[0768] 6,8-bis(trifluoromethyl)-3H-1,2,3-benzotriazin-4-one (I-41, 129 mg, 0.45 mmol, 1 eq), (1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethanamine;2,2,2-trifluoroacetic acid (1-43, 180 mg, 0.59 mmol, 1.3 eq) and N-ethyl-N-isopropyl-propan-2-amine (0.325 ml, 1.86 mmol, 4.1 eq) were dissolved in Dimethylsulfoxide (4.5 ml).

[0769] After stirring for 5 min at room temperature benzotriazol-1-yloxy(tripyrrolidin-1-yl)phosphonium;hexafluorophosphate (662 mg, 1.27 mmol, 2.8 eq) The resulting mixture was stirred for 16 h at room temperature. It was diluted with water (50 ml) and it was extracted with EtOAc (3×50 ml). The combined organic layer was dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded desired product (P. 145) (68 mg, 33% yield).

[0770] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm 9.64 (d, J=7.0 Hz, 1H) 9.34 (s, 1H) 8.98 (d, J=4.8 Hz, 2H) 8.61 (s, 1H) 8.17 (s, 1H) 7.64 (t, J=5.0 Hz, 1H) 6.57 (m, 1H) 1.82 (d, J=7.0 Hz, 3H).

[0771] .sup.19F NMR (377 MHz, DMSO-d6) δ ppm −58.5 (s, 3 F) −61.2 (s, 3 F).

[0772] LC-MS (method 3) retention time 0.92 min, m/z 456 [M+H.sup.+].

Example 15: Preparation of 3-fluoro-N-methyl-N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinolin-4-amine (compound P.176)

[0773] ##STR00149##

Step A: Preparation of N-methyl-N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinolin-4-amine (I-44)

[0774] ##STR00150##

[0775] A dry vial was charged with sodium hydride (60 mass %, 13.2 mg, 0.33 mmol, 1.5 eq) and cooled to 0° C. To this was added a solution of N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinolin-4-amine (P. 5 example 1, 100 mg, 0.22 mmol, 1 eq) in Tetrahydrofuran (0.88 ml). After 5 min stirring Iodomethane (20.8 μl, 0.33 mmol, 1.5 eq) was added and it was stirred at 25° C. for 3.5 h. It was quenched with sat. NH.sub.4Cl-solution (5 ml) and diluted with water (20 ml). It was extracted with ethyl acetate (3×20 ml). The combined organic layer was washed brine, dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure. Purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded desired product (I-44) (41 mg, 40%).

[0776] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm 8.65 (d, J=5.1 Hz, 1H) 8.43 (s, 1H) 8.20 (d, J=1.1 Hz, 1H) 8.09 (s, 1H) 8.08 (d, J=4.8 Hz, 2H) 6.93 (t, J=4.8 Hz, 1H) 6.68 (d, J=5.1 Hz, 1H) 6.25 (q, J=7.0 Hz, 1H) 2.88 (s, 3H) 2.08 (d, J=7.0 Hz, 3H).

[0777] LC-MS (method 3) retention time 1.04 min, m/z 468 [M+H.sup.+].

Step B: Preparation of 3-fluoro-N-methyl-N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinolin-4-amine (compound P.176)

[0778] ##STR00151##

[0779] N-methyl-N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinolin-4-amine (30 mg, 0.064 mmol, 1 eq) was dissolved in Acetonitrile (321 μl). Selectfluor (23.7 mg, 0.064 mmol, 1 eq) was added and it was stirred at room temperature for 17 h. A second batch of Selectfluor (12 mg, 0.032 mmol, 0.5 eq) was added and stirred for additional 7 h. A third batch of Selectfluor (12 mg, 0.032 mmol, 0.5 eq) was added and stirred for 17 h. It was quenched with MeOH, filtered and purified on RP18 silica. P. 176 (18 mg, 58% yield).

[0780] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm 8.68 (d, J=3.7 Hz, 1H) 8.51 (s, 1H) 8.15 (s, 3H) 8.11 (s, 1H) 6.91 (t, J=4.8 Hz, 1H) 6.03 (q, J=7.0 Hz, 1H) 3.09 (d, J=3.7 Hz, 3H) 2.02 (d, J=7.0 Hz, 3H).

[0781] .sup.19F NMR (377 MHz, CDCl.sub.3) δ ppm −60.52 (s, 3 F) −62.51 (s, 3 F) −133.71 (s, 1 F).

[0782] LC-MS (method 3) retention time 1.10 min, m/z 487 [M+H.sup.+].

Example 16: Preparation of 3-chloro-N-methyl-N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinolin-4-amine (P. 181)

[0783] ##STR00152##

Step A: Preparation of 3-chloro-N-methyl-N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinolin-4-amine (compound P. 181)

[0784] ##STR00153##

[0785] N-methyl-N-[(1S)-1-(2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-6,8-bis(trifluoromethyl)quinolin-4-amine (I-44 example 15, 41 mg, 0.088 mmol, 1 eq) was dissolved in Dichloromethane (0.88 ml) and cooled to −19° C. N-Chlorosuccinimide (13 mg, 0.096 mmol, 1.1 eq) was added and stirred for 1 h at −19° C. After that it was stirred for 20 h at room temperature. Additional N-Chlorosuccinimide (13 mg, 0.096 mmol, 1.1 eq) and Dimethylsulfoxide (31.5 μl) were added. After 17 h full conversion. It was concentrated under reduced pressure and purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) afforded desired product P.181 (14 mg, 32% yield).

[0786] .sup.1H NMR (600 MHz, DMSO-d6, 120° C.) δ ppm 8.86 (s, 1H) 8.41 (d, J=4.7 Hz, 2H) 8.24 (s, 1H) 8.13 (s, 1H) 7.24 (t, J=4.8 Hz, 1H) 5.91 (q, J=7.0 Hz, 1H) 3.15 (s, 3H) 1.86 (d, J=6.9 Hz, 3H).

[0787] LC-MS (method 3) retention time 1.14 min, m/z 502 [M+H.sup.+].

Example 17: Preparation of 6-[5-[(1S)-1-[[6,8-bis(trifluoromethyl)quinazolin-4-yl]-methyl-amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbothioamide (P. 190)

[0788] ##STR00154##

Step A: Preparation of 6-[5-[(1S)-1-aminoethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-45)

[0789] ##STR00155##

[0790] Tert-butyl N-[(1S)-1-[2-(5-cyano-2-pyridyl)-1,2,4-triazol-3-yl]ethyl]carbamate (I-34, 75% purity, 13 g, 31 mmol, 1 eq) was dissolved in Dichloromethane (195 ml) and Trifluoroacetic acid (78 ml, 982 mmol, 31.7 eq) was added. The mixture was stirred at 25° C. for 1 h. The reaction mixture was concentrated under reduced pressure.

[0791] Dichloromethane (195 ml) was added to the crude oil and it was basified with saturated Na.sub.2CO.sub.3-solution. The aqueous layer was extracted with dichloromethane (2×200 ml). The combined organic layer was dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure to give a white solid. This was washed TBME and was dried under reduced pressure to give (1-45) (7 g, 87%, 88% purity).

[0792] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm 9.06 (s, 1H) 8.55 (d, 1H) 8.23 (s, 1H) 8.06 (d, 1H) 4.67-4.87 (m, 1H) 1.47 (d, 3H).

Step B: Preparation of 6-[5-[(1S)-1-[[6,8-bis(trifluoromethyl)quinazolin-4-yl]amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-46)

[0793] ##STR00156##

[0794] 4-chloro-6,8-bis(trifluoromethyl)quinazoline (I-9 example 2, 4.0 g, 13.3 mmol, 1 eq) was dissolved in acetonitrile (40 ml). 6-[5-[(1S)-1-aminoethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-45, 85% purity, 3.35 g, 13.3 mmol, 1 eq) and cesium carbonate (8.67 g, 26.6 mmol, 2 eq) were added and it was stirred at 25° C. for 16 h. The reaction mixture was poured on ice-water and it was extracted with ethyl acetate (3×50 ml). The combined organic layer was dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure followed by purification by flash chromatography over silica gel (ethyl acetate in cyclohexane) to afford desired product (I-46) (5.1 g, 80%).

[0795] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm 9.47 (d, 1H) 9.27 (s, 1H) 9.04 (s, 1H) 8.58 (d, 1H) 8.44 (s, 1H) 8.36 (s, 1H) 8.21 (s, 1H) 8.09 (d, 1H) 6.42 (quin., 1H) 1.77 (d, 3H).

[0796] LC-MS (method 5) retention time 1.59 min, m/z 479 [M+H.sup.+].

Step C: Preparation of 6-[5-[(1S)-1-[[6,8-bis(trifluoromethyl)quinazolin-4-yl]-methyl-amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-47)

[0797] ##STR00157##

[0798] A sealable tube was charged with 6-[5-[(1S)-1-[[6,8-bis(trifluoromethyl)quinazolin-4-yl]amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-46, 294 mg, 0.61 mmol, 1 eq), acetonitrile (4.92 ml), cesium carbonate (601 mg, 1.84 mmol, 3 eq) and iodomethane (77.3 μl, 1.23 mmol, 2 eq). The vial was sealed and heated to 50° C. for 16 h. After cooling to 25° C. it was diluted with water (10 ml) and it was extracted with ethyl acetate (3×10 ml). The combined organics were washed with brine, dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure. It was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) and afforded desired product (I-47) (250 mg, 83%).

[0799] .sup.1H NMR (400 MHz, CDCl.sub.3) δ ppm 8.55 (s, 1H) 8.35 (d, J=5.9 Hz, 2H) 8.24 (s, 1H) 8.11-8.20 (m, 2H) 8.03 (s, 1H) 6.88 (q, J=6.97 Hz, 1H) 1.96 (d, J=6.97 Hz, 3H).

[0800] .sup.19F NMR (377 MHz, CDCl.sub.3) δ ppm −61.33 (s, 3F) −62.39 (s, 3F).

[0801] LC-MS (method 3) retention time 1.11 min, m/z 493 [M+H.sup.+].

Step D: Preparation of 6-[5-[(1S)-1-[[6,8-bis(trifluoromethyl)quinazolin-4-yl]-methyl-amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbothioamide (P. 190)

[0802] ##STR00158##

[0803] 6-[5-[(1S)-1-[[6,8-bis(trifluoromethyl)quinazolin-4-yl]-methyl-amino]ethyl]-1,2,4-triazol-1-yl]pyridine-3-carbonitrile (I-47, 300 mg, 0.61 mmol, 1 eq) was dissolved in Pyridine (2.4 ml) and ammonium sulfide solution (20 mass %, 1.04 ml, 3.05 mmol, 5 eq) was added. The reaction mixture was stirred at 25° C. for 16 h. It was diluted with water and it was extracted with ethyl acetate (4 times). The combined organic layer was washed with brine, dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure. It was purified by flash chromatography over silica gel (ethyl acetate in cyclohexane) to give (P. 190) (78 mg, 24%).

[0804] .sup.1H NMR (400 MHz, DMSO-d6) δ ppm 10.04 (br s, 1H) 9.65 (br s, 1H) 8.55 (s, 1H) 8.27-8.41 (m, 5H) 7.91 (d, J=8.44 Hz, 1H) 6.76 (br d, J=6.85 Hz, 1H).

[0805] .sup.19F NMR (377 MHz, DMSO-d6) δ ppm −59.74 (s, 3F) −60.75 (s, 3F).

[0806] LC-MS (method 4) retention time 1.12 min. m/z 528 [M+H.sup.+].

TABLE-US-00012 TABLE P Examples of compounds of formula I RT [M + H] Entry IUPAC name STRUCTURE (min) (measured) Method MP° C. P.1 N-[(1S)-1-(2-pyrimidin- 2-yl-1,2,4-triazol-3- yl)ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00159] 0.96 455 3 130- 132 P.2 6,7,8-trichloro-N-methyl- N-[1-(3-pyrimidin-2- ylpyrazin-2- yl)ethyl]quinazolin-4- amine [00160] 0.98 448 3 P.3 6,7,8-trichloro-N-[1-[3- (triazol-2-yl)pyrazin-2- yl]ethyl]quinazolin-4- amine [00161] 0.99 423 3 P.4 N-[1-(5-bromo-2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-N- methyl-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00162] 1.14 547-549 (Br pattern) 3 P.5 N-[(1S)-1-(2-pyrimidin- 2-yl-1,2,4-triazol-3- yl)ethyl]-6,8- bis(trifluoromethyl)quino- lin-4-amine [00163] 0.89 455 3 P.6 6-[5-[1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-ethyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00164] 1.17 507 3 P.7 6-[5-[1-[[6,8- bis(trifluroomethyl)quina- zolin-4-yl]- (methoxymethyl)amino] ethyl]-1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00165] 1.13 523 3 P.8 6-[5-[1-[benzyl-[6,8- bis(trifluoromethyl)quina- zolin-4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00166] 1.21 569 3 P.9 [6,8- bis(trifluoromethyl)quina- zolin-4-yl]-[1-[2-(5- cyano-2-pyridyl)-1,2,4- triazol-3- yl]ethyl]cyanamide [00167] 1.10 504 3 P.10 benzyl N-[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-N-[1-[2-(5- cyano-2-pyridyl)-1,2,4- triazol-3- yl]ethyl]carbamate [00168] 1.18 613 3 P.11 6-bromo-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]-8- (trifluoromethoxy)quina- zolin-4-amine [00169] 0.92 492-494 (Br pattern) 3 P.12 8-bromo-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]-6- (trifluoromethoxy)quina- zolin-4-amine [00170] 0.92 492-494 (Br pattern) 3 238- 239 P.13 8-bromo-N-[1-[3-(triazol- 2-yl)pyrazin-2-yl]ethyl]- 6- (trifluoromethoxy)quina- zolin-4-amine [00171] 1.00 481-483 (Br pattern) 3 P.14 6-bromo-N-[1-[3-(triazol- 2-yl)pyrazin-2-yl]ethyl]- 8- (trifluoromethoxy)quina- zolin-4-amine [00172] 0.99 481-483 (Br pattern) 3 P.15 6-[5-[1-[methyl-[2- methyl-6,8- bis(trifluoromethyl)quina- zolin-4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00173] 1.20 507 3 155- 158 P.16 N-[1-(2-pyrimidin-2-yl- 1,2,4-triazol-3-yl)ethyl]- 6,8- bis(trifluoromethyl)quina- zolin-4-amine [00174] 0.97 455 3 192- 194 P.17 6-[5-[(1S)-1-[[8-chloro-6- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00175] 0.99 445 3 P.18 8-chloro-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00176] 1.43 421 5 P.19 6-[5-[(1S)-1-[[8-chloro-6- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00177] 1.02 459 3 196- 198 P.20 8-chloro-N-methyl-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00178] 1.42 435 5 138- 140 P.21 6-[5-[(1S)-1-[[6-chloro-8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00179] 1.08 459 3 94-96 P.22 6-[5-[(1S)-1-[[6-chloro-8- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00180] 1.04 445 3 236- 238 P.23 6-chloro-N-methyl-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00181] 0.96 435 3 82-84 P.24 6-chloro-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00182] 0.91 421 3 234- 236 P.25 2-chloro-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00183] 1.09 489 4 188- 190 P.26 N-methyl-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00184] 1.01 469 3 160- 163 P.27 N-methyl-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00185] 1.01 469 3 P.28 6-[5-[1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00186] 1.11 493 3 P.29 6,8-dibromo-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]quinazolin-4- amine [00187] 0.85 473-478 (dibromo pattern) 3 138- 145 P.30 6-[5-[1-[(6,8- dibromoquinazolin-4- yl)amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00188] 0.98 499-504 (dibromo pattern) 3 167- 174 P.31 6-bromo-8- (difluoromethoxy)-N-[1- [3-(triazol-2-yl)pyrazin- 2-yl]ethyl]quinazolin-4- amine [00189] 0.89 463-465 (Br pattern) 3 154- 155 P.32 6-bromo-8- (difluoromethoxy)-N-[1- (3-pyrimidin-2-ylpyrazin- 2-yl)ethyl]quinazolin-4- amine [00190] 0.80 474-476 (Br pattern) 3 94-96 P.33 6-bromo-N-[1-[3-(triazol- 2-yl)pyrazin-2-yl]ethyl]- 8- (trifluoromethyl)quinazolin- 4-amine [00191] 1.07 465-467 (Br pattern) 4 P.34 8-bromo-N-[1-[3-(triazol- 2-yl)pyrazin-2-yl]ethyl]- 6- (trifluoromethyl)quinazolin- 4-amine [00192] 1.04 465-467 4 240- 242 P.35 8-chloro-N-[1-[3-(triazol- 2-yl)pyrazin-2-yl]ethyl]- 6- (trifluoromethyl)quinazolin- 4-amine [00193] 1.47 421 5 242- 244 P.36 8-chloro-N- (cyclopropylmethyl)-2- methoxy-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00194] 1.17 505 4 143- 145 P.37 6,8-dibromo-N-[1-[3- (triazol-2-yl)pyrazin-2- yl]ethyl]quinazolin-4- amine [00195] 0.96 475-479 (dibromo pattern) 3 164- 173 P.38 6,8-dibromo-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]quinazolin-4- amine [00196] 0.87 486-490 (dibromo pattern) 3 156- 163 P.39 6-chloro-N-[1-[3-(triazol- 2-yl)pyrazin-2-yl]ethyl]- 8- (trifluoromethyl)quinazolin- 4-amine [00197] 1.06 421 4 190- 194 P.40 6-chloro-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00198] 1.42 421 5 198- 200 P.41 6-[5-[1-[[6-chloro-8- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00199] 1.56 445 5 P.42 6-[5-[1-[[8-bromo-6- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00200] 1.07 489-491 (Br pattern) 4 P.43 8-chloro-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00201] 0.89 422 4 P.44 6-bromo-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00202] 0.96 465-467 (Br pattern) 4 208- 212 P.45 6-[5-[1-[[8-chloro-6- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00203] 1.58 445 5 P.46 8-bromo-2-chloro-N- (cyclopropylmethyl)-N- [1-(2-pyrimidin-2-yl- 1,2,4-triazol-3-yl)ethyl]- 6- (trifluoromethyl)quinazolin- 4-amine [00204] 1.22 553-555 (Br pattern) 4 87-89 P.47 8-bromo-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00205] 0.94 465-467 (Br pattern) 4 P.48 2,8-dichloro-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00206] 1.04 455-459 (dichloro pattern) 4 P.49 2,8-dichloro-N- (cyclopropylmethyl)-N- [1-(2-pyrimidin-2-yl- 1,2,4-triazol-3-yl)ethyl]- 6- (trifluoromethyl)quinazolin- 4-amine [00207] 1.20 509-5.13 (dichloro pattern) 4 81-83 P.50 6-[5-[1-[(6,7,8- trichloroquinazolin-4- yl)amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00208] 1.05 447 9 P.51 8-bromo-2-chloro-N-[1- (2-pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00209] 1.05 499-503 (Cl + Br pattern) 4 P.52 6-[5-[1-[[6-bromo-8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00210] 1.09 503-505 (Br pattern) 3 149- 152 P.53 6-[5-[(1R)-1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00211] P.54 6-[5-[(1S)-1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00212] 1.10 493 3 140- 142 P.55 N-[1-[3-(triazol-1- yl)pyrazin-2-yl]ethyl]- 6,8- bis(trifluoromethyl)quina- zolin-4-amine [00213] 1.08 456 3 P.56 N-[1-[3-(triazol-2- yl)pyrazin-2-yl]ethyl]- 6,8- bis(trifluoromethyl)quina- zolin-4-amine [00214] 1.09 456 3 189- 191 P.57 6-[5-[1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00215] 1.11 493 3 P.58 N-methyl-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00216] 1.01 469 3 P.59 6-[5-[1-[[2,6,8- tris(trifluoromethyl)quina- zolin-4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00217] 1.20 547 3 P.60 6-[5-[1-[[2-methyl-6,8- bis(trifluoromethyl)quina- zolin-4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00218] 1.16 494 3 P.61 6-[5-[1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00219] 1.07 479 3 P.62 6-[5-[1-[[8- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00220] 0.93 411 3 P.63 6-[5-[1-[[6-bromo-8- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00221] 1.05 489-491 (Br pattern) 3 P.64 6-[5-[1-[[6- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00222] 0.83 411 3 P.65 6-[5-[1-[(6,8- dichloroquinazolin-4- yl)amio]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00223] 0.96 411-415 (dichloro pattern) 3 P.66 6,8-dichloro-N-methyl- N-[1-(2-pyrimidin-2-yl- 1,2,4-triazol-3- yl)ethyl]quianzolin-4- amine [00224] 0.87 401-405 (dichloro pattern) 3 P.67 6,8-dichloro-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]quinolin-4-amine [00225] 0.63 386-390 (dichloro pattern) 1 P.68 6,8-dichloro-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl)quinazolin-4- amine [00226] 0.81 387-391 (dichloro pattern) 1 P.69 N-[1-[2-(2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-5- (trifluoromethyl)isoquino- lin-1-amine [00227] 1.12 385 3 P.70 7-bromo-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]isoquinolin-1- amine [00228] 0.92 396-398 (Br pattern) 3 P.71 8-bromo-N-methyl-N-[1- (2-pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00229] 0.97 481 4 178- 180 P.72 6-[3-[1-[[8-chloro-6- (trifluoromethyl)quinazolin- 4-yl]- (cyclopropylmethyl)amino] ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00230] 1.28 511 4 81-83 P.73 6-[3-[1-[[8-bromo-6- (trifluoromethyl)quinazolin- 4-yl]- (cyclopropylmethyl)amino] ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00231] 1.28 556 4 81-83 P.74 6-[3-[1-[[6-bromo-8- (trifluoromethyl)quinazolin- 4-yl]- (cyclopropylmethyl)amino] ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00232] 1.29 556 4 251- 253 P.75 N-(cyclopropylmethyl)- N-[1-[3-(triazol-2- yl)pyrazin-2-yl]ethyl]- 6,8- bis(trifluoromethyl)quina- zolin-4-amine [00233] 1.27 510 4 P.76 8-chloro-N- (cyclopropylmethyl)-N- [1-[3-(triazol-2- yl)pyrazin-2-yl]ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00234] 1.21 477 4 110- 112 P.77 6-chloro-N- (cyclopropylmethyl)-N- [1-[3-(triazol-2- yl)pyrazin-2-yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00235] 1.24 476 4 P.78 6-bromo-N- (cyclopropylmethyl)-N- [1-[3-(triazol-2- yl)pyrazin-2-yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00236] 1.27 521 4 P.79 6-bromo-N-[1-[2-(5- bromo-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00237] 1.62 544 5 214- 216 P.80 6-bromo-N- (cyclopropylmethyl)-N- [1-(3-pyrimidin-2- ylpyrazin-2-yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00238] 1.76 532 5 169- 171 P.81 8-chloro-N- (cyclopropylmethyl)-N- [1-(3-pyrimidin-2- ylpyrazin-2-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00239] 1.67 486 5 64-66 P.82 cyclopropyl-[4-[methyl- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]amino]-8- (trifluoromethyl)quinazolin- 6-yl]methanone [00240] 0.96 470 3 P.83 N-[1-(2-pyrimidin-2-yl- 1,2,4-triazol-3-yl)ethyl]- 5,7- bis(trifluoromethyl)iso- quinolin-1-amine [00241] 1.08 454 3 P.84 N-methyl-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-8- (trifluoromethyl)-6- (trifluoromethylsulfanyl) quinazolin-4-amine [00242] 1.08 502 3 P.85 N-[1-(3-pyrimidin-2- ylpyrazin-2-yl)ethyl]-6,8- bis(trifluoromethyl)quino- lin-4-amine [00243] 0.90 465 3 P.86 6-iodo-N-methyl-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3-o yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00244] 75-80 P.87 6-iodo-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00245] 0.96 513 3 252- 255 P.88 N-methyl-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6,8- bis(trifluoromethyl)quino- lin-4-amine [00246] 1.04 469 3 P.89 N-[1-[2-(5- bromopyrimidin-2-yl)- 1,2,4-triazol-3-yl]ethyl]- N-methyl-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00247] 1.11 547-549 (Br pattern) 3 P.90 6-chloro-8- (difluoromethoxy)-N- methyl-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]quinazolin-4- amine [00248] 0.83 433 3 P.91 8-chloro-6- (difluoromethoxy)-N- methyl-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]quinazolin-4- amine [00249] 0.83 433 3 P.92 N-[1-[2-(5- bromopyrimidin-2-yl)- 1,2,4-triazol-3-yl]ethyl]- 6,8- bis(trifluoromethyl)quina- zolin-4-amine [00250] 1.07 533-535 (Br pattern) 3 P.93 6-chloro-8- (difluoromethoxy)-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]quinazolin-4- amine [00251] 0.79 419-421 (Cl pattern) 3 P.94 8-chloro-6- (difluoromethoxy)-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]quinazolin-4- amine [00252] 0.80 419-421 (Cl pattern) 3 P.95 8-iodo-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00253] 0.96 513 3 174- 177 P.96 8-bromo-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00254] 0.93 476-478 (Br pattern) 4 250- 252 P.97 8-bromo-N-methyl-N-[1- (3-pyrimidin-2-ylpyrazin- 2-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00255] 1.03 490-492 (Br pattern) 4 110- 112 P.98 6-bromo-N-methyl-N-[1- (3-pyrimidin-2-ylpyrazin- 2-yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00256] 1.61 490-492 (Br pattern) 5 120- 122 P.99 8-bromo-N- (cyclopropylmethyl)-N- [1-(3-pyrimidin-2- ylpyrazin-2-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00257] 1.71 530-532 (Br pattern) 5 79-81 P.100 8-chloro-N-methyl-N-[1- (3-pyrimidin-2-ylpyrazin- 2-yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00258] 1.46 446 5 152- 154 P.101 8-chloro-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00259] 1.47 432 5 240- 242 P.102 8-chloro-N-methyl-N-[1- [3-(triazol-2-yl)pyrazin- 2-yl]ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00260] 1.59 435 5 164- 166 P.103 N-methyl-N-[1-[3- (triazol-2-yl)pyrazin-2- yl]ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00261] 1.16 470 4 134- 135 P.104 8-bromo-N-methyl-N-[1- [3-(triazol-2-yl)pyrazin- 2-yl]ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00262] 1.10 479-481 (Br pattern) 4 164- 165 P.105 6-bromo-N-methyl-N-[1- [3-(triazol-2-yl)pyrazin- 2-yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00263] 1.15 479-481 (Br pattern) 4 175- 177 P.106 N-[1-(3-pyrimidin-2- ylpyrazin-2-yl)ethyl]-6,8- bis(trifluromethyl)quina- zolin-4-amine [00264] 1.10 456 4 223- 225 P.107 N-methyl-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00265] 1.66 480 5 139- 141 P.108 N-(cyclopropylmethyl)- N-[1-(3-pyrimidin-2- ylpyrazin-2-yl)ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00266] 1.20 521 4 75-77 P.109 N-[1-[3-[5- (difluoromethoxy)-2- pyridyl]pyrazin-2- yl]ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00267] 1.21 532 4 141- 143 P.110 N-[1-[3-[5- (difluoromethoxy)-2- pyridyl]pyrazin-2- yl]ethyl]-N-methyl-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00268] 1.21 546 4 212- 123 P.111 8-bromo-N-[1-[3-[5- (difluoromethoxy)-2- pyridyl]pyrazin-2- yl]ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00269] 1.15 543 4 147- 149 P.112 8-chloro-N-[1-[3-[5- (difluroomethoxy)-2- pyridyl]pyrazin-2- yl]ethyl]-N-methyl-6- (trifluoromethyl)quinazolin- 4-amine [00270] 1.15 511 4 80-82 P.113 8-chloro-N-[1-[3-[5- (difluoromethoxy)-2- pyridyl]pyrazin-2- yl]ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00271] 1.12 498 4 109- 111 P.114 8-bromo-N-[1-[3-[5- (difluoromethoxy)-2- pyridyl]pyrazin-2- yl]ethyl]-N-methyl-6- (trifluoromethyl)quinazolin- 4-amine [00272] 1.17 557 4 76-78 P.115 6-[3-[1-[[6,8- bis(trifluoromethyl)quina- zolin-4- yl]amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00273] 1.15 491 4 248- 250 P.116 6-[3-[1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-methyl- amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00274] 1.18 505 4 192- 194 P.117 6-[3-[1-[[8-bromo-6- (trifluoromethyl)quinazolin- 4- yl]amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00275] 1.58 500-502 (Br pattern) 5 252- 254 P.118 6-[3-[1-[[6-chloro-8- (trifluoromethyl)quinazolin- 4- yl]amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00276] 159 456 5 216- 218 P.119 6-[3-[1-[[6-bromo-8- (trifluoromethyl)quinazolin- 4- yl]amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00277] 1.14 500-502 (Br pattern) 4 214- 216 P.120 6-chloro-N-[1-[3-[5- (difluoromethoxy)-2- pyridyl]pyrazin-2- yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00278] 1.69 497 5 248- 250 P.121 6-[3-[1-[[8-chloro-6- (trifluoromethyl)quinazolin- 4- yl]amino]ethyl]pryazin-2- yl]pyridine-3-carbonitrile [00279] 1.53 456 5 249- 251 P.122 6-[3-[1-[[[8-chloro-6- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00280] 1.55 470 5 201- 203 P.123 6-chloro-N-[1-[3-[5- (difluoromethoxy)-2- pyridyl]pyrazin-2- yl]ethyl]-N-methyl-8- (trifluoromethyl)quinazolin- 4-amine [00281] 1.20 511 4 140- 142 P.124 6-[3-[1-[[8-bromo-6- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00282] 1.67 514-516 (Br pattern) 5 186- 188 P.125 6-[3-[1-[[6-bromo-8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00283] 1.74 514-516 (Br pattern) 5 225- 227 P.126 6-[3-[1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]- (cyclopropylmethyl)amino] ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00284] 1.31 545 4 165- 167 P.127 6-bromo-N-methyl-N-[1- (2-pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00285] 1.53 479-481 (Br pattern) 5 200- 202 P.128 6-[5-[(1S)-1-[[6-chloro-8- (trifluoromethyl)quinazolin- 4-yl]-ethyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00286] 75-77 P.129 6-chloro-N-methyl-N-[1- [3-(triazol-2-yl)pyrazin- 2-yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00287] 1.16 470 4 150- 152 P.130 6-chloro-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00288] 1.04 446 4 226- 230 P.131 6-chloro-N- (cyclopropylmethyl)-N- [1-(3-pyrimidin-2- ylpyrazin-2-yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00289] 1.68 486 5 161- 163 P.132 6-chloro-N-methyl-N-[1- (3-pyrimidin-2-ylpyrazin- 2-yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00290] 1.04 446 4 144- 146 P.133 6-bromo-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00291] 1.61 490-492 (Br pattern) 5 193- 195 P.134 6-[5-[(1R)-1-[[6,8- bis(trifluoromethyl)cinnolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3- carboxamide [00292] 0.94 497 3 P.135 6-[5-[(1R)-1-[[6,8- bis(trifluoromethyl)cinnolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00293] 1.01 480 3 P.136 N-[1-(2-pyrimidin-2-yl- 1,2,4-triazol-3-yl)ethyl]- 6,8- bis(trifluoromethyl)cinnolin- 4-amine [00294] 0.91 455 3 P.137 6-chloro-N-methyl-N- [(1S)-1-[2-[5-(1H- tetrazol-5-yl)-2-pyridyl]- 1,2,4-triazol-3-yl]ethyl]- 8- (trifluoromethyl)quinazolin- 4-amine [00295] 1.06 502.27 4 77-79 P.138 4-[[(1S)-1-(2-pyrimidin- 2-yl-1,2,4-triazol-3- yl)ethyl]amino]-6,8- bis(trifluoromethyl)quino- line-3-carbonitrile [00296] 1.10 479.63 4 203- 205 P.139 4-[[(1S)-1-[2-(5-cyano-2- pyridyl)-1,2,4-triazol-3- yl]ethyl]amino]-6,8- bis(trifluoromethyl)quino- line-3-carbonitrile [00297] 1.18 503.21 4 204- 206 P.140 4-[methyl-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]amino]- 6,8- bis(trifluoromethyl)quino- line-3-carbonitrile [00298] 1.13 493.63 4 84-86 P.141 4-[[(1S)-1-[2-(5-cyano-2- pyridyl)-1,2,4-triazol-3- yl]ethyl]-methyl-amino]- 6,8- bis(trifluoromethyl)quino- line-3-carbonitrile [00299] 1.19 517.26 4 88-90 P.142 6-chloro-N-methyl-8- (trifluoromethyl)-N-[(1S)- 1-[2-[5-[4- (trifluoromethyl)thiazol- 2-yl]-2-pyridyl]-1,2,4- triazol-3- yl]ethyl]quinazolin-4- amine [00300] 1.26 535.24 4 84-86 P.143 6-chloro-N-methyl-N- [(1S)-1-[2-(5-thiazol-2- yl-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00301] 1.19 517.25 4 142- 144 P.144 6-bromo-8-chloro-N- methyl-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]quinazolin-4- amine [00302] 0.90 456 3 P.145 N-[(1S)-1-(2-pyrimidin- 2-yl-1,2,4-triazol-3- yl)ethyl]-6,8- bis(trifluoromethyl)- 1,2,3-benzotriazin-4- amine [00303] 0.92 456 3 P.146 6-cyclopropyl-N-methyl- N-[(1S)-1-(2-pyrimidin- 2-yl-1,2,4-triazol-3- yl)ethyl]-8- (trifluroomethyl)quinazolin- 4-amine [00304] 0.97 441 3 182- 184 P.147 8-cyclopropyl-N-methyl- N-[(1S)-1-(2-pyrimidin- 2-yl-1,2,4-triazol-3- yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00305] 0.89 441 3 P.148 6-[3-[(1S)-1-[[6-iodo-8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00306] 1.15 562 3 P.149 6-[3-[(1S)-1-[[8-iodo-6- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00307] 1.15 562 3 P.150 6-chloro-N-methyl-N- [(1S)-1-[2-[5-(1,2,4- oxadiazol-3-yl)-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00308] 1.16 502.39 4 144- 146 P.151 6-chloro-N-methyl-8- (trifluoromethyl)-N-[(1S)- 1-[2-[5-[5- (trifluoromethyl)-1,2,4- oxadiazol-3-yl]-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]quinazolin-4- amine [00309] 1.27 570.25 4 75-77 P.152 8-chloro-N-[1-[2-[5- (difluoromethoxy)-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00310] 1.52 486.1 5 240- 242 P.153 8-chloro-N-[1-[2-[5- (difluoromethoxy)-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]-N-methyl-6- (trifluoromethyl)quinazolin- 4-amine [00311] 1.53 500.2 5 102- 104 P.154 8-bromo-N-[1-[2-[5- (difluoromethoxy)-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]-N-methyl-6- (trifluoromethyl)quinazolin- 4-amine [00312] 1.55 546.1 5 75-77 P.155 6-[5-[(1S)-1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carboxamide [00313] 1.05 511.66 4 183- 185 P.156 6-[5-[(1S)-1-[[6-chloro-8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]-N′-hydroxy- pyridine-3- carboxamidine [00314] 1.01 492.26 4 223- 225 P.157 6-[5-[(1S)-1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3- carboxamide [00315] 1.03 497.27 4 P.158 6-[5-[1-[(8-bromo-6- chloro-quinazolin-4- yl)amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00316] 0.98 455 3 P.159 6-bromo-8-chloro-N-[1- (2-pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]quinazolin-4- amine [00317] 0.81 431 3 P.161 6-[3-[(1S)-1-[[8-iodo-6- (trifluoromethyl)quinazolin- 4- yl]amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00318] 1.12 548 3 153- 155 P.162 6-[3-[(1S)-1-[[6-iodo-8- (trifluoromethyl)quinazolin- 4- yl]amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00319] 1.12 548 3 205- 208 P.163 6-[5-[(1S)-1-[[6- [cyclopropyl(difluoro)meth- yl]-8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00320] 1.12 515 3 P.164 N-[(1S)-1-[2-(5- bromopyrimidin-2-yl)- 1,2,4-triazol-3-yl]ethyl]- N-methyl-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00321] 1.11 547-549 (Br pattern) 3 P.165 6,8-dichloro-7-fluoro-N- methyl-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]quinazolin-4- amine [00322] 0.91 419 3 145- 225 P.166 6,8-dichloro-7-fluoro-N- [1-(2-pyrimidin-2-yl- 1,2,4-triazol-3- yl)ethyl]quinazolin-4- amine [00323] 0.86 405 3 215- 155 P.167 methyl N-[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-N-[1-[2-(5- cyano-2-pyridyl)-1,2,4- triazol-3- yl]ethyl]carbamate [00324] 1.08 537 3 P.168 6-[5-[(1S)-1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-ethyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00325] 1.15 507 3 P.169 6-[5-[(1S)-1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]- (methoxymethyl)amino] ethyl]-1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00326] 1.14 523 3 P.170 6-[5-[(1S)-1-[[6- (cyclopropanecarbonyl)- 8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00327] 1.06 493 3 P.171 8-bromo-6-chloro-N-[1- (2-pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]quinazolin-4- amine [00328] 0.84 431 3 205- 238 P.172 8-bromo-6-chloro-N- methyl-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]quinazolin-4- amine [00329] 0.89 445 3 P.173 8-bromo-6-chloro-N-[1- [3-(triazol-2-yl)pyrazin- 2-yl]ethyl]quinazolin-4- amine [00330] 0.93 431 3 175- 200 P.174 8-bromo-6-chloro-N- methyl-N-[1-[3-(triazol- 2-yl)pyrazin-2- yl]ethyl]quinazolin-4- amine [00331] 1.00 445 3 105- 166 P.175 6-[3-[(1S)-1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-methyl- amino]ethyl]-5-methyl- pyraizn-2-yl]pyridine-3- carbonitrile [00332] 1.22 518 3 P.176 3-fluoro-N-methyl-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]-6,8- bis(trifluoromethyl)quino- lin-4-amine [00333] 1.10 486 3 P.177 6-[5-[(1S)-1-[[6- cyclopropyl-8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00334] 1.09 465 3 P.178 6-bromo-8-chloro-N-[1- (3-pyrimidin-2-ylpyrazin- 2-yl)ethyl]quinazolin-4- amine [00335] 0.83 442 3 P.179 8-bromo-N-methyl-N-[1- [3-(triazol-2-yl)pyrazin- 2-yl]ethyl]-6- (trifluoromethoxy)quinazo- lin-4-amine [00336] 1.07 495 3 P.180 6-bromo-8- (difluoromethoxy)-N- methyl-N-[1-[3-(triazol- 2-yl)pyrazin-2- yl]ethyl]quinazolin-4- amine [00337] 0.93 477 3 P.181 3-chloro-N-methyl-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]-6,8- bis(trifluoromethyl)quino- lin-4-amine [00338] 1.14 502 3 P.182 8-bromo-6-chloro-N- methyl-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]quinazolin-4- amine [00339] 0.90 456 3 P.183 8-bromo-6-chloro-N-[1- (3-pyrimidin-2-ylpyrazin- 2-yl)ethyl]quinazolin-4- amine [00340] 0.84 424 3 P.184 6-[5-[(1S)-1-[[6-iodo-8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00341] 1.10 551 3 100- 102 P.185 8-bromo-N-[1-[2-(5- fluoro-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-N- methyl-6- (trifluoromethyl)quinazolin- 4-amine [00342] 1.55 495.9 (Br pattern) 5 159- 161 P.186 8-bromo-N-[1-[2-(5- fluoro-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00343] 1.51 483.9 (Br pattern) 5 270- 272 P.187 6-chloro-N-[1-[2-(5- fluoro-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-N- methyl-8- (trifluoromethyl)quinazolin- 4-amine [00344] 1.57 452.3 5 140- 142 P.188 6-bromo-N-[1-[2-(5- fluoro-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-N- methyl-8- (trifluoromethyl)quinazolin- 4-amine [00345] 1.59 496.3 (Br pattern) 5 144- 146 P.189 N-[1-[2-(5-fluoro-2- pyridyl)-1,2,4-triazol-3- yl]ethyl]-N-methyl-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00346] 130- 132 P.190 6-[5-[(1S)-1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbothioamide [00347] 1.12 528.04 4 186- 188 P.191 6-[5-[(1S)-1-[[6-chloro-8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbothioamide [00348] 1.10 493.24 4 169- 171 P.192 N-[2-[2-[5- (difluoromethoxy)-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]-N-methyl-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00349] 1.61 534.1 5 124- 126 P.193 N-[1-[2-[5- (difluoromethoxy)-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00350] 1.59 520 5 226- 228 P.194 6-bromo-N-[1-[2-[5- (difluoromethoxy)-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]-N-methyl-8- (trifluoromethyl)quinazolin- 4-amine [00351] 1.19 545.74 4 138- 140 P.195 6-bromo-N-[1-[2-[5- (difluoromethoxy)-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00352] 1.59 430.0 5 247- 249 P.196 6-bromo-N-[1-[3-(5- bromo-2-pyridyl)pyrazin- 2-yl]ethyl]-N-methyl-8- (trifluoromethyl)quinazolin- 4-amine [00353] 1.29 569.24 4 166- 168 P.197 N-[1-[3-(5-bromo-2- pyridyl)pyrazin-2- yl]ethyl]-8-chloro-N- methyl-6- (trifluoromethyl)quinazolin- 4-amine [00354] 1.24 523.14 4 142- 144 P.198 6-bromo-N-[1-[3-(5- bromo-2-pyridyl)pyrazin- 2-yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00355] 1.28 553.04 4 232- 234 P.199 N-[1-[3-(5-bromo-2- pyridyl)pyrazin-2- yl]ethyl]-8-chloro-6- (trifluoromethyl)quinazolin- 4-amine [00356] 1.23 509.13 4 230- 232 P.200 6-[3-[1-[[6-chloro-8- (trifluoromethyl)quinazolin- 4-yl]- (cyclopropylmethyl)amino] ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00357] 1.28 510.36 4 254- 256 P.201 8- [cyclopropyl(difluoro)meth- yl]-N-methyl-N-[(1S)- 1-(2-pyrimidin-2-yl- 1,2,4-triazol-3-yl)ethyl]- 6- (trifluoromethyl)quinazolin- 4-amine [00358] 1.09 491 3 P.202 N-methyl-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethyl)-8- (trifluoromethylsulfonyl) quinazolin-4-amine [00359] 1.04 433 3 P.203 6-[5-[(1R)-1-[[6-bromo- 8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00360] 1.09 503 (Br pattern) 3 P.204 6-[5-[(1S)-1-[[6-bromo- 8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00361] 1.09 503 (Br pattern) 3 P.205 N-[1-(5-bromo-2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- chloro-N-methyl-8- (trifluoromethyl)quinazolin- 4-amine [00362] 1.05 513 3 149- 151 P.206 6-[5-[(1S)-1-[[6-bromo- 8-(trifluoromethyl)-4- quinolyl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00363] 1.09 502 3 P.207 N-[1-(5-bromo-2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-8- chloro-N-methyl-6- (trifluoromethyl)quinazolin- 4-amine [00364] 1.10 513 3 239- 242 P.208 6-bromo-N-methyl-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00365] 0.99 478-4.80 (Br pattern) 3 P.209 8-bromo-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethyl)quinolin- 4-amine [00366] 0.68 464-466 (Br pattern) 3 247- 250 P.210 6-[5-[1-[[5,7- bis(trifluoromethyl)-1- isoquinolyl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00367] 1.18 478 3 P.211 6-[5-[1-[[5,7- bis(trifluoromethyl)-1- isoquinolyl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3 carbonitrile [00368] 1.21 492 3 P.212 3-bromo-N-methyl-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]-6,8- bis(trifluoromethyl)quino- lin-4-amine [00369] 1.15 546-548 (Br pattern) 3 P.213 6-[5-[(1S)-1-[[8- [cyclopropyl(difluoro)meth- yl]-6- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00370] 1.18 515 3 90-92 P.214 6-[5-[(1S)-1-[[6,8- bis(trifluoromethyl)-4- quinolyl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00371] 1.13 492 3 P.215 6-[5-[(1S)-1-[methyl-[6- (trifluoromethyl)-8- (trifluoromethylsulfanyl) quinazolin-4- yl]amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00372] 1.19 525 3 75-78 P.216 6-[5-[1-[[6-bromo-8- (trifluoromethoxy)quinazo- lin-4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00373] 1.06 519 3 149- 150 P.217 6-[5-[1-[[8-bromo-6- (trifluoromethoxy)quinazo- lin-4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00374] 1.07 519 3 70-73 P.218 6-[5-[(1S)-1-[[6-iodo-8- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitirle [00375] 1.08 537 3 264- 266 P.219 8-iodo-N-methyl-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00376] 1.01 427 3 135- 137 P.220 6-[5-[1-[[6- (trifluoromethoxy)-8- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00377] 1.08 495 3 145- 157 P.221 6-[5-[1-[methyl-[6- (trifluoromethoxy)-8- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00378] 1.11 509 3 P.222 6-[5-[1-[(6,8-dichloro-7- fluoro-quinazolin-4- yl)amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00379] 0.98 429 3 215- 225 P.223 6-[5-[1-[(6,8-dichloro-7- fluoro-quinazolin-4-yl)- methyl-amino)ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00380] 1.01 443 3 145- 155 P.224 4-[1-[2-(5-cyano-2- pyridyl)-1,2,4-tirazol-3- yl]ethyl-methyl-amino]- 6,8- bis(trifluoromethy)quino- line-3-carbonitrile [00381] 1.61 515.0 5 174- 176 P.225 N-[(4- methoxyphenyl)methyl]- N-[1-(3-pyrimidin-2- ylpyrazin-2-yl)ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00382] 1.21 586.71 4 112- 114 P.226 phenyl N-[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-N-[(1S)-1-[2- (5-cyano-2-pyridyl)- 1,2,4-triazol-3- yl]ethyl]carbamate [00383] 1.21 599.74 4 95-97 P.227 6-[5-[(1S)-1-[[8- (cyclopropanecarbonyl)- 6- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00384] 0.97 493 3 P.228 6-[5-[(1S)-1-[[8-iodo-6- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00385] 1.12 551 3 86-90 P.229 8-bromo-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-6- (trifluoromethoxy)quinazo- line-4-amine [00386] 0.91 481 3 P.230 6-[5-[1-[[6-bromo-8- (difluoromethoxy)quinazo- lin-4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00387] 0.96 501-503 (Br pattern) 3 P.231 6-bromo-N-[1-[2-(5- fluoro-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00388] 1.57 481.9 (Br pattern) 5 282- 284 P.232 8-chloro-N-[1-[2-(5- fluoro-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-N- methyl-6- (trifluoromethyl)quinazolin- 4-amine [00389] 1.52 452.0 5 184- 186 P.233 N-[1-[2-(5-fluoro-2- pyridyl)-1,2,4-triazol-3- yl]ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00390] 1.59 472.0 5 274- 276 P.234 6-chloro-N-[1-[2-(5- fluroo-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00391] 1.56 438.0 5 262- 264 P.235 6-chloro-N-[1-[2-[5- (difluoromethoxy)-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00392] 1.12 486.31 4 236- 238 P.236 6-chloro-N-[1-[2-[5- (difluoromethoxy)-2- pyridyl]-1,2,4-triazol-3- yl]ethyl]-N-methyl-8- (trifluoromethyl)quinazolin- 4-amine [00393] 1.59 500 5 131- 133 P.237 6-bromo-N-[1-[2-(5- bromo-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-N- methyl-8- (trifluoromethyl)quinazolin- 4-amine [00394] 1.65 557.8 (Di- bromo pattern) 5 119- 121 P.238 N-[1-[2-(5-bromo-2- pyridyl)-1,2,4-triazol-3- yl]ethyl]-6-chloro-N- methyl-8- (trifluoromethyl)quinazolin- 4-amine [00395] 1.65 513.9 (Br + Cl pattern) 5 122- 124 P.239 8-bromo-N-[1-[2-(5- bromo-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-N- methyl-6- (trifluoromethyl)quinazolin- 4-amine [00396] 1.63 557.8 (Di- bromo pattern) 5 123- 125 P.240 N-[1-[2-(5-bromo-2- pyridyl)-1,2,4-triazol-3- yl]ethyl]-8-chloro-N- methyl-6- (trifluoromethyl)quinazolin- 4-amine [00397] 1.59 513.9 (Br, Cl pattern) 5 130- 132 P.241 N-[1-[2-(5-bromo-2- pyridyl)-1,2,4-triazol-3- yl]ethyl]-N-methyl-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00398] 1.67 547.9 (Br pattern) 5 157- 159 P.242 4-[1-[2-(5-cyano-2- pyridyl)-1,2,4-triazol-3- yl]ethylamino]-6,8- bis(trifluoromethyl)quino- ine-3-carbonitrile [00399] 1.18 503.64 4 261- 263 P.243 6-bromo-8- (difluoromethoxy)-N-[1- (2-pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]quinazolin-4- amine [00400] 0.80 363-465 (Br pattern) 3 220- 223 P.244 6-[5-[1-[[6-bromo-8- (difluoromethoxy)quinazo- lin-4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00401] 0.93 487-489 (Br pattern) 3 P.245 6-bromo-8- (difluoromethoxy)-N- methyl-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3- yl)ethyl]quinazolin-4- amine [00402] 0.84 477-479 (Br pattern) 3 P.246 6-[5-[1-[[8-bromo-6- (trifluoromethoxy)quinazo- lin-4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00403] 1.02 505-507 (Br patterns) 3 P.247 6-[5-[1-[[6-bromo-8- (trifluoromethoxy)quinazo- lin-4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00404] 1.03 505-507 (Br pattern) 3 P.248 6-bromo-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-8- (trifluoromethoxy)quina- zolin-4-amine [00405] 0.91 481-483 (Br pattern) 3 133- 135 P.249 N-methyl-N-[1-(3- pyrimidin-2-ylpyrazin-2- yl)ethyl]-6,8- bis(trifluoromethyl)quino- lin-4-amine [00406] 1.08 479 3 P.250 N-methyl-N-[1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-5,7- bis(trifluoromethyl)isoquino- lin-1-amine [00407] 1.12 468 3 P.251 6-[5-[(1S)-1-[[6,8- bis(trifluoromethyl)-4- quinolyl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00408] 1.02 478 3 P.252 6-[5-[(1S)-1-[[6-bromo- 8-(trifluoromethyl)-4- quinolyl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00409] 0.89 488-490 (Br pattern) 3 P.253 6-bromo-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-8- (trifluoromethyl)quinolin- 4-amine [00410] 0.76 464-466 (Br pattern) 3 245- 250 P.254 6-[5-[(1S)-1-[[8-bromo- 6-(trifluoromethyl)-4- quinolyl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00411] 098 502-504 (Br pattern) 3 170- 172 P.255 8-bromo-N-methyl-N- [(1S)-1-(2-pyrimidn-2- yl-1,2,4-triazol-3- yl)ethyl]-6- (trifluoromethyl)quinolin- 4-amine [00412] 0.88 478-480 (Br pattern) 3 162- 165 P.256 6-[5-[(1S)-1-[[8-bromo- 6-(trifluoromethyl)-4- quinolyl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00413] 0.78 488-490 (Br pattern) 3 262- 265 P.257 6-[5-[1-[(6,8- dibromoquinazolin-4-yl)- methyl-amino]ethyl]- 1,2,4-triazol-1- yl]pyridin-3-carbonitrile [00414] 1.02 513 3 155- 159 P.258 6,8-dibromo-N-methyl- N-[1-(2-pyrimidin-2-yl- 1,2,4-triazol-3- yl)ethyl]quinazolin-4- amine [00415] 0.90 489 3 135- 142 P.259 N-[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-N-[1-[2-(5- cyano-2-pyridyl)-1,2,4- triazol-3- yl]ethyl]acetamide [00416] 1.03 521 3 P.260 6-[5-[1-[allyl-[6,8- bis(trifluoromethyl)quina- zolin-4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00417] 1.18 519 3 P.261 6-[5-[1-[[6,8- bis(trifluoromethyl)quina- zolin-4-yl]-prop-2-ynyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00418] 1.10 517 3 P.262 N-methyl-N-[(1S)-1-(2- pyrimidin-2-yl-1,2,4- triazol-3-yl)ethyl]-8- (trifluoromethyl)-6- (trifluoromethylsulfonyl) quinazolin-4-amine [00419] 1.04 533 3 P.263 6-[5-[(1S)-1-[[8-iodo-6- (trifluoromethyl)quinazolin- 4-yl]amino]ethyl]- 1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00420] 1.08 537 3 236- 238 P.264 6-[5-[(1S)-1-[[6-chloro-8- (trifluoromethyl)quinazolin- 4-yl]- (cyclopropylmethyl)amino] ethyl]-1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00421] 1.25 499.26 4 75-77 P.265 6-chloro-N- (cyclopropylmethyl)-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]-8- (trifluoromethyl)quinazolin- 4-amine [00422] 1.17 475.29 4 110- 112 P.266 6-[5-[1-[[8-bromo-6- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00423] 1.10 503.13 4 165- 167 P.267 N-[1-[2-(5-bromo-2- pyridyl)-1,2,4-triazol-3- yl]ethyl]-8-chloro-6- (trifluoromethyl)quinazolin- 4-amine [00424] 1.59 497.8 (Cl pattern) 5 273- 275 P.268 N-[1-[2-(5-bromo-2- pyridyl)-1,2,4-triazol-3- yl]ethyl]-6,8- bis(trifluoromethyl)quina- zolin-4-amine [00425] 1.21 532.11 4 274- 276 P.269 8-bromo-N-[1-[2-(5- bromo-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00426] 1.17 542.07 (Di- bromo pattern) 4 280- 282 P.270 N-[1-[2-(5-bromo-2- pyridyl)-1,2,4-triazol-3- yl]ethyl]-6-chloro-8- (trifluoromethyl)quinazolin- 4-amine [00427] 1.61 5 274- 276 P.271 6-[5-[(1S)-1-[[8-chloro-6- (trifluoromethyl)quinazolin- 4-yl]- (cyclopropylmethyl)amino] ethyl]-1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00428] 1.18 499.27 4 128- 130 P.272 8-chloro-N- (cyclopropylmethyl)-N- [(1S)-1-(2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00429] 1.50 475.0 5 72-74 P.273 6-bromo-N-[1-[3-[5- (difluoromethoxy)-2- pyridyl]pyrazin-2- yl]ethyl]-N-methyl-8- (trifluoromethyl)quinazolin- 4-amine [00430] 1.21 554.74 4 120- 122 P.274 8-chloro-N-[1-[2-(5- fluroo-2-pyridyl)-1,2,4- triazol-3-yl]ethyl]-6- (trifluoromethyl)quinazolin- 4-amine [00431] 1.51 437.9 5 P.275 6-[3-[1-[[6-chloro-8- (trifluoromethyl)quinazolin- 4-yl]-methyl- amino]ethyl]pyrazin-2- yl]pyridine-3-carbonitrile [00432] 1.20 470.21 4 217- 219 P.276 6- [cyclopropyl(difluoro)meth- yl]-N-methyl-N-[(1S)- 1-(2-pyrimidin-2-yl- 1,2,4-triazol-3-yl)ethyl]- 8- (trifluromethyl)quinazolin- 4-amine [00433] 1.05 491 3 P.277 8-chloro-N-[1-[3-(triazol- 2-yl)pyrazin-2- yl]ethyl]pyrido[3,4- d]pyrimidin-4-amine [00434] 0.72 354 3

[0807] Table for Compounds of formula III(i):

TABLE-US-00013 RT [M + H] Entry IUPAC name STRUCTURE (min) (measured) Method NMR III(i).1 6-[5-(1-aminoethyl)-3- bromo-1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00435] 0.65 293, 295 1 III(i).2 1-[5-bromo-2-[5-(2,2- difluoroethoxy)pyrimidin-2- yl]-1,2,4-triazol-3- yl]ethanamine [00436] 0.37 349, 351 1 III(i).3 1-[2-[5-(2,2- difluoroethoxy)pyrimidin-2- yl]-1,2,4-triazol-3- yl]ethanamine [00437] 1 III(i).4 6-[5-(1-aminoethyl)-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00438] 0.22 215 1 III(i).5 1-[2-[5- (difluoromethoxy)pyrimidin- 2-yl]-1,2,4-triazol-3- yl]ethanamine [00439] 2 III(i).6 1-[5-bromo-2-[5-(2,2,2- trifluoroethoxy)pyrimidin-2- yl]-1,2,4-triazol-3- yl]ethanamine [00440] III(i).7 1-[2-(5-fluoro-2-pyridyl)- 1,2,4-triazol-3- yl]ethanamine [00441] 0.24 208 1 III(i).8 1-[5-bromo-2-(5-fluoro-2- pyridyl)-1,2,4-triazol-3- yl]ethanamine [00442] 3 III(i).9 1-(5-bromo-2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethanamine [00443] 0.52 269, 271 1 III(i).10 1-(5-methoxy-2-pyrimidin- 2-yl-1,2,4-triazol-3- yl)ethanamine [00444] 0.18 221 1 III(i).11 5-(1-aminoethyl)-1- pyrimidin-2-yl-1,2,4- triazole-3-carbonitrile [00445] 0.56 216 1 III(i).12 1-[5-(2-methoxyethoxy)-2- pyrimidin-2-yl-1,2,4- 3-yl]ethanamine [00446] 0.19 265 1 III(i).13 1-(5-chloro-2-pyrimidin-2- yl-1,2,4-triazol-3- yl)ethanamine) [00447] 0.20 225, 227 1 III(i).14 1-(5-methylsulfonyl-2- pyrimidin-2-yl-1,2,4-triazol- 3-yl)ethanamine) [00448] 0.31 269 1 III(i).15 1-[3-(5-fluoro-2- pyridyl)pyrazin-2- 3-yl)ethanamine [00449] 0.32 219 1 III(i).16 1-(3-pyrimidin-2-ylpyrazin- 2-yl)ethanamine [00450] 0.40 202 1 III(i).17 1-[3-(2-pyridyl)pyrazin-2- yl]ethanamine [00451] III(i).18 1-[3-(5- cyclopropylpyrimidin-2- yl)pyrazin-2-yl]ethanamine [00452] III(i).19 1-[3-[5-(2,2- difluoroethoxy)pyrimidin-2- yl]pyrazin-2-yl]ethanamine [00453] III(i).20 1-[3-(5-bromo-2- pyridyl)pyrazin-2- yl]ethanamine [00454] III(i).21 6-[3-(1-aminoethyl)pyrazin- 2-yl]pyridine-3-carbonitrile [00455] III(i).22 1-[3-(triazol-2-yl)pyrazin-2- yl]ethanamine [00456] 0.18 191 1

TABLE-US-00014 RT [M + H] Entry IUPAC name STRUCTURE (min (measured) Method V(i).1 2-(1-bromoethyl)-3- pyrimidin-2-yl-pyrazine [00457] 0.65 265, 267 1 V(i).2 2-[5-(1-bromoethyl)-1,2,4- triazol-1-yl]pyridine [00458] 0.82 253, 255 1 V(i).3 2-[5-(1-bromoethyl)-1,2,4- triazol-1-yl]pyrimidine [00459] 0.63 254, 256 1 V(i).4 2-[3-bromo-5-(1- bromoethyl)-1,2,4-triazol-1- yl]pyrimidine [00460] 0.85 332, 334, 336 1 V(i).5 2-[3-bromo-5-(1- bromoethyl)-1,2,4-triazol-1- yl]-5-(2,2,2- trifluoroethoxy)pyrimidine [00461] V(i).6 6-[5-(1-bromoethyl)-1,2,4- triazol-1-yl]pyridine-3- carbonitrile [00462] 0.88 278, 280 1 V(i).7 6-[3-bromo-5-(1- bromoethyl)-1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00463] 1.01 356, 358, 360 1 V(i).8 2-[5-(1-bromoethyl)-1,2,4- triazol-1-yl]-5- (difluoromethoxy)pyrimidine [00464] 0.82 320, 322 1 V(i).9 2-[3-bromo-5-(1- bromoethyl)-1,2,4-triazol-1- yl]-5- (difluoromethoxy)pyridine [00465] V(i).10 2-[5-(1-bromoethyl)-1,2,4- triazol-1-yl]-5-(2,2- difluoroethoxy) pyrimidine [00466] 0.82 334, 336 1 V(i).11 5-(1-bromoethyl)-1-[4- (trifluoromethoxy)phenyl]- 1,2,4-triazole [00467] 1.04 336, 338 1 V(i).12 5-(1-chloroethyl)-1-[4- (trifluoromethoxy)phenyl]- 1,2,4-triazole [00468] 1.02 292 1 V(i)-13 2-[3-bromo-5-(1- bromoethyl)-1,2,4-triazol-1- yl]-5-(2,2- difluoroethoxy)pyrimidine [00469] 0.96 412, 414, 416 1 V(i).14 2-[5-(1-bromoethyl)-3- methoxy-1,2,4-triazol-1- yl]pyrimidine [00470] 0.75 284, 286 1 V(i).15 2-[5-(1-bromoethyl)-1,2,4- triazol-1-yl]-5-fluoro- pyridine [00471] 0.88 271, 273 1 V(i).16 5-(1-bromoethyl)-1- pyrimidin-2-yl-1,2,4- triazole-3-carbonitrile [00472] 0.85 279, 281 1 V(i).17 2-[5-(1-bromoethyl)-3- chloro-1,2,4-triazol-1- yl]pyrimidine [00473] 0.84 288, 290, 292 1 V(i).18 2-[5-(1-bromoethyl)-3-(2- methoxyethoxy)-1,2,4- triazol-1-yl]pyrimidine [00474] 0.78 328, 330 1 V(i).19 4-[3-bromo-5-(1- bromoethyl)-1,2,4-triazol-1- yl]-2-fluoro-pyridine [00475] 0.97 349, 351, 353 1 V(i).20 2-[3-bromo-5-(1- bromoethyl)-1,2,4-triazol-1- yl]-5-fluoro-pyridine [00476] 1.07 349, 351, 353 1 V(i).21 6-[5-(1-bromoethyl)-3- cyano-1,2,4-triazol-1- yl]pyridine-3-carbonitrile [00477] 1.00 303, 305 1 V(i).22 5-bromo-2-[5-(1- bromoethyl)-1,2,4-triazol-1- yl]pyrimidine [00478]

[0808] Table for Compounds of formula VII(i):

TABLE-US-00015 RT [M + H] Entry IUPAC name STRUCTURE (min) (measured) Method VII(i).1 1-[2-(2-pyridyl)-1,2,4- triazol-3-yl]ethanone [00479] 0.50 189 1 VII(i).2 1-(3-pyrimidin-2-ylpyrazin- 2-yl)ethanone [00480] 0.41 201 1 VII(i).3 1-[3-(5-fluoro-2- pyridyl)pyrazin-2- yl]ethanone [00481] 0.77 218 1 VII(i).4 1-[3-(2-pyridyl)pyrazin-2- yl]ethanone [00482] 0.35 200 1 VII(i).5 1-[3-(5- cyclopropylpyrimidin-2- yl)pyrazin-2-yl]ethanone [00483] VII(i).6 6-(3-acetylpyrazin-2- yl)pyridine-3-carbonitrile [00484] 0.73 225 1 VII(i).7 1-[3-[5-(2,2,2- trifluoroethoxy)-2- pyridyl]pyrazin-2- yl]ethanone [00485] VII(i).8 1-[3-[5- (difluoro methoxy) pyrimidin- 2-yl]pyrazin-2-yl]ethanone [00486] VII(i).9 1-[3-(5-chloro-2- pyridyl)pyrazin-2- yl]ethanone [00487] VII(i).10 1-[3-(5-bromo-2- pyridyl)pyrazin-2- yl]ethanone [00488] VII(i).11 1-[3-(triazol-2-yl)pyrazin-2- yl]ethanone [00489] 0.53 190 1 [0809] 1. 1H NMR (400 MHz, DMSO) δ ppm 1.57 (d, J=6.97 Hz, 3H) 4.65 (td, J=14.67, 3.30 Hz, 2H) 5.10 (q, J=6.85 Hz, 1H) 6.34-6.67 (m, 1H) 7.47 (br s, 2H) 8.30 (s, 1H) 8.85 (s, 2H); [0810] 2. 1 H NMR (400 MHz, DMSO d6) δ ppm 1.57-1.62 (d, 3H) 5.02-5.33 (q, 1H) 7.28-7.72 (t, 1H) 7.73-7.99 (s, 2H) 8.25-8.44 (s, 1H) 8.93-9.10 (s, 2H); [0811] 3. 1H NMR (400 MHz, DMSO) δ ppm 1.54 (d, J=6.97 Hz, 3H) 5.04 (d, J=6.60 Hz, 1H) 6.97-7.16 (m, 2H) 7.91-7.99 (m, 1H) 8.06-8.15 (m, 1H) 8.65 (d, J=2.93 Hz, 1H); 19F NMR (377 MHz, DMSO) δ ppm −126.89 (s, 1 F)

[0812] The activity of the compositions according to the invention can be broadened considerably, and adapted to prevailing circumstances, by adding other insecticidally, acaricidally and/or fungicidally active ingredients. The mixtures of the compounds of formula I with other insecticidally, acaricidally and/or fungicidally active ingredients may also have further surprising advantages which can also be described, in a wider sense, as synergistic activity. For example, better tolerance by plants, reduced phytotoxicity, insects can be controlled in their different development stages or better behaviour during their production, for example during grinding or mixing, during their storage or during their use.

[0813] Suitable additions to active ingredients here are, for example, representatives of the following classes of active ingredients: organophosphorus compounds, nitrophenol derivatives, thioureas, juvenile hormones, formamidines, benzophenone derivatives, ureas, pyrrole derivatives, carbamates, pyrethroids, chlorinated hydrocarbons, acylureas, pyridylmethyleneamino derivatives, macrolides, neonicotinoids and Bacillus thuringiensis preparations.

[0814] The following mixtures of a compound of formula I with an active substances are preferred (the abbreviation “TX” means “one compound selected from the compounds defined in Tables D-1 to D-66 and Table P”):

[0815] an adjuvant selected from the group of substances consisting of petroleum oils (alternative name) (628)+TX,

[0816] an insect control active substance selected from Abamectin+TX, Acequinocyl+TX, Acetamiprid+TX, Acetoprole+TX, Acrinathrin+TX, Acynonapyr+TX, Afidopyropen+TX, Afoxolaner+TX, Alanycarb+TX, Allethrin+TX, Alpha-Cypermethrin+TX, Alphamethrin+TX, Amidoflumet+TX, Aminocarb+TX, Azocyclotin+TX, Bensultap+TX, Benzoximate+TX, Benzpyrimoxan+TX, Betacyfluthrin+TX, Beta-cypermethrin+TX, Bifenazate+TX, Bifenthrin+TX, Binapacryl+TX, Bioallethrin+TX, Bioallethrin S)-cyclopentylisomer+TX, Bioresmethrin+TX, Bistrifluron+TX, Broflanilide+TX, Brofluthrinate+TX, Bromophos-ethyl+TX, Buprofezine+TX, Butocarboxim+TX, Cadusafos+TX, Carbaryl+TX, Carbosulfan+TX, Cartap+TX, CAS number: 1472050-04-6+TX, CAS number: 1632218-00-8+TX, CAS number: 1808115-49-2+TX, CAS number: 2032403-97-5+TX, CAS number: 2044701-44-0+TX, CAS number: 2128706-05-6+TX, CAS number: 2249718-27-0 (or CAS 2246757-58-2)+TX, CAS number: 907187-07-9+TX, Chlorantraniliprole+TX, Chlordane+TX, Chlorfenapyr+TX, Chloroprallethrin+TX, Chromafenozide+TX, Clenpirin+TX, Cloethocarb+TX, Clothianidin+TX, 2-chlorophenyl N-methylcarbamate (CPMC)+TX, Cyanofenphos+TX, Cyantraniliprole+TX, Cyclaniliprole+TX, Cyclobutrifluram+TX, Cycloprothrin+TX, Cycloxaprid+TX, Cycloxaprid+TX, Cyenopyrafen+TX, Cyetpyrafen+TX, Cyflumetofen+TX, Cyfluthrin+TX, Cyhalodiamide+TX, Cyhalothrin+TX, Cypermethrin+TX, Cyphenothrin+TX, Cyproflanilide+TX, Cyromazine+TX, Deltamethrin+TX, Diafenthiuron+TX, Dialifos+TX, Dibrom+TX, Dicloromezotiaz+TX, Diflovidazine+TX, Diflubenzuron+TX, dimpropyridaz+TX, Dinactin+TX, Dinocap+TX, Dinotefuran+TX, Dioxabenzofos+TX, Emamectin (Emamectin Benzoate)+TX, Empenthrin+TX, Epsilon−momfluorothrin+TX, Epsilon-metofluthrin+TX, Esfenvalerate+TX, Ethion+TX, Ethiprole+TX, Etofenprox+TX, Etoxazole+TX, Famphur+TX, Fenazaquin+TX, Fenfluthrin+TX, Fenitrothion+TX, Fenobucarb+TX, Fenothiocarb+TX, Fenoxycarb+TX, Fenpropathrin+TX, Fenpyroxymate+TX, Fensulfothion+TX, Fenthion+TX, Fentinacetate+TX, Fenvalerate+TX, Fipronil+TX, Flometoquin+TX, Flonicamid+TX, Fluacrypyrim+TX, Fluazaindolizine+TX, Fluazuron+TX, Flubendiamide+TX, Flubenzimine+TX, Flucitrinate+TX, Flucycloxuron+TX, Flucythrinate+TX, Fluensulfone+TX, Flufenerim+TX, Flufenprox+TX, Flufiprole+TX, Fluhexafon+TX, Flumethrin+TX, Fluopyram+TX, Flupentiofenox+TX, Flupyradifurone+TX, Flupyrimin+TX, Fluralaner+TX, Fluvalinate+TX, Fluxametamide+TX, Fosthiazate+TX, Gamma-Cyhalothrin+TX, Gossyplure™+TX, Guadipyr+TX, Halofenozide+TX, Halofenozide+TX, Halfenprox+TX, Heptafluthrin+TX, Hexythiazox+TX, Hydramethylnon+TX, Imicyafos+TX, Imidacloprid+TX, Imiprothrin+TX, Indoxacarb+TX, Iodomethane+TX, Iprodione+TX, Isocycloseram+TX, Isothioate+TX, Ivermectin+TX, Kappa-bifenthrin+TX, Kappa-tefluthrin+TX, Lambda-Cyhalothrin+TX, Lepimectin+TX, Lufenuron+TX, Metaflumizone+TX, Metaldehyde+TX, Metam+TX, Methomyl+TX, Methoxyfenozide+TX, Metofluthrin+TX, Metolcarb+TX, Mexacarbate+TX, Milbemectin+TX, Momfluorothrin+TX, Niclosamide+TX, Nicofluprole+TX; Nitenpyram+TX, Nithiazine+TX, Omethoate+TX, Oxamyl+TX, Oxazosulfyl+TX, Parathion-ethyl+TX, Permethrin+TX, Phenothrin+TX, Phosphocarb+TX, Piperonylbutoxide+TX, Pirimicarb+TX, Pirimiphos-ethyl+TX, Polyhedrosis virus+TX, Prallethrin+TX, Profenofos+TX, Profenofos+TX, Profluthrin+TX, Propargite+TX, Propetamphos+TX, Propoxur+TX, Prothiophos+TX, Protrifenbute+TX, Pyflubumide+TX, Pymetrozine+TX, Pyraclofos+TX, Pyrafluprole+TX, Pyridaben+TX, Pyridalyl+TX, Pyrifluquinazon+TX, Pyrimidifen+TX, Pyriminostrobin+TX, Pyriprole+TX, Pyriproxyfen+TX, Resmethrin+TX, Sarolaner+TX, Selamectin+TX, Silafluofen+TX, Spinetoram+TX, Spinosad+TX, Spirodiclofen+TX, Spiromesifen+TX, Spiropidion+TX, Spirotetramat+TX, Sulfoxaflor+TX, Tebufenozide+TX, Tebufenpyrad+TX, Tebupirimiphos+TX, Tefluthrin+TX, Temephos+TX, Tetrachlorantraniliprole+TX, Tetradiphon+TX, Tetramethrin+TX, Tetramethylfluthrin+TX, Tetranactin+TX, Tetraniliprole+TX, Theta-cypermethrin+TX, Thiacloprid+TX, Thiamethoxam+TX, Thiocyclam+TX, Thiodicarb+TX, Thiofanox+TX, Thiometon+TX, Thiosultap+TX, Tioxazafen+TX, Tolfenpyrad+TX, Toxaphene+TX, Tralomethrin+TX, Transfluthrin+TX, Triazamate+TX, Triazophos+TX, Trichlorfon+TX, Trichloronate+TX, Trichlorphon+TX, Triflumezopyrim+TX, Tyclopyrazoflor+TX, Zeta-Cypermethrin+TX, Extract of seaweed and fermentation product derived from melasse+TX, Extract of seaweed and fermentation product derived from melasse comprising urea+TX, amino acids+TX, potassium and molybdenum and EDTA-chelated manganese+TX, Extract of seaweed and fermented plant products+TX, Extract of seaweed and fermented plant products comprising phytohormones+TX, vitamins+TX, EDTA-chelated copper+TX, zinc+TX, and iron+TX, Azadirachtin+TX, Bacillus aizawai+TX, Bacillus chitinosporus AQ746 (NRRL Accession No B-21 618)+TX, Bacillus firmus+TX, Bacillus kurstaki+TX, Bacillus mycoides AQ726 (NRRL Accession No. B-21664)+TX, Bacillus pumilus (NRRL Accession No B-30087)+TX, Bacillus pumilus AQ717 (NRRL Accession No. B-21662)+TX, Bacillus sp. AQ178 (ATCC Accession No. 53522)+TX, Bacillus sp. AQ175 (ATCC Accession No. 55608)+TX, Bacillus sp. AQ177 (ATCC Accession No. 55609)+TX, Bacillus subtilis unspecified+TX, Bacillus subtilis AQ153 (ATCC Accession No. 55614)+TX, Bacillus subtilis AQ30002 (NRRL Accession No. B-50421)+TX, Bacillus subtilis AQ30004 (NRRL Accession No. B-50455)+TX, Bacillus subtilis AQ713 (NRRL Accession No. B-21661)+TX, Bacillus subtilis AQ743 (NRRL Accession No. B-21665)+TX, Bacillus thuringiensis AQ52 (NRRL Accession No. B-21619)+TX, Bacillus thuringiensis BD #32 (NRRL Accession No B-21530)+TX, Bacillus thuringiensis subspec. kurstaki BMP 123+TX, Beauveria bassiana+TX, D-limonene+TX, Granulovirus+TX, Harpin+TX, Helicoverpa armigera Nucleopolyhedrovirus+TX, Helicoverpa zea Nucleopolyhedrovirus+TX, Heliothis virescens Nucleopolyhedrovirus+TX, Heliothis punctigera Nucleopolyhedrovirus+TX, Metarhizium spp.+TX, Muscodor albus 620 (NRRL Accession No. 30547)+TX, Muscodor roseus A.sub.3-5 (NRRL Accession No. 30548)+TX, Neem tree based products+TX, Paecilomyces fumosoroseus+TX, Paecilomyces lilacinus+TX, Pasteuria nishizawae+TX, Pasteuria penetrans+TX, Pasteuria ramosa+TX, Pasteuria thornei+TX, Pasteuria usgae+TX, P-cymene+TX, Plutella xylostella Granulosis virus+TX, Plutella xylostella Nucleopolyhedrovirus+TX, Polyhedrosis virus+TX, pyrethrum+TX, QRD 420 (a terpenoid blend)+TX, QRD 452 (a terpenoid blend)+TX, QRD 460 (a terpenoid blend)+TX, Quillaja saponaria+TX, Rhodococcus globerulus AQ719 (NRRL Accession No B-21663)+TX, Spodoptera frugiperda Nucleopolyhedrovirus+TX, Streptomyces galbus (NRRL Accession No. 30232)+TX, Streptomyces sp. (NRRL Accession No. B-30145)+TX, Terpenoid blend+TX, and Verticillium spp.;

[0817] an algicide selected from the group of substances consisting of bethoxazin [CCN]+TX, copper dioctanoate (IUPAC name) (170)+TX, copper sulfate (172)+TX, cybutryne [CCN]+TX, dichlone (1052)+TX, dichlorophen (232)+TX, endothal (295)+TX, fentin (347)+TX, hydrated lime [CCN]+TX, nabam (566)+TX, quinoclamine (714)+TX, quinonamid (1379)+TX, simazine (730)+TX, triphenyltin acetate (IUPAC name) (347) and triphenyltin hydroxide (IUPAC name) (347)+TX;

[0818] an anthelmintic selected from the group of substances consisting of abamectin (1)+TX, crufomate (1011)+TX, Cyclobutrifluram+TX, doramectin (alternative name) [CCN]+TX, emamectin (291)+TX, emamectin benzoate (291)+TX, eprinomectin (alternative name) [CCN]+TX, ivermectin (alternative name) [CCN]+TX, milbemycin oxime (alternative name) [CCN]+TX, moxidectin (alternative name) [CCN]+TX, piperazine [CCN]+TX, selamectin (alternative name) [CCN]+TX, spinosad (737) and thiophanate (1435)+TX;

[0819] an avicide selected from the group of substances consisting of chloralose (127)+TX, endrin (1122)+TX, fenthion (346)+TX, pyridin-4-amine (IUPAC name) (23) and strychnine (745)+TX;

[0820] a bactericide selected from the group of substances consisting of 1-hydroxy-1H-pyridine-2-thione (IUPAC name) (1222)+TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (IUPAC name) (748)+TX, 8-hydroxyquinoline sulfate (446)+TX, bronopol (97)+TX, copper dioctanoate (IUPAC name) (170)+TX, copper hydroxide (IUPAC name) (169)+TX, cresol [CCN]+TX, dichlorophen (232)+TX, dipyrithione (1105)+TX, dodicin (1112)+TX, fenaminosulf (1144)+TX, formaldehyde (404)+TX, hydrargaphen (alternative name) [CCN]+TX, kasugamycin (483)+TX, kasugamycin hydrochloride hydrate (483)+TX, nickel bis(dimethyldithiocarbamate) (IUPAC name) (1308)+TX, nitrapyrin (580)+TX, octhilinone (590)+TX, oxolinic acid (606)+TX, oxytetracycline (611)+TX, potassium hydroxyquinoline sulfate (446)+TX, probenazole (658)+TX, streptomycin (744)+TX, streptomycin sesquisulfate (744)+TX, tecloftalam (766)+TX, and thiomersal (alternative name) [CCN]+TX;

[0821] a biological agent selected from the group of substances consisting of Adoxophyes orana GV (alternative name) (12)+TX, Agrobacterium radiobacter (alternative name) (13)+TX, Amblyseius spp. (alternative name) (19)+TX, Anagrapha falcifera NPV (alternative name) (28)+TX, Anagrus atomus (alternative name) (29)+TX, Aphelinus abdominalis (alternative name) (33)+TX, Aphidius colemani (alternative name) (34)+TX, Aphidoletes aphidimyza (alternative name) (35)+TX, Autographa californica NPV (alternative name) (38)+TX, Bacillus firmus (alternative name) (48)+TX, Bacillus sphaericus Neide (scientific name) (49)+TX, Bacillus thuringiensis Berliner (scientific name) (51)+TX, Bacillus thuringiensis subsp. aizawai (scientific name) (51)+TX, Bacillus thuringiensis subsp. israelensis (scientific name) (51)+TX, Bacillus thuringiensis subsp. japonensis (scientific name) (51)+TX, Bacillus thuringiensis subsp. kurstaki (scientific name) (51)+TX, Bacillus thuringiensis subsp. tenebrionis (scientific name) (51)+TX, Beauveria bassiana (alternative name) (53)+TX, Beauveria brongniartii (alternative name) (54)+TX, Chrysoperla carnea (alternative name) (151)+TX, Cryptolaemus montrouzieri (alternative name) (178)+TX, Cydia pomonella GV (alternative name) (191)+TX, Dacnusa sibirica (alternative name) (212)+TX, Diglyphus isaea (alternative name) (254)+TX, Encarsia formosa (scientific name) (293)+TX, Eretmocerus eremicus (alternative name) (300)+TX, Helicoverpa zea NPV (alternative name) (431)+TX, Heterorhabditis bacteriophora and H. megidis (alternative name) (433)+TX, Hippodamia convergens (alternative name) (442)+TX, Leptomastix dactylopii (alternative name) (488)+TX, Macrolophus caliginosus (alternative name) (491)+TX, Mamestra brassicae NPV (alternative name) (494)+TX, Metaphycus helvolus (alternative name) (522)+TX, Metarhizium anisopliae var. acridum (scientific name) (523)+TX, Metarhizium anisopliae var. anisopliae (scientific name) (523)+TX, Neodiprion sertifer NPV and N. lecontei NPV (alternative name) (575)+TX, Orius spp. (alternative name) (596)+TX, Paecilomyces fumosoroseus (alternative name) (613)+TX, Phytoseiulus persimilis (alternative name) (644)+TX, Spodoptera exigua multicapsid nuclear polyhedrosis virus (scientific name) (741)+TX, Steinernema bibionis (alternative name) (742)+TX, Steinernema carpocapsae (alternative name) (742)+TX, Steinernema feltiae (alternative name) (742)+TX, Steinernema glaseri (alternative name) (742)+TX, Steinernema riobrave (alternative name) (742)+TX, Steinernema riobravis (alternative name) (742)+TX, Steinernema scapterisci (alternative name) (742)+TX, Steinernema spp. (alternative name) (742)+TX, Trichogramma spp. (alternative name) (826)+TX, Typhlodromus occidentalis (alternative name) (844) and Verticillium lecanii (alternative name) (848)+TX;

[0822] a soil sterilant selected from the group of substances consisting of iodomethane (IUPAC name) (542) and methyl bromide (537)+TX;

[0823] a chemosterilant selected from the group of substances consisting of apholate [CCN]+TX, bisazir (alternative name) [CCN]+TX, busulfan (alternative name) [CCN]+TX, diflubenzuron (250)+TX, dimatif (alternative name) [CCN]+TX, hemel [CCN]+TX, hempa [CCN]+TX, metepa [CCN]+TX, methiotepa [CCN]+TX, methyl apholate [CCN]+TX, morzid [CCN]+TX, penfluron (alternative name) [CCN]+TX, tepa [CCN]+TX, thiohempa (alternative name) [CCN]+TX, thiotepa (alternative name) [CCN]+TX, tretamine (alternative name) [CCN] and uredepa (alternative name) [CCN]+TX;

[0824] an insect pheromone selected from the group of substances consisting of (E)-dec-5-en-1-yl acetate with (E)-dec-5-en-1-ol (IUPAC name) (222)+TX, (E)-tridec-4-en-1-yl acetate (IUPAC name) (829)+TX, (E)-6-methylhept-2-en-4-ol (IUPAC name) (541)+TX, (E,Z)-tetradeca-4,10-dien-1-yl acetate (IUPAC name) (779)+TX, (Z)-dodec-7-en-1-yl acetate (IUPAC name) (285)+TX, (Z)-hexadec-11-enal (IUPAC name) (436)+TX, (Z)-hexadec-11-en-1-yl acetate (IUPAC name) (437)+TX, (Z)-hexadec-13-en-11-yn-1-yl acetate (IUPAC name) (438)+TX, (Z)-icos-13-en-10-one (IUPAC name) (448)+TX, (Z)-tetradec-7-en-1-al (IUPAC name) (782)+TX, (Z)-tetradec-9-en-1-ol (IUPAC name) (783)+TX, (Z)-tetradec-9-en-1-yl acetate (IUPAC name) (784)+TX, (7E,9Z)-dodeca-7,9-dien-1-yl acetate (IUPAC name) (283)+TX, (9Z,11E)-tetradeca-9,11-dien-1-yl acetate (IUPAC name) (780)+TX, (9Z,12E)-tetradeca-9,12-dien-1-yl acetate (IUPAC name) (781)+TX, 14-methyloctadec-1-ene (IUPAC name) (545)+TX, 4-methylnonan-5-ol with 4-methylnonan-5-one (IUPAC name) (544)+TX, alpha-multistriatin (alternative name) [CCN]+TX, brevicomin (alternative name) [CCN]+TX, codlelure (alternative name) [CCN]+TX, codlemone (alternative name) (167)+TX, cuelure (alternative name) (179)+TX, disparlure (277)+TX, dodec-8-en-1-yl acetate (IUPAC name) (286)+TX, dodec-9-en-1-yl acetate (IUPAC name) (287)+TX, dodeca-8+TX, 10-dien-1-yl acetate (IUPAC name) (284)+TX, dominicalure (alternative name) [CCN]+TX, ethyl 4-methyloctanoate (IUPAC name) (317)+TX, eugenol (alternative name) [CCN]+TX, frontalin (alternative name) [CCN]+TX, gossyplure (alternative name) (420)+TX, grandlure (421)+TX, grandlure I (alternative name) (421)+TX, grandlure II (alternative name) (421)+TX, grandlure III (alternative name) (421)+TX, grandlure IV (alternative name) (421)+TX, hexalure [CCN]+TX, ipsdienol (alternative name) [CCN]+TX, ipsenol (alternative name) [CCN]+TX, japonilure (alternative name) (481)+TX, lineatin (alternative name) [CCN]+TX, litlure (alternative name) [CCN]+TX, looplure (alternative name) [CCN]+TX, medlure [CCN]+TX, megatomoic acid (alternative name) [CCN]+TX, methyl eugenol (alternative name) (540)+TX, muscalure (563)+TX, octadeca-2,13-dien-1-yl acetate (IUPAC name) (588)+TX, octadeca-3,13-dien-1-yl acetate (IUPAC name) (589)+TX, orfralure (alternative name) [CCN]+TX, oryctalure (alternative name) (317)+TX, ostramone (alternative name) [CCN]+TX, siglure [CCN]+TX, sordidin (alternative name) (736)+TX, sulcatol (alternative name) [CCN]+TX, tetradec-11-en-1-yl acetate (IUPAC name) (785)+TX, trimedlure (839)+TX, trimedlure A (alternative name) (839)+TX, trimedlure B.sub.1 (alternative name) (839)+TX, trimedlure B.sub.2 (alternative name) (839)+TX, trimedlure C (alternative name) (839) and trunc-call (alternative name) [CCN]+TX;

[0825] an insect repellent selected from the group of substances consisting of 2-(octylthio)ethanol (IUPAC name) (591)+TX, butopyronoxyl (933)+TX, butoxy(polypropylene glycol) (936)+TX, dibutyl adipate (IUPAC name) (1046)+TX, dibutyl phthalate (1047)+TX, dibutyl succinate (IUPAC name) (1048)+TX, diethyltoluamide [CCN]+TX, dimethyl carbate [CCN]+TX, dimethyl phthalate [CCN]+TX, ethyl hexanediol (1137)+TX, hexamide [CCN]+TX, methoquin-butyl (1276)+TX, methylneodecanamide [CCN]+TX, oxamate [CCN] and picaridin [CCN]+TX;

[0826] a molluscicide selected from the group of substances consisting of bis(tributyltin) oxide (IUPAC name) (913)+TX, bromoacetamide [CCN]+TX, calcium arsenate [CCN]+TX, cloethocarb (999)+TX, copper acetoarsenite [CCN]+TX, copper sulfate (172)+TX, fentin (347)+TX, ferric phosphate (IUPAC name) (352)+TX, metaldehyde (518)+TX, methiocarb (530)+TX, niclosamide (576)+TX, niclosamide-olamine (576)+TX, pentachlorophenol (623)+TX, sodium pentachlorophenoxide (623)+TX, tazimcarb (1412)+TX, thiodicarb (799)+TX, tributyltin oxide (913)+TX, trifenmorph (1454)+TX, trimethacarb (840)+TX, triphenyltin acetate (IUPAC name) (347) and triphenyltin hydroxide (IUPAC name) (347)+TX, pyriprole [394730-71-3]+TX;

[0827] a nematicide selected from the group of substances consisting of AKD-3088 (compound code)+TX, 1,2-dibromo-3-chloropropane (IUPAC/Chemical Abstracts name) (1045)+TX, 1,2-dichloropropane (IUPAC/Chemical Abstracts name) (1062)+TX, 1,2-dichloropropane with 1,3-dichloropropene (IUPAC name) (1063)+TX, 1,3-dichloropropene (233)+TX, 3,4-dichlorotetrahydrothiophene 1,1-dioxide (IUPAC/Chemical Abstracts name) (1065)+TX, 3-(4-chlorophenyl)-5-methylrhodanine (IUPAC name) (980)+TX, 5-methyl-6-thioxo-1,3,5-thiadiazinan-3-ylacetic acid (IUPAC name) (1286)+TX, 6-isopentenylaminopurine (alternative name) (210)+TX, abamectin (1)+TX, acetoprole [CCN]+TX, alanycarb (15)+TX, aldicarb (16)+TX, aldoxycarb (863)+TX, AZ 60541 (compound code)+TX, benclothiaz [CCN]+TX, benomyl (62)+TX, butylpyridaben (alternative name)+TX, cadusafos (109)+TX, carbofuran (118)+TX, carbon disulfide (945)+TX, carbosulfan (119)+TX, chloropicrin (141)+TX, chlorpyrifos (145)+TX, cloethocarb (999)+TX, Cyclobutrifluram+TX, cytokinins (alternative name) (210)+TX, dazomet (216)+TX, DBCP (1045)+TX, DCIP (218)+TX, diamidafos (1044)+TX, dichlofenthion (1051)+TX, dicliphos (alternative name)+TX, dimethoate (262)+TX, doramectin (alternative name) [CCN]+TX, emamectin (291)+TX, emamectin benzoate (291)+TX, eprinomectin (alternative name) [CCN]+TX, ethoprophos (312)+TX, ethylene dibromide (316)+TX, fenamiphos (326)+TX, fenpyrad (alternative name)+TX, fensulfothion (1158)+TX, fosthiazate (408)+TX, fosthietan (1196)+TX, furfural (alternative name) [CCN]+TX, GY-81 (development code) (423)+TX, heterophos [CCN]+TX, iodomethane (IUPAC name) (542)+TX, isamidofos (1230)+TX, isazofos (1231)+TX, ivermectin (alternative name) [CCN]+TX, kinetin (alternative name) (210)+TX, mecarphon (1258)+TX, metam (519)+TX, metam-potassium (alternative name) (519)+TX, metam-sodium (519)+TX, methyl bromide (537)+TX, methyl isothiocyanate (543)+TX, milbemycin oxime (alternative name) [CCN]+TX, moxidectin (alternative name) [CCN]+TX, Myrothecium verrucaria composition (alternative name) (565)+TX, NC-184 (compound code)+TX, oxamyl (602)+TX, phorate (636)+TX, phosphamidon (639)+TX, phosphocarb [CCN]+TX, sebufos (alternative name)+TX, selamectin (alternative name) [CCN]+TX, spinosad (737)+TX, terbam (alternative name)+TX, terbufos (773)+TX, tetrachlorothiophene (IUPAC/Chemical Abstracts name) (1422)+TX, thiafenox (alternative name)+TX, thionazin (1434)+TX, triazophos (820)+TX, triazuron (alternative name)+TX, xylenols [CCN]+TX, YI-5302 (compound code) and zeatin (alternative name) (210)+TX, fluensulfone [318290-98-1]+TX, fluopyram+TX;

[0828] a nitrification inhibitor selected from the group of substances consisting of potassium ethylxanthate [CCN] and nitrapyrin (580)+TX;

[0829] a plant activator selected from the group of substances consisting of acibenzolar (6)+TX, acibenzolar-S-methyl (6)+TX, probenazole (658) and Reynoutria sachalinensis extract (alternative name) (720)+TX;

[0830] a rodenticide selected from the group of substances consisting of 2-isovalerylindan-1,3-dione (IUPAC name) (1246)+TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (IUPAC name) (748)+TX, alpha-chlorohydrin [CCN]+TX, aluminium phosphide (640)+TX, antu (880)+TX, arsenous oxide (882)+TX, barium carbonate (891)+TX, bisthiosemi (912)+TX, brodifacoum (89)+TX, bromadiolone (including alpha-bromadiolone)+TX, bromethalin (92)+TX, calcium cyanide (444)+TX, chloralose (127)+TX, chlorophacinone (140)+TX, cholecalciferol (alternative name) (850)+TX, coumachlor (1004)+TX, coumafuryl (1005)+TX, coumatetralyl (175)+TX, crimidine (1009)+TX, difenacoum (246)+TX, difethialone (249)+TX, diphacinone (273)+TX, ergocalciferol (301)+TX, flocoumafen (357)+TX, fluoroacetamide (379)+TX, flupropadine (1183)+TX, flupropadine hydrochloride (1183)+TX, gamma-HCH (430)+TX, HCH (430)+TX, hydrogen cyanide (444)+TX, iodomethane (IUPAC name) (542)+TX, lindane (430)+TX, magnesium phosphide (IUPAC name) (640)+TX, methyl bromide (537)+TX, norbormide (1318)+TX, phosacetim (1336)+TX, phosphine (IUPAC name) (640)+TX, phosphorus [CCN]+TX, pindone (1341)+TX, potassium arsenite [CCN]+TX, pyrinuron (1371)+TX, scilliroside (1390)+TX, sodium arsenite [CCN]+TX, sodium cyanide (444)+TX, sodium fluoroacetate (735)+TX, strychnine (745)+TX, thallium sulfate [CCN]+TX, warfarin (851) and zinc phosphide (640)+TX;

[0831] a synergist selected from the group of substances consisting of 2-(2-butoxyethoxy)ethyl piperonylate (IUPAC name) (934)+TX, 5-(1,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone (IUPAC name) (903)+TX, farnesol with nerolidol (alternative name) (324)+TX, MB-599 (development code) (498)+TX, MGK 264 (development code) (296)+TX, piperonyl butoxide (649)+TX, piprotal (1343)+TX, propyl isomer (1358)+TX, S421 (development code) (724)+TX, sesamex (1393)+TX, sesasmolin (1394) and sulfoxide (1406)+TX;

[0832] an animal repellent selected from the group of substances consisting of anthraquinone (32)+TX, chloralose (127)+TX, copper naphthenate [CCN]+TX, copper oxychloride (171)+TX, diazinon (227)+TX, dicyclopentadiene (chemical name) (1069)+TX, guazatine (422)+TX, guazatine acetates (422)+TX, methiocarb (530)+TX, pyridin-4-amine (IUPAC name) (23)+TX, thiram (804)+TX, trimethacarb (840)+TX, zinc naphthenate [CCN] and ziram (856)+TX;

[0833] a virucide selected from the group of substances consisting of imanin (alternative name) [CCN] and ribavirin (alternative name) [CCN]+TX; a wound protectant selected from the group of substances consisting of mercuric oxide (512)+TX, octhilinone (590) and thiophanate-methyl (802)+TX;

[0834] a biologically active substance selected from 1,1-bis(4-chlorophenyl)-2-ethoxyethanol+TX, 2,4-dichlorophenyl benzenesulfonate+TX, 2-fluoro-N-methyl-N-1-naphthylacetamide+TX, 4-chlorophenyl phenyl sulfone+TX, acetoprole+TX, aldoxycarb+TX, amidithion+TX, amidothioate+TX, amiton+TX, amiton hydrogen oxalate+TX, amitraz+TX, aramite+TX, arsenous oxide+TX, azobenzene+TX, azothoate+TX, benomyl+TX, benoxafos+TX, benzyl benzoate+TX, bixafen+TX, brofenvalerate+TX, bromocyclen+TX, bromophos+TX, bromopropylate+TX, buprofezin+TX, butocarboxim+TX, butoxycarboxim+TX, butylpyridaben+TX, calcium polysulfide+TX, camphechlor+TX, carbanolate+TX, carbophenothion+TX, cymiazole+TX, chinomethionat+TX, chlorbenside+TX, chlordimeform+TX, chlordimeform hydrochloride+TX, chlorfenethol+TX, chlorfenson+TX, chlorfensulfide+TX, chlorobenzilate+TX, chloromebuform+TX, chloromethiuron+TX, chloropropylate+TX, chlorthiophos+TX, cinerin I+TX, cinerin II+TX, cinerins+TX, closantel+TX, coumaphos+TX, crotamiton+TX, crotoxyphos+TX, cufraneb+TX, cyanthoate+TX, DCPM+TX, DDT+TX, demephion+TX, demephion-O+TX, demephion-S+TX, demeton-methyl+TX, demeton-O+TX, demeton-O-methyl+TX, demeton-S+TX, demeton-S-methyl+TX, demeton-S-methylsulfon+TX, dichlofluanid+TX, dichlorvos+TX, dicliphos+TX, dienochlor+TX, dimefox+TX, dinex+TX, dinex-diclexine+TX, dinocap-4+TX, dinocap-6+TX, dinocton+TX, dinopenton+TX, dinosulfon+TX, dinoterbon+TX, dioxathion+TX, diphenyl sulfone+TX, disulfiram+TX, DNOC+TX, dofenapyn+TX, doramectin+TX, endothion+TX, eprinomectin+TX, ethoate-methyl+TX, etrimfos+TX, fenazaflor+TX, fenbutatin oxide+TX, fenothiocarb+TX, fenpyrad+TX, fenpyroximate+TX, fenpyrazamine+TX, fenson+TX, fentrifanil+TX, flubenzimine+TX, flucycloxuron+TX, fluenetil+TX, fluorbenside+TX, FMC 1137+TX, formetanate+TX, formetanate hydrochloride+TX, formparanate+TX, gamma-HCH+TX, glyodin+TX, halfenprox+TX, hexadecyl cyclopropanecarboxylate+TX, isocarbophos+TX, jasmolin I+TX, jasmolin II+TX, jodfenphos+TX, lindane+TX, malonoben+TX, mecarbam+TX, mephosfolan+TX, mesulfen+TX, methacrifos+TX, methyl bromide+TX, metolcarb+TX, mexacarbate+TX, milbemycin oxime+TX, mipafox+TX, monocrotophos+TX, morphothion+TX, moxidectin+TX, naled+TX, 4-chloro-2-(2-chloro-2-methyl-propyl)-5-[(6-iodo-3-pyridyl)methoxy]pyridazin-3-one+TX, nifluridide+TX, nikkomycins+TX, nitrilacarb+TX, nitrilacarb 1:1 zinc chloride complex+TX, omethoate+TX, oxydeprofos+TX, oxydisulfoton+TX, pp′-DDT+TX, parathion+TX, permethrin+TX, phenkapton+TX, phosalone+TX, phosfolan+TX, phosphamidon+TX, polychloroterpenes+TX, polynactins+TX, proclonol+TX, promacyl+TX, propoxur+TX, prothidathion+TX, prothoate+TX, pyrethrin I+TX, pyrethrin II+TX, pyrethrins+TX, pyridaphenthion+TX, pyrimitate+TX, quinalphos+TX, quintiofos+TX, R-1492+TX, phosglycin+TX, rotenone+TX, schradan+TX, sebufos+TX, selamectin+TX, sophamide+TX, SSI-121+TX, sulfiram+TX, sulfluramid+TX, sulfotep+TX, sulfur+TX, diflovidazin+TX, tau-fluvalinate+TX, TEPP+TX, terbam+TX, tetradifon+TX, tetrasul+TX, thiafenox+TX, thiocarboxime+TX, thiofanox+TX, thiometon+TX, thioquinox+TX, thuringiensin+TX, triamiphos+TX, triarathene+TX, triazophos+TX, triazuron+TX, trifenofos+TX, trinactin+TX, vamidothion+TX, vaniliprole+TX, bethoxazin+TX, copper dioctanoate+TX, copper sulfate+TX, cybutryne+TX, dichlone+TX, dichlorophen+TX, endothal+TX, fentin+TX, hydrated lime+TX, nabam+TX, quinoclamine+TX, quinonamid+TX, simazine+TX, triphenyltin acetate+TX, triphenyltin hydroxide+TX, crufomate+TX, piperazine+TX, thiophanate+TX, chloralose+TX, fenthion+TX, pyridin-4-amine+TX, strychnine+TX, 1-hydroxy-1H-pyridine-2-thione+TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide+TX, 8-hydroxyquinoline sulfate+TX, bronopol+TX, copper hydroxide+TX, cresol+TX, dipyrithione+TX, dodicin+TX, fenaminosulf+TX, formaldehyde+TX, hydrargaphen+TX, kasugamycin+TX, kasugamycin hydrochloride hydrate+TX, nickel bis(dimethyldithiocarbamate)+TX, nitrapyrin+TX, octhilinone+TX, oxolinic acid+TX, oxytetracycline+TX, potassium hydroxyquinoline sulfate+TX, probenazole+TX, streptomycin+TX, streptomycin sesquisulfate+TX, tecloftalam+TX, thiomersal+TX, Adoxophyes orana GV+TX, Agrobacterium radiobacter+TX, Amblyseius spp.+TX, Anagrapha falcifera NPV+TX, Anagrus atomus+TX, Aphelinus abdominalis+TX, Aphidius colemani+TX, Aphidoletes aphidimyza+TX, Autographa californica NPV+TX, Bacillus sphaericus Neide+TX, Beauveria brongniartii+TX, Chrysoperla carnea+TX, Cryptolaemus montrouzieri+TX, Cydia pomonella GV+TX, Dacnusa sibirica+TX, Diglyphus isaea+TX, Encarsia formosa+TX, Eretmocerus eremicus+TX, Heterorhabditis bacteriophora and H. megidis+TX, Hippodamia convergens+TX, Leptomastix dactylopii+TX, Macrolophus caliginosus+TX, Mamestra brassicae NPV+TX, Metaphycus helvolus+TX, Metarhizium anisopliae var. acridum+TX, Metarhizium anisopliae var. anisopliae+TX, Neodiprion sertifer NPV and N. lecontei NPV+TX, Orius spp.+TX, Paecilomyces fumosoroseus+TX, Phytoseiulus persimilis+TX, Steinernema bibionis+TX, Steinernema carpocapsae+TX, Steinernema feltiae+TX, Steinernema glaseri+TX, Steinernema riobrave+TX, Steinernema riobravis+TX, Steinernema scapterisci+TX, Steinernema spp.+TX, Trichogramma spp.+TX, Typhlodromus occidentalis+TX, Verticillium lecanii+TX, apholate+TX, bisazir+TX, busulfan+TX, dimatif+TX, hemel+TX, hempa+TX, metepa+TX, methiotepa+TX, methyl apholate+TX, morzid+TX, penfluron+TX, tepa+TX, thiohempa+TX, thiotepa+TX, tretamine+TX, uredepa+TX, (E)-dec-5-en-1-yl acetate with (E)-dec-5-en-1-ol+TX, (E)-tridec-4-en-1-yl acetate+TX, (E)-6-methylhept-2-en-4-ol+TX, (E,Z)-tetradeca-4,10-dien-1-yl acetate+TX, (Z)-dodec-7-en-1-yl acetate+TX, (Z)-hexadec-11-enal+TX, (Z)-hexadec-11-en-1-yl acetate+TX, (Z)-hexadec-13-en-11-yn-1-yl acetate+TX, (Z)-icos-13-en-10-one+TX, (Z)-tetradec-7-en-1-al+TX, (Z)-tetradec-9-en-1-ol+TX, (Z)-tetradec-9-en-1-yl acetate+TX, (7E,9Z)-dodeca-7,9-dien-1-yl acetate+TX, (9Z,11E)-tetradeca-9,11-dien-1-yl acetate+TX, (9Z,12E)-tetradeca-9,12-dien-1-yl acetate+TX, 14-methyloctadec-1-ene+TX, 4-methylnonan-5-ol with 4-methylnonan-5-one+TX, alpha-multistriatin+TX, brevicomin+TX, codlelure+TX, codlemone+TX, cuelure+TX, disparlure+TX, dodec-8-en-1-yl acetate+TX, dodec-9-en-1-yl acetate+TX, dodeca-8+TX, 10-dien-1-yl acetate+TX, dominicalure+TX, ethyl 4-methyloctanoate+TX, eugenol+TX, frontalin+TX, grandlure+TX, grandlure I+TX, grandlure II+TX, grandlure III+TX, grandlure IV+TX, hexalure+TX, ipsdienol+TX, ipsenol+TX, japonilure+TX, lineatin+TX, litlure+TX, looplure+TX, medlure+TX, megatomoic acid+TX, methyl eugenol+TX, muscalure+TX, octadeca-2,13-dien-1-yl acetate+TX, octadeca-3,13-dien-1-yl acetate+TX, orfralure+TX, oryctalure+TX, ostramone+TX, siglure+TX, sordidin+TX, sulcatol+TX, tetradec-11-en-1-yl acetate+TX, trimedlure+TX, trimedlure A+TX, trimedlure B.sub.1+TX, trimedlure B.sub.2+TX, trimedlure C+TX, trunc-call+TX, 2-(octylthio)ethanol+TX, butopyronoxyl+TX, butoxy(polypropylene glycol)+TX, dibutyl adipate+TX, dibutyl phthalate+TX, dibutyl succinate+TX, diethyltoluamide+TX, dimethyl carbate+TX, dimethyl phthalate+TX, ethyl hexanediol+TX, hexamide+TX, methoquin-butyl+TX, methylneodecanamide+TX, oxamate+TX, picaridin+TX, 1-dichloro-1-nitroethane+TX, 1,1-dichloro-2,2-bis(4-ethylphenyl)ethane+TX, 1,2-dichloropropane with 1,3-dichloropropene+TX, 1-bromo-2-chloroethane+TX, 2,2,2-trichloro-1-(3,4-dichlorophenyl)ethyl acetate+TX, 2,2-dichlorovinyl 2-ethylsulfinylethyl methyl phosphate+TX, 2-(1,3-dithiolan-2-yl)phenyl dimethylcarbamate+TX, 2-(2-butoxyethoxy)ethyl thiocyanate+TX, 2-(4,5-dimethyl-1,3-dioxolan-2-yl)phenyl methylcarbamate+TX, 2-(4-chloro-3,5-xylyloxy)ethanol+TX, 2-chlorovinyl diethyl phosphate+TX, 2-imidazolidone+TX, 2-isovalerylindan-1,3-dione+TX, 2-methyl(prop-2-ynyl)aminophenyl methylcarbamate+TX, 2-thiocyanatoethyl laurate+TX, 3-bromo-1-chloroprop-1-ene+TX, 3-methyl-1-phenylpyrazol-5-yl dimethylcarbamate+TX, 4-methyl(prop-2-ynyl)amino-3,5-xylyl methylcarbamate+TX, 5,5-dimethyl-3-oxocyclohex-1-enyl dimethylcarbamate+TX, acethion+TX, acrylonitrile+TX, aldrin+TX, allosamidin+TX, allyxycarb+TX, alpha-ecdysone+TX, aluminium phosphide+TX, aminocarb+TX, anabasine+TX, athidathion+TX, azamethiphos+TX, Bacillus thuringiensis delta endotoxins+TX, barium hexafluorosilicate+TX, barium polysulfide+TX, barthrin+TX, Bayer 22/190+TX, Bayer 22408+TX, beta-cyfluthrin+TX, beta-cypermethrin+TX, bioethanomethrin+TX, biopermethrin+TX, bis(2-chloroethyl) ether+TX, borax+TX, bromfenvinfos+TX, bromo-DDT+TX, bufencarb+TX, butacarb+TX, butathiofos+TX, butonate+TX, calcium arsenate+TX, calcium cyanide+TX, carbon disulfide+TX, carbon tetrachloride+TX, cartap hydrochloride+TX, cevadine+TX, chlorbicyclen+TX, chlordane+TX, chlordecone+TX, chloroform+TX, chloropicrin+TX, chlorphoxim+TX, chlorprazophos+TX, cis-resmethrin+TX, cismethrin+TX, clocythrin+TX, copper acetoarsenite+TX, copper arsenate+TX, copper oleate+TX, coumithoate+TX, cryolite+TX, CS 708+TX, cyanofenphos+TX, cyanophos+TX, cyclethrin+TX, cythioate+TX, d-tetramethrin+TX, DAEP+TX, dazomet+TX, decarbofuran+TX, diamidafos+TX, dicapthon+TX, dichlofenthion+TX, dicresyl+TX, dicyclanil+TX, dieldrin+TX, diethyl 5-methylpyrazol-3-yl phosphate+TX, dilor+TX, dimefluthrin+TX, dimetan+TX, dimethrin+TX, dimethylvinphos+TX, dimetilan+TX, dinoprop+TX, dinosam+TX, dinoseb+TX, diofenolan+TX, dioxabenzofos+TX, dithicrofos+TX, DSP+TX, ecdysterone+TX, EI 1642+TX, EMPC+TX, EPBP+TX, etaphos+TX, ethiofencarb+TX, ethyl formate+TX, ethylene dibromide+TX, ethylene dichloride+TX, ethylene oxide+TX, EXD+TX, fenchlorphos+TX, fenethacarb+TX, fenitrothion+TX, fenoxacrim+TX, fenpirithrin+TX, fensulfothion+TX, fenthion-ethyl+TX, flucofuron+TX, fosmethilan+TX, fospirate+TX, fosthietan+TX, furathiocarb+TX, furethrin+TX, guazatine+TX, guazatine acetates+TX, sodium tetrathiocarbonate+TX, halfenprox+TX, HCH+TX, HEOD+TX, heptachlor+TX, heterophos+TX, HHDN+TX, hydrogen cyanide+TX, hyquincarb+TX, IPSP+TX, isazofos+TX, isobenzan+TX, isodrin+TX, isofenphos+TX, isolane+TX, isoprothiolane+TX, isoxathion+TX, juvenile hormone I+TX, juvenile hormone II+TX, juvenile hormone III+TX, kelevan+TX, kinoprene+TX, lead arsenate+TX, leptophos+TX, lirimfos+TX, lythidathion+TX, m-cumenyl methylcarbamate+TX, magnesium phosphide+TX, mazidox+TX, mecarphon+TX, menazon+TX, mercurous chloride+TX, mesulfenfos+TX, metam+TX, metam-potassium+TX, metam-sodium+TX, methanesulfonyl fluoride+TX, methocrotophos+TX, methoprene+TX, methothrin+TX, methoxychlor+TX, methyl isothiocyanate+TX, methylchloroform+TX, methylene chloride+TX, metoxadiazone+TX, mirex+TX, naftalofos+TX, naphthalene+TX, NC-170+TX, nicotine+TX, nicotine sulfate+TX, nithiazine+TX, nornicotine+TX, O-5-dichloro-4-iodophenyl O-ethyl ethylphosphonothioate+TX, O,O-diethyl O-4-methyl-2-oxo-2H-chromen-7-yl phosphorothioate+TX, O,O-diethyl O-6-methyl-2-propylpyrimidin-4-yl phosphorothioate+TX, O,O,O′,O′-tetrapropyl dithiopyrophosphate+TX, oleic acid+TX, para-dichlorobenzene+TX, parathion-methyl+TX, pentachlorophenol+TX, pentachlorophenyl laurate+TX, PH 60-38+TX, phenkapton+TX, phosnichlor+TX, phosphine+TX, phoxim-methyl+TX, pirimetaphos+TX, polychlorodicyclopentadiene isomers+TX, potassium arsenite+TX, potassium thiocyanate+TX, precocene I+TX, precocene II+TX, precocene III+TX, primidophos+TX, profluthrin+TX, promecarb+TX, prothiofos+TX, pyrazophos+TX, pyresmethrin+TX, quassia+TX, quinalphos-methyl+TX, quinothion+TX, rafoxanide+TX, resmethrin+TX, rotenone+TX, kadethrin+TX, ryania+TX, ryanodine+TX, sabadilla)+TX, schradan+TX, sebufos+TX, SI-0009+TX, thiapronil+TX, sodium arsenite+TX, sodium cyanide+TX, sodium fluoride+TX, sodium hexafluorosilicate+TX, sodium pentachlorophenoxide+TX, sodium selenate+TX, sodium thiocyanate+TX, sulcofuron+TX, sulcofuron-sodium+TX, sulfuryl fluoride+TX, sulprofos+TX, tar oils+TX, tazimcarb+TX, TDE+TX, tebupirimfos+TX, temephos+TX, terallethrin+TX, tetrachloroethane+TX, thicrofos+TX, thiocyclam+TX, thiocyclam hydrogen oxalate+TX, thionazin+TX, thiosultap+TX, thiosultap-sodium+TX, tralomethrin+TX, transpermethrin+TX, triazamate+TX, trichlormetaphos-3+TX, trichloronat+TX, trimethacarb+TX, tolprocarb+TX, triclopyricarb+TX, triprene+TX, veratridine+TX, veratrine+TX, XMC+TX, zetamethrin+TX, zinc phosphide+TX, zolaprofos+TX, and meperfluthrin+TX, tetramethylfluthrin+TX, bis(tributyltin) oxide+TX, bromoacetamide+TX, ferric phosphate+TX, niclosamide-olamine+TX, tributyltin oxide+TX, pyrimorph+TX, trifenmorph+TX, 1,2-dibromo-3-chloropropane+TX, 1,3-dichloropropene+TX, 3,4-dichlorotetrahydrothiophene 1,1-dioxide+TX, 3-(4-chlorophenyl)-5-methylrhodanine+TX, 5-methyl-6-thioxo-1,3,5-thiadiazinan-3-ylacetic acid+TX, 6-isopentenylaminopurine+TX, 2-fluoro-N-(3-methoxyphenyl)-9H-purin-6-amine+TX, benclothiaz+TX, cytokinins+TX, DCIP+TX, furfural+TX, isamidofos+TX, kinetin+TX, Myrothecium verrucaria composition+TX, tetrachlorothiophene+TX, xylenols+TX, zeatin+TX, potassium ethylxanthate+TX,acibenzolar+TX, acibenzolar-S-methyl+TX, Reynoutria sachalinensis extract+TX, alpha-chlorohydrin+TX, antu+TX, barium carbonate+TX, bisthiosemi+TX, brodifacoum+TX, bromadiolone (including alpha-bromadiolone)+TX, bromethalin+TX, chlorophacinone+TX, cholecalciferol+TX, coumachlor+TX, coumafuryl+TX, coumatetralyl+TX, crimidine+TX, difenacoum+TX, difethialone+TX, diphacinone+TX, ergocalciferol+TX, flocoumafen+TX, fluoroacetamide+TX, flupropadine+TX, flupropadine hydrochloride+TX, norbormide+TX, phosacetim+TX, phosphorus+TX, pindone+TX, pyrinuron+TX, scilliroside+TX, sodium fluoroacetate+TX, thallium sulfate+TX, warfarin+TX, 2-(2-butoxyethoxy)ethyl piperonylate+TX, 5-(1,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone+TX, farnesol with nerolidol+TX, verbutin+TX, MGK 264+TX, piperonyl butoxide+TX, piprotal+TX, propyl isomer+TX, S421+TX, sesamex+TX, sesasmolin+TX, sulfoxide+TX, anthraquinone+TX, copper naphthenate+TX, copper oxychloride+TX, dicyclopentadiene+TX, thiram+TX, zinc naphthenate+TX, ziram+TX, imanin+TX, ribavirin+TX, mercuric oxide+TX, thiophanate-methyl+TX, azaconazole+TX, bitertanol+TX, bromuconazole+TX, cyproconazole+TX, difenoconazole+TX, diniconazole+TX, epoxiconazole+TX, fenbuconazole+TX, fluquinconazole+TX, flusilazole+TX, flutriafol+TX, furametpyr+TX, hexaconazole+TX, imazalil+TX, imiben-conazole+TX, ipconazole+TX, metconazole+TX, myclobutanil+TX, paclobutrazole+TX, pefurazoate+TX, penconazole+TX, prothioconazole+TX, pyrifenox+TX, prochloraz+TX, propiconazole+TX, pyrisoxazole+TX, simeconazole+TX, tebuconazole+TX, tetraconazole+TX, triadimefon+TX, triadimenol+TX, triflumizole+TX, triticonazole+TX, ancymidol+TX, fenarimol+TX, nuarimol+TX, bupirimate+TX, dimethirimol+TX, ethirimol+TX, dodemorph+TX, fenpropidin+TX, fenpropimorph+TX, spiroxamine+TX, tridemorph+TX, cyprodinil+TX, mepanipyrim+TX, pyrimethanil+TX, fenpiclonil+TX, fludioxonil+TX, benalaxyl+TX, furalaxyl+TX, metalaxyl-+TX, R-metalaxyl+TX, ofurace+TX, oxadixyl+TX, carbendazim+TX, debacarb+TX, fuberidazole+TX, thiabendazole+TX, chlozolinate+TX, dichlozoline+TX, myclozoline+TX, procymidone+TX, vinclozoline+TX, boscalid+TX, carboxin+TX, fenfuram+TX, flutolanil+TX, mepronil+TX, oxycarboxin+TX, penthiopyrad+TX, thifluzamide+TX, dodine+TX, iminoctadine+TX, azoxystrobin+TX, dimoxystrobin+TX, enestroburin+TX, fenaminstrobin+TX, flufenoxystrobin+TX, fluoxastrobin+TX, kresoxim-methyl+TX, metominostrobin+TX, trifloxystrobin+TX, orysastrobin+TX, picoxystrobin+TX, pyraclostrobin+TX, pyrametostrobin+TX, pyraoxystrobin+TX, ferbam+TX, mancozeb+TX, maneb+TX, metiram+TX, propineb+TX, zineb+TX, captafol+TX, captan+TX, fluoroimide+TX, folpet+TX, tolylfluanid+TX, bordeaux mixture+TX, copper oxide+TX, mancopper+TX, oxine-copper+TX, nitrothal-isopropyl+TX, edifenphos+TX, iprobenphos+TX, phosdiphen+TX, tolclofos-methyl+TX, anilazine+TX, benthiavalicarb+TX, blasticidin-S+TX, chloroneb+TX, chlorothalonil+TX, cyflufenamid+TX, cymoxanil+TX, cyclobutrifluram+TX, diclocymet+TX, diclomezine+TX, dicloran+TX, diethofencarb+TX, dimethomorph+TX, flumorph+TX, dithianon+TX, ethaboxam+TX, etridiazole+TX, famoxadone+TX, fenamidone+TX, fenoxanil+TX, ferimzone+TX, fluazinam+TX, fluopicolide+TX, flusulfamide+TX, fluxapyroxad+TX, fenhexamid+TX, fosetyl-aluminium+TX, hymexazol+TX, iprovalicarb+TX, cyazofamid+TX, methasulfocarb+TX, metrafenone+TX, pencycuron+TX, phthalide+TX, polyoxins+TX, propamocarb+TX, pyribencarb+TX, proquinazid+TX, pyroquilon+TX, pyriofenone+TX, quinoxyfen+TX, quintozene+TX, tiadinil+TX, triazoxide+TX, tricyclazole+TX, triforine+TX, validamycin+TX, valifenalate+TX, zoxamide+TX, mandipropamid+TX, flubeneteram+TX, isopyrazam+TX, sedaxane+TX, benzovindiflupyr+TX, pydiflumetofen+TX, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (3′,4′,5′-trifluoro-biphenyl-2-yl)-amide+TX, isoflucypram+TX, isotianil+TX, dipymetitrone+TX, 6-ethyl-5,7-dioxo-pyrrolo[4,5][1,4]dithiino[1,2-c]isothiazole-3-carbonitrile+TX, 2-(difluoromethyl)-N-[3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide+TX, 4-(2,6-difluorophenyl)-6-methyl-5-phenyl-pyridazine-3-carbonitrile+TX, (R)-3-(difluoromethyl)-1-methyl-N-[1,1,3-trimethylindan-4-yl]pyrazole-4-carboxamide+TX, 4-(2-bromo-4-fluoro-phenyl)-N-(2-chloro-6-fluoro-phenyl)-2,5-dimethyl-pyrazol-3-amine+TX, 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1, 3-dimethyl-1H-pyrazol-5-amine+TX, fluindapyr+TX, coumethoxystrobin (jiaxiangjunzhi)+TX, Ivbenmixianan+TX, dichlobentiazox+TX, mandestrobin+TX, 3-(4,4-difluoro-3,4-dihydro-3,3-dimethylisoquinolin-1-yl)quinolone+TX, 2-[2-fluoro-6-[(8-fluoro-2-methyl-3-quinolyl)oxy]phenyl]propan-2-ol+TX, oxathiapiprolin+TX, tert-butyl N-[6-[[[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate+TX, pyraziflumid+TX, inpyrfluxam+TX, trolprocarb+TX, mefentrifluconazole+TX, ipfentrifluconazole+TX, 2-(difluoromethyl)-N-[(3R)-3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide+TX, N′-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine+TX, N′-[4-(4,5-dichlorothiazol-2-yl)oxy-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine+TX, [2-[3-[2-[1-[2-[3,5-bis(difluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]-3-chloro-phenyl] methanesulfonate+TX, but-3-ynyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate+TX, methyl N-[[5-[4-(2,4-dimethylphenyl)triazol-2-yl]-2-methyl-phenyl]methyl]carbamate+TX, 3-chloro-6-methyl-5-phenyl-4-(2,4,6-trifluorophenyl)pyridazine+TX, pyridachlometyl+TX, 3-(difluoromethyl)-1-methyl-N-[1,1,3-trimethylindan-4-yl]pyrazole-4-carboxamide+TX, 1-[2-[[1-(4-chlorophenyl)pyrazol-3-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one+TX, 1-methyl-4-[3-methyl-2-[[2-methyl-4-(3,4,5-trimethylpyrazol-1-yl)phenoxy]methyl]phenyl]tetrazol-5-one+TX, aminopyrifen+TX, ametoctradin+TX, amisulbrom+TX, penflufen+TX, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide+TX, florylpicoxamid+TX, fenpicoxamid+TX, tebufloquin+TX, ipflufenoquin+TX, quinofumelin+TX, isofetamid+TX, N-[2-[2,4-dichloro-phenoxy]phenyl]-3-(difluoromethyl)-1-methyl-pyrazole-4-carboxamide+TX, N-[2-[2-chloro-4-(trifluoromethyl)phenoxy]phenyl]-3-(difluoromethyl)-1-methyl-pyrazole-4-carboxamide+TX, benzothiostrobin+TX, phenamacril+TX, 5-amino-1,3,4-thiadiazole-2-thiol zinc salt (2:1)+TX, fluopyram+TX, flutianil+TX, fluopimomide+TX, pyrapropoyne+TX, picarbutrazox+TX, 2-(difluoromethyl)-N-(3-ethyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide+TX, 2-(difluoromethyl)-N-((3R)-1, 1, 3-trimethylindan-4-yl) pyridine-3-carboxamide+TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile+TX, metyltetraprole+TX, 2-(difluoromethyl)-N-((3R)-1, 1, 3-trimethylindan-4-yl) pyridine-3-carboxamide+TX, α-(1, 1-dimethylethyl)-α-[4′-(trifluoromethoxy) [1, 1′-biphenyl]-4-yl]-5-pyrimidinemethanol+TX, fluoxapiprolin+TX, enoxastrobin+TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy] benzonitrile+TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-sulfanyl-1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy] benzonitrile+TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4H-1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile+TX, trinexapac+TX, coumoxystrobin+TX, zhongshengmycin+TX, thiodiazole copper+TX, zinc thiazole+TX, amectotractin+TX, iprodione+TX, N-octyl-N′-[2-(octylamino)ethyl]ethane-1,2-diamine+TX; N′-[5-bromo-2-methyl-6-[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine+TX, N′-[5-bromo-2-methyl-6-[(1R)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine+TX, N′-[5-bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine+TX, N′-[5-chloro-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine+TX, N′-[5-bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-isopropyl-N-methyl-formamidine+TX (these compounds may be prepared from the methods described in WO2015/155075); N′-[5-bromo-2-methyl-6-(2-propoxypropoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine+TX (this compound may be prepared from the methods described in IPCOM000249876D); N-isopropyl-N′-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenyl-ethyl)phenyl]-N-methyl-formamidine+TX, N′-[4-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxy-ethyl)-5-methoxy-2-methyl-phenyl]-N-isopropyl-N-methyl-formamidine+TX (these compounds may be prepared from the methods described in WO2018/228896); N-ethyl-N′-[5-methoxy-2-methyl-4-[(2-trifluoromethyl)oxetan-2-yl]phenyl]-N-methyl-formamidine+TX, N-ethyl-N′-[5-methoxy-2-methyl-4-[(2-trifuoromethyl)tetrahydrofuran-2-yl]phenyl]-N-methyl-formamidine+TX (these compounds may be prepared from the methods described in WO2019/110427); N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide+TX, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide+TX, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide+TX, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide+TX, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide+TX, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide+TX, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide+TX, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide+TX, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide+TX, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide+TX, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide+TX, N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide+TX (these compounds may be prepared from the methods described in WO2017/153380);

[0835] 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethyl-isoquinoline+TX, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethyl-isoquinoline+TX, 4,4-difluoro-3,3-dimethyl-1-(6-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline+TX, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline+TX, 1-(6-chloro-7-methyl-pyrazolo[1,5-a]pyridin-3-yl)-4,4-difluoro-3,3-dimethyl-isoquinoline+TX (these compounds may be prepared from the methods described in WO2017/025510); 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethyl-isoquinoline+TX, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethyl-isoquinoline+TX, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline+TX, 4,4-difluoro-1-(5-fluoro-4-methyl-benzimidazol-1-yl)-3,3-dimethyl-isoquinoline+TX, 3-(4,4-difluoro-3,3-dimethyl-1-isoquinolyl)-7,8-dihydro-6H-cyclopenta[e]benzimidazole+TX (these compounds may be prepared from the methods described in WO2016/156085); N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide+TX, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide+TX, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide+TX, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea+TX, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea+TX, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea+TX, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide+TX, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one+TX, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one+TX, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate+TX, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine+TX. The compounds in this paragraph may be prepared from the methods described in WO 2017/055473, WO 2017/055469, WO 2017/093348 and WO 2017/118689; 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol+TX (this compound may be prepared from the methods described in WO 2017/029179); 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol+TX (this compound may be prepared from the methods described in WO 2017/029179); 3-[2-(1-chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile+TX (this compound may be prepared from the methods described in WO 2016/156290); 3-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile+TX (this compound may be prepared from the methods described in WO 2016/156290); (4-phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3-carboxylate+TX (this compound may be prepared from the methods described in WO 2014/006945); 2,6-Dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c′]dipyrrole-1,3,5,7(2H,6H)-tetrone+TX (this compound may be prepared from the methods described in WO 2011/138281); N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzenecarbothioamide+TX; N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide+TX; (Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide+TX (this compound may be prepared from the methods described in WO 2018/153707); N′-(2-chloro-5-methyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine+TX; N′-[2-chloro-4-(2-fluorophenoxy)-5-methyl-phenyl]-N-ethyl-N-methyl-formamidine+TX (this compound may be prepared from the methods described in WO 2016/202742); 2-(difluoromethyl)-N-[(3S)-3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide+TX (this compound may be prepared from the methods described in WO 2014/095675); (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone+TX, (3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone+TX (these compounds may be prepared from the methods described in WO 2017/220485); 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide+TX (this compound may be prepared from the methods described in WO 2018/065414); ethyl 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylate+TX (this compound may be prepared from the methods described in WO 2018/158365); 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide+TX, N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide+TX, N—[(Z)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide+TX, N—[N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide+TX (these compounds may be prepared from the methods described in WO 2018/202428); microbials including: Acinetobacter Iwoffii+TX, Acremonium alternatum+TX+TX, Acremonium cephalosporium+TX+TX, Acremonium diospyri+TX, Acremonium obclavatum+TX, Adoxophyes orana granulovirus (AdoxGV) (Capex®)+TX, Agrobacterium radiobacter strain K84 (Galltrol-A®)+TX, Alternaria alternate+TX, Alternaria cassia+TX, Alternaria destruens (Smolder®)+TX, Ampelomyces quisqualis (AQ10®)+TX, Aspergillus flavus AF36 (AF36®)+TX, Aspergillus flavus NRRL 21882 (Aflaguard®)+TX, Aspergillus spp.+TX, Aureobasidium pullulans+TX, Azospirillum+TX, (MicroAZ®+TX, TAZO B®)+TX, Azotobacter+TX, Azotobacter chroocuccum (Azotomeal®)+TX, Azotobacter cysts (Bionatural Blooming Blossoms®)+TX, Bacillus amyloliquefaciens+TX, Bacillus cereus+TX, Bacillus chitinosporus strain CM-1+TX, Bacillus chitinosporus strain AQ746+TX, Bacillus licheniformis strain HB-2 (Biostart™ Rhizoboost®)+TX, Bacillus licheniformis strain 3086 (EcoGuard®+TX, Green Releaf®)+TX, Bacillus circulans+TX, Bacillus firmus (BioSafe®+TX, BioNem-WP®+TX, VOTiVO®)+TX, Bacillus firmus strain 1-1582+TX, Bacillus macerans+TX, Bacillus marismortui+TX, Bacillus megaterium+TX, Bacillus mycoides strain AQ726+TX, Bacillus papillae (Milky Spore Powder®)+TX, Bacillus pumilus spp.+TX, Bacillus pumilus strain GB34 (Yield Shield®)+TX, Bacillus pumilus strain AQ717+TX, Bacillus pumilus strain QST 2808 (Sonata®+TX, Ballad Plus®)+TX, Bacillus spahericus (VectoLex®)+TX, Bacillus spp.+TX, Bacillus spp. strain AQ175+TX, Bacillus spp. strain AQ177+TX, Bacillus spp. strain AQ178+TX, Bacillus subtilis strain QST 713 (CEASE®+TX, Serenade®+TX, Rhapsody®)+TX, Bacillus subtilis strain QST 714 (JAZZ®)+TX, Bacillus subtilis strain AQ153+TX, Bacillus subtilis strain AQ743+TX, Bacillus subtilis strain QST3002+TX, Bacillus subtilis strain QST3004+TX, Bacillus subtilis var. amyloliquefaciens strain FZB24 (Taegro®+TX, Rhizopro®)+TX, Bacillus thuringiensis Cry 2Ae+TX, Bacillus thuringiensis Cry1 Ab+TX, Bacillus thuringiensis aizawai GC 91 (Agree®)+TX, Bacillus thuringiensis israelensis (BMP123®+TX, Aquabac®+TX, VectoBac®)+TX, Bacillus thuringiensis kurstaki (Javelin®+TX, Deliver®+TX, CryMax®+TX, Bonide®+TX, Scutella WP®+TX, Turilav WP®+TX, Astuto®+TX, Dipel WP®+TX, Biobit®+TX, Foray®)+TX, Bacillus thuringiensis kurstaki BMP 123 (Baritone®)+TX, Bacillus thuringiensis kurstaki HD-1 (Bioprotec-CAF/3P®)+TX, Bacillus thuringiensis strain BD #32+TX, Bacillus thuringiensis strain AQ52+TX, Bacillus thuringiensis var. aizawai (XenTari®+TX, DiPel®)+TX, bacteria spp. (GROWMEND®+TX, GROWSWEET®+TX, Shootup®)+TX, bacteriophage of Clavipacter michiganensis (AgriPhage®)+TX, Bakflor®+TX, Beauveria bassiana (Beaugenic®+TX, Brocaril WP®)+TX, Beauveria bassiana GHA (Mycotrol ES®+TX, Mycotrol O®+TX, BotaniGuard®)+TX, Beauveria brongniartii (Engerlingspilz®+TX, Schweizer Beauveria®+TX, Melocont®)+TX, Beauveria spp.+TX, Botrytis cineria+TX, Bradyrhizobium japonicum (TerraMax®)+TX, Brevibacillus brevis+TX, Bacillus thuringiensis tenebrionis (Novodor®)+TX, BtBooster+TX, Burkholderia cepacia (Deny®+TX, Intercept®+TX, Blue Circle®)+TX, Burkholderia gladii+TX, Burkholderia gladioli+TX, Burkholderia spp.+TX, Canadian thistle fungus (CBH Canadian Bioherbicide®)+TX, Candida butyri+TX, Candida famata+TX, Candida fructus+TX, Candida glabrata+TX, Candida guilliermondii+TX, Candida melibiosica+TX, Candida oleophila strain O+TX, Candida parapsilosis+TX, Candida pelliculosa+TX, Candida pulcherrima+TX, Candida reukaufii+TX, Candida saitoana (Bio-Coat®+TX, Biocure®)+TX, Candida sake+TX, Candida spp.+TX, Candida tenius+TX, Cedecea dravisae+TX, Cellulomonas flavigena+TX, Chaetomium cochliodes (Nova-Cide®)+TX, Chaetomium globosum (Nova-Cide®)+TX, Chromobacterium subtsugae strain PRAA4-1T (Grandevo®)+TX, Cladosporium cladosporioides+TX, Cladosporium oxysporum+TX, Cladosporium chlorocephalum+TX, Cladosporium spp.+TX, Cladosporium tenuissimum+TX, Clonostachys rosea (EndoFine®)+TX, Colletotrichum acutatum+TX, Coniothyrium minitans (Cotans WG®)+TX, Coniothyrium spp.+TX, Cryptococcus albidus (YIELDPLUS®)+TX, Cryptococcus humicola+TX, Cryptococcus infirmominiatus+TX, Cryptococcus laurentii+TX, Cryptophlebia leucotreta granulovirus (Cryptex®)+TX, Cupriavidus campinensis+TX, Cydia pomonella granulovirus (CYD-X®)+TX, Cydia pomonella granulovirus (Madex®+TX, Madex Plus®+TX, Madex Max/Carpovirusine®)+TX, Cylindrobasidium laeve (Stumpout®)+TX, Cylindrocladium+TX, Debaryomyces hansenii+TX, Drechslera hawaiinensis+TX, Enterobacter cloacae+TX, Enterobacteriaceae+TX, Entomophtora virulenta (Vektor®)+TX, Epicoccum nigrum+TX, Epicoccum purpurascens+TX, Epicoccum spp.+TX, Filobasidium floriforme+TX, Fusarium acuminatum+TX, Fusarium chlamydosporum+TX, Fusarium oxysporum (Fusaclean®/Biofox C®)+TX, Fusarium proliferatum+TX, Fusarium spp.+TX, Galactomyces geotrichum+TX, Gliocladium catenulatum (Primastop®+TX, Prestop®)+TX, Gliocladium roseum+TX, Gliocladium spp. (SoilGard®)+TX, Gliocladium virens (Soilgard®)+TX, Granulovirus (Granupom®)+TX, Halobacillus halophilus+TX, Halobacillus litoralis+TX, Halobacillus trueperi+TX, Halomonas spp.+TX, Halomonas subglaciescola+TX, Halovibrio variabilis+TX, Hanseniaspora uvarum+TX, Helicoverpa armigera nucleopolyhedrovirus (Helicovex®)+TX, Helicoverpa zea nuclear polyhedrosis virus (Gemstar®)+TX, Isoflavone—formononetin (Myconate®)+TX, Kloeckera apiculata+TX, Kloeckera spp.+TX, Lagenidium giganteum (Laginex®)+TX, Lecanicillium longisporum (Vertiblast®)+TX, Lecanicillium muscarium (Vertikil®)+TX, Lymantria Dispar nucleopolyhedrosis virus (Disparvirus®)+TX, Marinococcus halophilus+TX, Meira geulakonigii+TX, Metarhizium anisopliae (Met52®)+TX, Metarhizium anisopliae (Destruxin WP®)+TX, Metschnikowia fruticola (Shemer®)+TX, Metschnikowia pulcherrima+TX, Microdochium dimerum (Antibot®)+TX, Micromonospora coerulea+TX, Microsphaeropsis ochracea+TX, Muscodor albus 620 (Muscudor®)+TX, Muscodor roseus strain A.sub.3-5+TX, Mycorrhizae spp. (AMykor®+TX, Root Maximizer®)+TX, Myrothecium verrucaria strain AARC-0255 (DiTera®)+TX, BROS PLUS®+TX, Ophiostoma piliferum strain D97 (Sylvanex®)+TX, Paecilomyces farinosus+TX, Paecilomyces fumosoroseus (PFR-97®+TX, PreFeRal®)+TX, Paecilomyces linacinus (Biostat WP®)+TX, Paecilomyces lilacinus strain 251 (MeloCon WG®)+TX, Paenibacillus polymyxa+TX, Pantoea agglomerans (BlightBan C9-1®)+TX, Pantoea spp.+TX, Pasteuria spp. (Econem®)+TX, Pasteuria nishizawae+TX, Penicillium aurantiogriseum+TX, Penicillium billai (Jumpstart®+TX, TagTeam®)+TX, Penicillium brevicompactum+TX, Penicillium frequentans+TX, Penicillium griseofulvum+TX, Penicillium purpurogenum+TX, Penicillium spp.+TX, Penicillium viridicatum+TX, Phlebiopsis gigantean (Rotstop®)+TX, phosphate solubilizing bacteria (Phosphomeal®)+TX, Phytophthora cryptogea+TX, Phytophthora palmivora (Devine®)+TX, Pichia anomala+TX, Pichia guilermondii+TX, Pichia membranaefaciens+TX, Pichia onychis+TX, Pichia stipites+TX, Pseudomonas aeruginosa+TX, Pseudomonas aureofasciens (Spot-Less Biofungicide®)+TX, Pseudomonas cepacia+TX, Pseudomonas chlororaphis (AtEze®)+TX, Pseudomonas corrugate+TX, Pseudomonas fluorescens strain A506 (BlightBan A506®)+TX, Pseudomonas putida+TX, Pseudomonas reactans+TX, Pseudomonas spp.+TX, Pseudomonas syringae (Bio-Save®)+TX, Pseudomonas viridiflava+TX, Pseudomons fluorescens (Zequanox®)+TX, Pseudozyma flocculosa strain PF-A22 UL (Sporodex L®)+TX, Puccinia canaliculata+TX, Puccinia thlaspeos (Wood Warrior®)+TX, Pythium paroecandrum+TX, Pythium oligandrum (Polygandron®+TX, Polyversum®)+TX, Pythium periplocum+TX, Rhanella aquatilis+TX, Rhanella spp.+TX, Rhizobia (Dormal®+TX, Vault®)+TX, Rhizoctonia+TX, Rhodococcus globerulus strain AQ719+TX, Rhodosporidium diobovatum+TX, Rhodosporidium toruloides+TX, Rhodotorula spp.+TX, Rhodotorula glutinis+TX, Rhodotorula graminis+TX, Rhodotorula mucilagnosa+TX, Rhodotorula rubra+TX, Saccharomyces cerevisiae+TX, Salinococcus roseus+TX, Sclerotinia minor+TX, Sclerotinia minor (SARRITOR®)+TX, Scytalidium spp.+TX, Scytalidium uredinicola+TX, Spodoptera exigua nuclear polyhedrosis virus (Spod-X®+TX, Spexit®)+TX, Serratia marcescens+TX, Serratia plymuthica+TX, Serratia spp.+TX, Sordaria fimicola+TX, Spodoptera littoralis nucleopolyhedrovirus (Littovir®)+TX, Sporobolomyces roseus+TX, Stenotrophomonas maltophilia+TX, Streptomyces ahygroscopicus+TX, Streptomyces albaduncus+TX, Streptomyces exfoliates+TX, Streptomyces galbus+TX, Streptomyces griseoplanus+TX, Streptomyces griseoviridis (Mycostop®)+TX, Streptomyces lydicus (Actinovate®)+TX, Streptomyces lydicus WYEC-108 (ActinoGrow®)+TX, Streptomyces violaceus+TX, Tilletiopsis minor+TX, Tilletiopsis spp.+TX, Trichoderma asperellum (T34 Biocontrol®)+TX, Trichoderma gamsii (Tenet®)+TX, Trichoderma atroviride (Plantmate®)+TX, Trichoderma hamatum TH 382+TX, Trichoderma harzianum rifai (Mycostar®)+TX, Trichoderma harzianum T-22 (Trianum-P®+TX, PlantShield HCO+TX, RootShield®+TX, Trianum-G®)+TX, Trichoderma harzianum T-39 (Trichodex®)+TX, Trichoderma inhamatum+TX, Trichoderma koningii+TX, Trichoderma spp. LC 52 (Sentinel®)+TX, Trichoderma lignorum+TX, Trichoderma longibrachiatum+TX, Trichoderma polysporum (Binab T®)+TX, Trichoderma taxi+TX, Trichoderma virens+TX, Trichoderma virens (formerly Gliocladium virens GL-21) (SoilGuard®)+TX, Trichoderma viride+TX, Trichoderma viride strain ICC 080 (Remedier®)+TX, Trichosporon pullulans+TX, Trichosporon spp.+TX, Trichothecium spp.+TX, Trichothecium roseum+TX, Typhula phacorrhiza strain 94670+TX, Typhula phacorrhiza strain 94671+TX, Ulocladium atrum+TX, Ulocladium oudemansii (Botry-Zen®)+TX, Ustilago maydis+TX, various bacteria and supplementary micronutrients (Natural II®)+TX, various fungi (Millennium Microbes®)+TX, Verticillium chlamydosporium+TX, Verticillium lecanii (Mycotal®+TX, Vertalec®)+TX, Vip3Aa20 (VIPtera®)+TX, Virgibaclillus marismortui+TX, Xanthomonas campestris pv. Poae (Camperico®)+TX, Xenorhabdus bovienii+TX, Xenorhabdus nematophilus;

[0836] Plant extracts including: pine oil (Retenol®)+TX, azadirachtin (Plasma Neem Oil®+TX, AzaGuard®+TX, MeemAzal®+TX, Molt-X®+TX, Botanical IGR (Neemazad®+TX, Neemix®)+TX, canola oil (Lilly Miller Vegol®)+TX, Chenopodium ambrosioides near ambrosioides (Requiem®)+TX, Chrysanthemum extract (Crisant®)+TX, extract of neem oil (Trilogy®)+TX, essentials oils of Labiatae (Botania®)+TX, extracts of clove rosemary peppermint and thyme oil (Garden insect Killer®)+TX, Glycinebetaine (Greenstim®)+TX, garlic+TX, lemongrass oil (GreenMatch®)+TX, neem oil+TX, Nepeta cataria (Catnip oil)+TX, Nepeta catarina+TX, nicotine+TX, oregano oil (MossBuster®)+TX, Pedaliaceae oil (Nematon®)+TX, pyrethrum+TX, Quillaja saponaria (NemaQ®)+TX, Reynoutria sachalinensis (Regalia®+TX, Sakalia®)+TX, rotenone (Eco Roten®)+TX, Rutaceae plant extract (Soleo®)+TX, soybean oil (Ortho Ecosense®)+TX, tea tree oil (Timorex Gold®)+TX, thymus oil+TX, AGNIQUE® MMF+TX, BugOil®+TX, mixture of rosemary sesame pepermint thyme and cinnamon extracts (EF 300®)+TX, mixture of clove rosemary and peppermint extract (EF 400®)+TX, mixture of clove pepermint garlic oil and mint (Soil Shot®)+TX, kaolin (Screen®)+TX, storage glucam of brown algae (Laminarin®);

[0837] pheromones including: blackheaded fireworm pheromone (3M Sprayable Blackheaded Fireworm Pheromone®)+TX, Codling Moth Pheromone (Paramount dispenser-(CM)/Isomate C-Plus®)+TX, Grape Berry Moth Pheromone (3M MEC-GBM Sprayable Pheromone®)+TX, Leafroller pheromone (3M MEC-LR Sprayable Pheromone®)+TX, Muscamone (Snip7 Fly Bait®+TX, Starbar Premium Fly Bait®)+TX, Oriental Fruit Moth Pheromone (3M oriental fruit moth sprayable Pheromone®)+TX, Peachtree Borer Pheromone (Isomate-P®)+TX, Tomato Pinworm Pheromone (3M Sprayable Pheromone®)+TX, Entostat powder (extract from palm tree) (Exosex CM®)+TX, (E+TX,Z+TX,Z)-3+TX,8+TX,11 Tetradecatrienyl acetate+TX, (Z+TX,Z+TX,E)-7+TX,11+TX,13-Hexadecatrienal+TX, (E+TX,Z)-7+TX,9-Dodecadien-1-yl acetate+TX, 2-Methyl-1-butanol+TX, Calcium acetate+TX, Scenturion®+TX, Biolure®+TX, Check-Mate®+TX, Lavandulyl senecioate; Macrobials including: Aphelinus abdominalis+TX, Aphidius ervi (Aphelinus-System®)+TX, Acerophagus papaya+TX, Adalia bipunctata (Adalia-System®)+TX, Adalia bipunctata (Adaline®)+TX, Adalia bipunctata (Aphidalia®)+TX, Ageniaspis citricola+TX, Ageniaspis fuscicollis+TX, Amblyseius andersoni (Anderline®+TX, Andersoni-System®)+TX, Amblyseius californicus (Amblyline®+TX, Spical®)+TX, Amblyseius cucumeris (Thripex®+TX, Bugline Cucumeris®)+TX, Amblyseius fallacis (Fallacis®)+TX, Amblyseius swirskii (Bugline Swirskii®+TX, Swirskii-Mite®)+TX, Amblyseius womersleyi (WomerMite®)+TX, Amitus hesperidum+TX, Anagrus atomus+TX, Anagyrus fusciventris+TX, Anagyrus kamali+TX, Anagyrus loecki+TX, Anagyrus pseudococci (Citripar®)+TX, Anicetus benefices+TX, Anisopteromalus calandrae+TX, Anthocoris nemoralis (Anthocoris-System®)+TX, Aphelinus abdominalis (Apheline®+TX, Aphiline®)+TX, Aphelinus asychis+TX, Aphidius colemani (Aphipar®)+TX, Aphidius ervi (Ervipar®)+TX, Aphidius gifuensis+TX, Aphidius matricariae (Aphipar-M®)+TX, Aphidoletes aphidimyza (Aphidend®)+TX, Aphidoletes aphidimyza (Aphidoline®)+TX, Aphytis lingnanensis+TX, Aphytis melinus+TX, Aprostocetus hagenowii+TX, Atheta coriaria (Staphyline®)+TX, Bombus spp.+TX, Bombus terrestris (Natupol Beehive®)+TX, Bombus terrestris (Beeline®+TX, Tripol®)+TX, Cephalonomia stephanoderis+TX, Chilocorus nigritus+TX, Chrysoperla carnea (Chrysoline®)+TX, Chrysoperla carnea (Chrysopa®)+TX, Chrysoperla rufilabris+TX, Cirrospilus ingenuus+TX, Cirrospilus quadristriatus+TX, Citrostichus phyllocnistoides+TX, Closterocerus chamaeleon+TX, Closterocerus spp.+TX, Coccidoxenoides perminutus (Planopar®)+TX, Coccophagus cowperi+TX, Coccophagus lycimnia+TX, Cotesia flavipes+TX, Cotesia plutellae+TX, Cryptolaemus montrouzieri (Cryptobug®+TX, Cryptoline®)+TX, Cybocephalus nipponicus+TX, Dacnusa sibirica+TX, Dacnusa sibirica (Minusa®)+TX, Diglyphus isaea (Diminex®)+TX, Delphastus catalinae (Delphastus®)+TX, Delphastus pusillus+TX, Diachasmimorpha krausii+TX, Diachasmimorpha longicaudata+TX, Diaparsis jucunda+TX, Diaphorencyrtus aligarhensis+TX, Diglyphus isaea+TX, Diglyphus isaea (Miglyphus®+TX, Digline®)+TX, Dacnusa sibirica (DacDigline®+TX, Minex®)+TX, Diversinervus spp.+TX, Encarsia citrina+TX, Encarsia formosa (Encarsia Max®+TX, Encarline®+TX, En-Strip®)+TX, Eretmocerus eremicus (Enermix®)+TX, Encarsia guadeloupae+TX, Encarsia haitiensis+TX, Episyrphus balteatus (Syrphidend®)+TX, Eretmoceris siphonini+TX, Eretmocerus californicus+TX, Eretmocerus eremicus (Ercal®+TX, Eretline e®)+TX, Eretmocerus eremicus (Bemimix®)+TX, Eretmocerus hayati+TX, Eretmocerus mundus (Bemipar®+TX, Eretline m®)+TX, Eretmocerus siphonini+TX, Exochomus quadripustulatus+TX, Feltiella acarisuga (Spidend®)+TX, Feltiella acarisuga (Feltiline®)+TX, Fopius arisanus+TX, Fopius ceratitivorus+TX, Formononetin (Wirless Beehome®)+TX, Franklinothrips vespiformis (Vespop®)+TX, Galendromus occidentalis+TX, Goniozus legneri+TX, Habrobracon hebetor+TX, Harmonia axyridis (HarmoBeetle®)+TX, Heterorhabditis spp. (Lawn Patrol®)+TX, Heterorhabditis bacteriophora (NemaShield HB®+TX, Nemaseek®+TX, Terranem-Nam®+TX, Terranem®+TX, Larvanem®+TX, B-Green®+TX, NemAttack®+TX, Nematop®)+TX, Heterorhabditis megidis (Nemasys H®+TX, BioNem H®+TX, Exhibitline hm®+TX, Larvanem-M®)+TX, Hippodamia convergens+TX, Hypoaspis aculeifer (Aculeifer-System®+TX, Entomite-A®)+TX, Hypoaspis miles (Hypoline m®+TX, Entomite-M®)+TX, Lbalia leucospoides+TX, Lecanoideus floccissimus+TX, Lemophagus errabundus+TX, Leptomastidea abnormis+TX, Leptomastix dactylopii (Leptopar®)+TX, Leptomastix epona+TX, Lindorus lophanthae+TX, Lipolexis oregmae+TX, Lucilia caesar (Natufly®)+TX, Lysiphlebus testaceipes+TX, Macrolophus caliginosus (Mirical-N®+TX, Macroline c®+TX, Mirical®)+TX, Mesoseiulus longipes+TX, Metaphycus flavus+TX, Metaphycus lounsburyi+TX, Micromus angulatus (Milacewing®)+TX, Microterys flavus+TX, Muscidifurax raptorellus and Spalangia cameroni (Biopar®)+TX, Neodryinus typhlocybae+TX, Neoseiulus californicus+TX, Neoseiulus cucumeris (THRYPEX®)+TX, Neoseiulus fallacis+TX, Nesideocoris tenuis (NesidioBug®+TX, Nesibug®)+TX, Ophyra aenescens (Biofly®)+TX, Orius insidiosus (Thripor-I®+TX, Oriline i®)+TX, Orius laevigatus (Thripor-L®+TX, Oriline I®)+TX, Orius majusculus (Oriline m®)+TX, Orius strigicollis (Thripor-S®)+TX, Pauesia juniperorum+TX, Pediobius foveolatus+TX, Phasmarhabditis hermaphrodita (Nemaslug®)+TX, Phymastichus coffea+TX, Phytoseiulus macropilus+TX, Phytoseiulus persimilis (Spidex®+TX, Phytoline p®)+TX, Podisus maculiventris (Podisus®)+TX, Pseudacteon curvatus+TX, Pseudacteon obtusus+TX, Pseudacteon tricuspis+TX, Pseudaphycus maculipennis+TX, Pseudleptomastix mexicana+TX, Psyllaephagus pilosus+TX, Psyttalia concolor (complex)+TX, Quadrastichus spp.+TX, Rhyzobius lophanthae+TX, Rodolia cardinalis+TX, Rumina decollate+TX, Semielacher petiolatus+TX, Sitobion avenae (Ervibank®)+TX, Steinernema carpocapsae (Nematac C®+TX, Millenium®+TX, BioNem C®+TX, NemAttack®+TX, Nemastar®+TX, Capsanem®)+TX, Steinernema feltiae (NemaShield®+TX, Nemasys F®+TX, BioNem F®+TX, Steinernema-System®+TX, NemAttack®+TX, Nemaplus®+TX, Exhibitline sf®+TX, Scia-Rid®+TX, Entonem®)+TX, Steinernema kraussei (Nemasys L®+TX, BioNem L®+TX, Exhibitline srb®)+TX, Steinernema riobrave (BioVector®+TX, BioVektor®)+TX, Steinernema scapterisci (Nematac S®)+TX, Steinernema spp.+TX, Steinernematid spp. (Guardian Nematodes®)+TX, Stethorus punctillum (Stethorus®)+TX, Tamarixia radiate+TX, Tetrastichus setifer+TX, Thripobius semiluteus+TX, Torymus sinensis+TX, Trichogramma brassicae (Tricholine b®)+TX, Trichogramma brassicae (Tricho-Strip®)+TX, Trichogramma evanescens+TX, Trichogramma minutum+TX, Trichogramma ostriniae+TX, Trichogramma platneri+TX, Trichogramma pretiosum+TX, Xanthopimpla stemmator; other biologicals including: abscisic acid+TX, bioSea®+TX, Chondrostereum purpureum (Chontrol Paste®)+TX, Colletotrichum gloeosporioides (Collego®)+TX, Copper Octanoate (Cueva®)+TX, Delta traps (Trapline d®)+TX, Erwinia amylovora (Harpin) (ProAct®+TX, Ni-HIBIT Gold CST®)+TX, Ferri-phosphate (Ferramol®)+TX, Funnel traps (Trapline y®)+TX, Gallex®+TX, Grower's Secret®+TX, Homo-brassonolide+TX, Iron Phosphate (Lilly Miller Worry Free Ferramol Slug & Snail Bait®)+TX, MCP hail trap (Trapline f®)+TX, Microctonus hyperodae+TX, Mycoleptodiscus terrestris (Des-X®)+TX, BioGain®+TX, Aminomite®+TX, Zenox®+TX, Pheromone trap (Thripline Ams®)+TX, potassium bicarbonate (MilStop®)+TX, potassium salts of fatty acids (Sanova®)+TX, potassium silicate solution (Sil-Matrix®)+TX, potassium iodide+potassiumthiocyanate (Enzicur®)+TX, SuffOil-X®+TX, Spider venom+TX, Nosema locustae (Semaspore Organic Grasshopper Control®)+TX, Sticky traps (Trapline YF®+TX, Rebell Amarillo®)+TX and Traps (Takitrapline y+b®)+TX; and

[0838] a safener, such as benoxacor+TX, cloquintocet (including cloquintocet-mexyl)+TX, cyprosulfamide+TX, dichlormid+TX, fenchlorazole (including fenchlorazole-ethyl)+TX, fenclorim+TX, fluxofenim+TX, furilazole+TX, isoxadifen (including isoxadifen-ethyl)+TX, mefenpyr (including mefenpyr-diethyl)+TX, metcamifen+TX and oxabetrinil+TX.

[0839] The references in brackets behind the active ingredients, e.g. [3878-19-1] refer to the Chemical Abstracts Registry number. The above described mixing partners are known. Where the active ingredients are included in “The Pesticide Manual” [The Pesticide Manual—A World Compendium; Thirteenth Edition; Editor: C. D. S. TomLin; The British Crop Protection Council], they are described therein under the entry number given in round brackets hereinabove for the particular compound; for example, the compound “abamectin” is described under entry number (1). Where “[CCN]” is added hereinabove to the particular compound, the compound in question is included in the “Compendium of Pesticide Common Names”, which is accessible on the internet [A. Wood; Compendium of Pesticide Common Names, Copyright © 1995-2004]; for example, the compound “acetoprole” is described under the internet address http://www.alanwood.net/pesticides/acetoprole.html.

[0840] Most of the active ingredients described above are referred to hereinabove by a so-called “common name”, the relevant “ISO common name” or another “common name” being used in individual cases. If the designation is not a “common name”, the nature of the designation used instead is given in round brackets for the particular compound; in that case, the IUPAC name, the IUPAC/Chemical Abstracts name, a “chemical name”, a “traditional name”, a “compound name” or a “develoment code” is used or, if neither one of those designations nor a “common name” is used, an “alternative name” is employed. “CAS Reg. No” means the Chemical Abstracts Registry Number.

[0841] The active ingredient mixture of the compounds of formula I selected from the compounds defined in the Tables D-1 to D-66 and Table P with active ingredients described above comprises a compound selected from one compound defined in the Tables D-1 to D-66 and Table P and an active ingredient as described above preferably in a mixing ratio of from 100:1 to 1:6000, especially from 50:1 to 1:50, more especially in a ratio of from 20:1 to 1:20, even more especially from 10:1 to 1:10, very especially from 5:1 to 1:5, special preference being given to a ratio of from 2:1 to 1:2, and a ratio of from 4:1 to 2:1 being likewise preferred, above all in a ratio of 1:1, or 5:1, or 5:2, or 5:3, or 5:4, or 4:1, or 4:2, or 4:3, or 3:1, or 3:2, or 2:1, or 1:5, or 2:5, or 3:5, or 4:5, or 1:4, or 2:4, or 3:4, or 1:3, or 2:3, or 1:2, or 1:600, or 1:300, or 1:150, or 1:35, or 2:35, or 4:35, or 1:75, or 2:75, or 4:75, or 1:6000, or 1:3000, or 1:1500, or 1:350, or 2:350, or 4:350, or 1:750, or 2:750, or 4:750. Those mixing ratios are by weight.

[0842] The compounds and mixtures as described above can be used in a method for controlling pests, which comprises applying a composition comprising a compound or mixture respectively as described above to the pests or their environment, with the exception of a method for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body.

[0843] The mixtures comprising a compound of formula I selected from the compounds defined in the Tables D-1 to D-66 and Table P and one or more active ingredients as described above can be applied, for example, in a single “ready-mix” form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a “tank-mix”, and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the compounds of formula I and the active ingredients as described above is not essential for working the present invention.

[0844] The compositions according to the invention can also comprise further solid or liquid auxiliaries, such as stabilizers, for example unepoxidized or epoxidized vegetable oils (for example epoxidized coconut oil, rapeseed oil or soya oil), antifoams, for example silicone oil, preservatives, viscosity regulators, binders and/or tackifiers, fertilizers or other active ingredients for achieving specific effects, for example bactericides, fungicides, nematocides, plant activators, molluscicides or herbicides.

[0845] The compositions according to the invention are prepared in a manner known per se, in the absence of auxiliaries for example by grinding, screening and/or compressing a solid active ingredient and in the presence of at least one auxiliary for example by intimately mixing and/or grinding the active ingredient with the auxiliary (auxiliaries). These processes for the preparation of the compositions and the use of the compounds I for the preparation of these compositions are also a subject of the invention.

[0846] The application methods for the compositions, that is the methods of controlling pests of the abovementioned type, such as spraying, atomizing, dusting, brushing on, dressing, scattering or pouring—which are to be selected to suit the intended aims of the prevailing circumstances—and the use of the compositions for controlling pests of the abovementioned type are other subjects of the invention. Typical rates of concentration are between 0.1 and 1000 ppm, preferably between 0.1 and 500 ppm, of active ingredient. The rate of application per hectare is generally 1 to 2000 g of active ingredient per hectare, in particular 10 to 1000 g/ha, preferably 10 to 600 g/ha.

[0847] A preferred method of application in the field of crop protection is application to the foliage of the plants (foliar application), it being possible to select frequency and rate of application to match the danger of infestation with the pest in question. Alternatively, the active ingredient can reach the plants via the root system (systemic action), by drenching the locus of the plants with a liquid composition or by incorporating the active ingredient in solid form into the locus of the plants, for example into the soil, for example in the form of granules (soil application). In the case of paddy rice crops, such granules can be metered into the flooded paddy-field.

[0848] The compounds of formula I of the invention and compositions thereof are also be suitable for the protection of plant propagation material, for example seeds, such as fruit, tubers or kernels, or nursery plants, against pests of the abovementioned type. The propagation material can be treated with the compound prior to planting, for example seed can be treated prior to sowing. Alternatively, the compound can be applied to seed kernels (coating), either by soaking the kernels in a liquid composition or by applying a layer of a solid composition. It is also possible to apply the compositions when the propagation material is planted to the site of application, for example into the seed furrow during drilling. These treatment methods for plant propagation material and the plant propagation material thus treated are further subjects of the invention. Typical treatment rates would depend on the plant and pest/fungi to be controlled and are generally between 1 to 200 grams per 100 kg of seeds, preferably between 5 to 150 grams per 100 kg of seeds, such as between 10 to 100 grams per 100 kg of seeds.

[0849] The term seed embraces seeds and plant propagules of all kinds including but not limited to true seeds, seed pieces, suckers, corns, bulbs, fruit, tubers, grains, rhizomes, cuttings, cut shoots and the like and means in a preferred embodiment true seeds.

[0850] The present invention also comprises seeds coated or treated with or containing a compound of formula I. The term “coated or treated with and/or containing” generally signifies that the active ingredient is for the most part on the surface of the seed at the time of application, although a greater or lesser part of the ingredient may penetrate into the seed material, depending on the method of application. When the said seed product is (re)planted, it may absorb the active ingredient. In an embodiment, the present invention makes available a plant propagation material adhered thereto with a compound of formula I. Further, it is hereby made available, a composition comprising a plant propagation material treated with a compound of formula I.

[0851] Seed treatment comprises all suitable seed treatment techniques known in the art, such as seed dressing, seed coating, seed dusting, seed soaking and seed pelleting. The seed treatment application of the compound formula I can be carried out by any known methods, such as spraying or by dusting the seeds before sowing or during the sowing/planting of the seeds.

[0852] The compounds of the invention can be distinguished from other similar compounds by virtue of greater efficacy at low application rates and/or different pest control, which can be verified by the person skilled in the art using the experimental procedures, using lower concentrations if necessary, for example 10 ppm, 5 ppm, 2 ppm, 1 ppm or 0.2 ppm; or lower application rates, such as 300, 200 or 100, mg of Al per m.sup.2. The greater efficacy can be observed by an increased safety profile (against non-target organisms above and below ground (such as fish, birds and bees), improved physico-chemical properties, or increased biodegradability).

[0853] In each aspect and embodiment of the invention, “consisting essentially” and inflections thereof are a preferred embodiment of “comprising” and its inflections, and “consisting of” and inflections thereof are a preferred embodiment of “consisting essentially of” and its inflections.

[0854] The disclosure in the present application makes available each and every combination of embodiments disclosed herein.

[0855] It should be noted that the disclosure herein in respect of a compound of formula I applies equally in respect of a compound of each of formulae I*, I′a, Iaa, Iab, Iac, I′ab, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Im, In and Tables D-1 to D-66.

BIOLOGICAL EXAMPLES

[0856] The Examples which follow serve to illustrate the invention. Certain compounds of the invention can be distinguished from known compounds by virtue of greater efficacy at low application rates, which can be verified by the person skilled in the art using the experimental procedures outlined in the Examples, using lower application rates if necessary, for example 50 ppm, 24 ppm, 12.5 ppm, δ ppm, 3 ppm, 1.5 ppm, 0.8 ppm or 0.2 ppm.

Example B1: Diabrotica Balteata (Corn Root Worm)

[0857] Maize sprouts placed onto an agar layer in 24-well microtiter plates were treated with aqueous test solutions prepared from 10′000 ppm DMSO stock solutions by spraying. After drying, the plates were infested with L2 larvae (6 to 10 per well). The samples were assessed for mortality and growth inhibition in comparison to untreated samples 4 days after infestation.

[0858] The following compounds gave an effect of at least 80% control in at least one of the two categories (mortality or growth inhibition) at an application rate of 200 ppm: P.1, P.4, P.5, P.6, P.7, P.8, P.9, P.10, P.11, P.12, P.13, P.14, P.15, P.16, P.17, P.18, P.19, P.20, P.21, P.22, P.23, P.24, P.25, P.26, P.27, P.28, P.29, P.30, P.31, P.32, P.33, P.34, P.35, P.36, P.37, P.38, P.39, P.40, P.43, P.44, P.47, P.52, P.54, P.55, P.56, P.57, P.58, P.64, P.66, P.67, P.68, P.71, P.72, P.73, P.75, P.76, P.77, P.78, P.80, P.81, P.82, P.83, P.84, P.85, P.86, P.87, P.88, P.89, P.90, P.91, P.92, P.93, P.94, P.95, P.96, P.97, P.98, P.99, P.100, P.101, P.102, P.103, P.104, P.105, P.106, P.107, P.108, P.109, P.110, P.111, P.112, P.113, P.114, P.115, P.116, P.117, P.118, P.119, P.120, P.122, P.123, P.124, P.126, P.127, P.128, P.129, P.130, P.131, P.132, P.133, P.159, P.161, P.162, P.163, P.166, P.168, P.169, P.171, P.172, P.173, P.174, P.175, P.176, P.177, P.178, P.179, P.180, P.181, P.182, P.183, P.184, P.185, P.186, P.187, P.188, P.189, P.190, P.191, P.192, P.193, P.194, P.196, P.201, P.202, P.203, P.205, P.206, P.207, P.208, P.209, P.210, P.211, P.213, P.214, P.215, P.216, P.217, P.218, P.219, P.220, P.221, P.224, P.225, P.226, P.227, P.228, P.229, P.230, P.232, P.234, P.235, P.236, P.237, P.238, P.239, P.240, P.241, P.243, P.244, P.245, P.247, P.248, P.249, P.250, P.251, P.252, P.253, P.254, P.255, P.256, P.257, P.258, P.259, P.260, P.261, P.262, P.263, P.264, P.265, P.266, P.268, P.271, P.272, P.273, P.274, P.276.

Example B2: Euschistus heros (Neotropical Brown Stink Bug)

[0859] Soybean leaves on agar in 24-well microtiter plates were sprayed with aqueous test solutions prepared from 10′000 ppm DMSO stock solutions. After drying the leaves were infested with N2 nymphs. The samples were assessed for mortality and growth inhibition in comparison to untreated samples 5 days after infestation.

[0860] The following compounds gave an effect of at least 80% control in at least one of the two categories (mortality or growth inhibition) at an application rate of 200 ppm: P.1, P.6, P.7, P.8, P.10, P.16, P.21, P.23, P.26, P.27, P.28, P.36, P.40, P.43, P.47, P.54, P.58, P.71, P.75, P.78, P.82, P.83, P.84, P.86, P.87, P.89, P.90, P.93, P.95, P.106, P.107, P.128, P.168, P.169, P.172, P.175, P.187, P.188, P.190, P.191, P.201, P.202, P.203, P.213, P.215, P.216, P.219, P.220, P.221, P.227, P.228, P.245, P.248, P.259, P.260, P.261, P.262, P.263, P.264, P.265, P.266, P.271, P.272, P.276.

Example B3: Chilo suppressalis (Striped Rice Stemborer)

[0861] 24-well microtiter plates with artificial diet were treated with aqueous test solutions prepared from 10′000 ppm DMSO stock solutions by pipetting. After drying, the plates were infested with L2 larvae (6-8 per well). The samples were assessed for mortality, anti-feeding effect, and growth inhibition in comparison to untreated samples 6 days after infestation. Control of Chilo suppressalis by a test sample is given when at least one of the categories mortality, anti-feedant effect, and growth inhibition is higher than the untreated sample.

[0862] The following compounds resulted in at least 80% control in at least one of the three categories (mortality, anti-feedant effect, or growth inhibition) at an application rate of 200 ppm: P.1, P.4, P.5, P.6, P.7, P.8, P.9, P.10, P.11, P.12, P.13, P.14, P.15, P.16, P.17, P.18, P.19, P.20, P.21, P.22, P.23, P.24, P.25, P.26, P.27, P.28, P.29, P.30, P.31, P.32, P.33, P.34, P.35, P.37, P.38, P.39, P.40, P.41, P.42, P.43, P.44, P.45, P.47, P.48, P.51, P.52, P.53, P.54, P.56, P.57, P.58, P.60, P.61, P.62, P.63, P.64, P.65, P.66, P.67, P.68, P.71, P.72, P.73, P.75, P.76, P.77, P.78, P.80, P.81, P.82, P.83, P.84, P.85, P.86, P.87, P.88, P.89, P.90, P.91, P.92, P.93, P.94, P.95, P.96, P.97, P.98, P.99, P.100, P.101, P.102, P.103, P.104, P.105, P.106, P.107, P.108, P.109, P.110, P.111, P.112, P.113, P.114, P.115, P.116, P.117, P.118, P.119, P.120, P.121, P.122, P.123, P.124, P.126, P.127, P.128, P.129, P.130, P.131, P.132, P.133, P.158, P.159, P.161, P.162, P.163, P.167, P.168, P.169, P.170, P.171, P.172, P.173, P.174, P.175, P.176, P.177, P.178, P.179, P.180, P.183, P.184, P.185, P.186, P.187, P.188, P.189, P.190, P.191, P.192, P.193, P.194, P.195, P.198, P.201, P.202, P.203, P.205, P.206, P.207, P.208, P.209, P.211, P.213, P.214, P.215, P.216, P.217, P.218, P.219, P.220, P.221, P.224, P.225, P.226, P.227, P.228, P.229, P.230, P.232, P.235, P.236, P.237, P.238, P.239, P.240, P.241, P.243, P.244, P.245, P.246, P.247, P.248, P.249, P.250, P.251, P.252, P.253, P.254, P.255, P.256, P.257, P.258, P.259, P.260, P.261, P.262, P.263, P.264, P.265, P.266, P.267, P.271, P.272, P.273, P.274, P.275, P.276.

Example B4: Plutella xylostella (Diamond Back Moth)

[0863] 24-well microtiter plates with artificial diet were treated with aqueous test solutions prepared from 10′000 ppm DMSO stock solutions by pipetting. After drying, Plutella eggs were pipetted through a plastic stencil onto a gel blotting paper and the plate was closed with it. The samples were assessed for mortality and growth inhibition in comparison to untreated samples 8 days after infestation.

[0864] The following compounds gave an effect of at least 80% control in at least one of the two categories (mortality or growth inhibition) at an application rate of 200 ppm: P.1, P.4, P.5, P.6, P.7, P.8, P.9, P.10, P.11, P.12, P.13, P.14, P.15, P.16, P.17, P.18, P.19, P.20, P.21, P.22, P.23, P.24, P.26, P.27, P.28, P.29, P.30, P.31, P.32, P.33, P.34, P.35, P.37, P.38, P.39, P.40, P.41, P.42, P.43, P.44, P.45, P.47, P.52, P.53, P.54, P.56, P.57, P.58, P.60, P.61, P.62, P.63, P.64, P.65, P.66, P.67, P.68, P.71, P.72, P.73, P.75, P.76, P.77, P.78, P.80, P.81, P.82, P.83, P.84, P.85, P.86, P.87, P.88, P.89, P.90, P.91, P.92, P.93, P.94, P.95, P.96, P.97, P.98, P.99, P.100, P.101, P.102, P.103, P.104, P.105, P.106, P.107, P.108, P.109, P.110, P.111, P.112, P.113, P.114, P.115, P.116, P.117, P.118, P.119, P.120, P.122, P.123, P.124, P.125, P.126, P.127, P.128, P.129, P.130, P.131, P.132, P.133, P.158, P.159, P.161, P.162, P.163, P.167, P.168, P.169, P.170, P.171, P.172, P.173, P.174, P.175, P.176, P.177, P.178, P.179, P.180, P.181, P.182, P.183, P.184, P.185, P.186, P.187, P.188, P.189, P.190, P.191, P.192, P.193, P.194, P.198, P.201, P.202, P.203, P.204, P.205, P.206, P.207, P.208, P.209, P.210, P.211, P.213, P.214, P.215, P.216, P.217, P.218, P.219, P.220, P.221, P.224, P.225, P.226, P.227, P.228, P.229, P.230, P.232, P.233, P.234, P.235, P.236, P.237, P.238, P.239, P.240, P.241, P.243, P.244, P.245, P.246, P.247, P.248, P.249, P.250, P.251, P.252, P.253, P.254, P.255, P.256, P.257, P.258, P.259, P.260, P.261, P.262, P.263, P.264, P.265, P.266, P.268, P.271, P.272, P.273, P.274, P.276.

Example B5: Myzus persicae (Green Peach Aphid) Feeding/Contact Activity

[0865] Sunflower leaf discs were placed onto agar in a 24-well microtiter plate and sprayed with aqueous test solutions prepared from 10′000 ppm DMSO stock solutions. After drying, the leaf discs were infested with an aphid population of mixed ages. The samples were assessed for mortality 6 days after infestation.

[0866] The following compounds resulted in at least 80% mortality at an application rate of 200 ppm: P.1, P.6, P.20, P.21, P.23, P.24, P.26, P.27, P.28, P.52, P.54, P.59, P.86, P.90, P.94, P.95, P.127, P.128, P.130, P.165, P.168, P.172, P.184, P.187, P.188, P.190, P.191, P.201, P.203, P.215, P.217, P.219, P.221, P.227, P.228, P.236, P.245, P.248, P.258, P.264, P.265, P.271.

Example B6: Myzus persicae (Green Peach Aphid) Intrinsic Activity

[0867] Test compounds prepared from 10′000 ppm DMSO stock solutions were applied by pipette into 24-well microtiter plates and mixed with sucrose solution. The plates were closed with a stretched Parafilm. A plastic stencil with 24 holes was placed onto the plate and infested pea seedlings were placed directly on the Parafilm. The infested plate was closed with a gel blotting paper and another plastic stencil and then turned upside down. The samples were assessed for mortality 5 days after infestation.

[0868] The following compounds resulted in at least 80% mortality at a test rate of 12 ppm: P.1, P.6, P.10, P.11, P.12, P.16, P.18, P.20, P.21, P.22, P.23, P.24, P.26, P.27, P.28, P.29, P.32, P.40, P.44, P.52, P.54, P.58, P.66, P.71, P.82, P.84, P.86, P.87, P.88, P.90, P.91, P.93, P.94, P.95, P.98, P.127, P.128, P.130, P.132, P.133, P.162, P.168, P.169, P.171, P.172, P.177, P.182, P.183, P.184, P.187, P.188, P.190, P.191, P.194, P.201, P.202, P.203, P.208, P.215, P.217, P.219, P.220, P.221, P.227, P.228, P.229, P.230, P.236, P.243, P.245, P.248, P.258, P.260, P.262, P.263, P.264, P.265, P.266, P.271, P.272.

Example B7: Spodoptera littoralis (Egyptian Cotton Leaf Worm)

[0869] Cotton leaf discs were placed onto agar in 24-well microtiter plates and sprayed with aqueous test solutions prepared from 10′000 ppm DMSO stock solutions. After drying the leaf discs were infested with five L1 larvae. The samples were assessed for mortality, anti-feeding effect, and growth inhibition in comparison to untreated samples 3 days after infestation. Control of Spodoptera littoralis by a test sample is given when at least one of the categories mortality, anti-feedant effect, and growth inhibition is higher than the untreated sample.

[0870] The following compounds resulted in at least 80% control in at least one of the three categories (mortality, anti-feedant effect, or growth inhibition) at an application rate of 200 ppm: P.1, P.4, P.5, P.6, P.7, P.8, P.9, P.10, P.11, P.12, P.13, P.14, P.15, P.16, P.17, P.18, P.19, P.20, P.21, P.22, P.23, P.24, P.25, P.26, P.27, P.28, P.29, P.30, P.31, P.32, P.33, P.34, P.35, P.37, P.38, P.39, P.40, P.41, P.42, P.44, P.45, P.47, P.52, P.53, P.54, P.56, P.57, P.58, P.61, P.63, P.64, P.67, P.68, P.93, P.95, P.96, P.97, P.98, P.99, P.100, P.101, P.102, P.103, P.104, P.105, P.106, P.107, P.108, P.109, P.110, P.111, P.112, P.113, P.114, P.115, P.116, P.117, P.118, P.119, P.120, P.121, P.122, P.123, P.124, P.125, P.126, P.127, P.128, P.129, P.130, P.131, P.132, P.133, P.159, P.161, P.162, P.163, P.166, P.168, P.169, P.171, P.172, P.173, P.174, P.176, P.177, P.178, P.182, P.183, P.185, P.189, P.192, P.194, P.195, P.201, P.202, P.203, P.204, P.205, P.206, P.207, P.208, P.209, P.211, P.213, P.214, P.215, P.216, P.217, P.218, P.219, P.220, P.221, P.224, P.227, P.228, P.229, P.230, P.232, P.234, P.235, P.236, P.237, P.238, P.239, P.240, P.241, P.243, P.244, P.245, P.246, P.247, P.248, P.249, P.250, P.251, P.252, P.253, P.254, P.255, P.256, P.257, P.258, P.259, P.260, P.261, P.262, P.263, P.264, P.265, P.266, P.271, P.272, P.273, P.274, P.275, P.276.

Example B8: Spodoptera littoralis (Egyptian Cotton Leaf Worm)

[0871] Test compounds were applied by pipette from 10′000 ppm DMSO stock solutions into 24-well plates and mixed with agar. Lettuce seeds were placed onto the agar and the multi well plate was closed by another plate which contained also agar. After 7 days the compound was absorbed by the roots and the lettuce grew into the lid plate. The lettuce leaves were then cut off into the lid plate. Spodoptera eggs were pipetted through a plastic stencil onto a humid gel blotting paper and the lid plate was closed with it. The samples were assessed for mortality, anti-feedant effect and growth inhibition in comparison to untreated samples 6 days after infestation.

[0872] The following compounds gave an effect of at least 80% control in at least one of the three categories (mortality, anti-feeding, or growth inhibition) at a test rate of 12.5 ppm: P.58, P.93, P.94, P.95, P.130, P.254, P.256.

Example B9: Plutella xylostella (Diamondback Moth)

[0873] 96-well microtiter plates containing artificial diet were treated with aqueous test solutions, prepared from 10′000 ppm DMSO stock solutions, by a liquid handling robot. After drying, eggs (˜30 per well) were infested onto a netted lid which was suspended above the diet. The eggs hatch and L1 larvae move down to the diet. The samples were assessed for mortality 9 days after infestation.

[0874] The following compounds resulted in at least 80% control in mortality at an application rate of 500 ppm: P.52, P.55, P.58, P.60, P.61, P.62, P.63, P.64, P.65, P.66, P.67, P.68, P.69, P.93, P.94, P.95, P.277.